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Introduction
The first British Association for Psychopharmacology evidence-
based guidelines for ‘the pharmacological management of substance 
misuse, addiction and comorbidity’ were published in 2004 
(Lingford-Hughes et al., 2004). This is a substantial revision of that 
original document but using the same criteria (Table 1) and taking 
into account a number of recent documents from the National 
Institute for Health and Clinical Excellence (NICE) and other organ-
isations which significantly enhanced the knowledge base. As 
before, the guidelines are not intended to provide an equivalent com-
prehensive review of psychosocial interventions since this is a major 
topic in its own right. In addition, the word ‘patient’ is used through-
out the document for consistency, although it is acknowledged that 
in many treatment centres, ‘client’ or ‘user’ is the preferred term.
Scope of these guidelines
Our aim is to provide helpful and pragmatic guidelines for clini-
cians such as psychiatrists and GPs involved in prescribing to peo-
ple with substance abuse or harmful use or addiction alone and with 
psychiatric comorbidity. However, the update should also be of 
interest to other practitioners in the substance misuse field, non-
specialists, patients and their families. This revision was undertaken 
to update the guidelines in the light of new evidence focussing on 
areas not covered by guidelines published since the original BAP 
guidelines (e.g. from NICE). We have searched for new evidence 
concerning pharmacological management of alcohol, nicotine, opi-
oids, benzodiazepines, stimulants and associated comorbidity with 
mental health problems and substance use or abuse in pregnancy. 
In addition we have covered pharmacotherapy for younger and 
older people, for those with personality disorder, as well as for ‘club 
drugs’ and cannabis and polydrug users. We review pharmacothera-
pies in common clinical use as well as those with limited but prom-
ising evidence and highlight important areas of ‘key uncertainty’. 
We have reviewed the evidence in as brief a format as possible and 
refer readers to the other guidelines such as NICE, where more 
detail is provided. Whilst some avenues have developed, it is nota-
ble that many key uncertainties remained unchanged since 2004.
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Table 1. Categories of evidence and strength of recommendations
Categories of evidence for causal relationships and treatment
Ia: evidence from meta-analysis of randomised controlled trials
Ib: evidence from at least one randomised controlled trial
IIa: evidence from at least one controlled study without randomisation
IIb: evidence from at least one other type of quasi-experimental study
III: evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case-control studies
IV: evidence from expert committee reports or opinions and/or clinical experience of respected authorities
Proposed categories of evidence for observational relationships
I: evidence from large representative population samples
II: evidence from small, well-designed, but not necessarily representative samples
III: evidence from non-representative surveys, case reports
IV: evidence from expert committee reports or opinions and/or clinical experience of respected authorities
Strength of recommendation
A: directly based on category I evidence
B: directly based on category II evidence or extrapolated recommendation from category I evidence
C: directly based on category III evidence or extrapolated recommendation from category I or II evidence
D: directly based on category IV evidence or extrapolated recommendation from category I, II or III evidence
S: Standard of care
Table 2. Classification of substance abuse, harmful use and dependence
DSM IV ICD-10 F10 – F19
Substance abuse (1 or more criteria for over 1 year) and never met criteria for 
dependence
Harmful Substance use:
Actual damage should have been caused to the mental or 
physical health of the user in the absence of diagnosis of 
dependence syndrome.
A. recurrent substance use resulting in a failure to fulfil major role obligations  
at work, school or home
B. recurrent substance use in situations in which it is physically hazardous
C. recurrent substance-related legal problems
D. continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the substance
Substance dependence (3 criteria or more over 1 year) Substance dependence (3+ in last year)
A. tolerance: a need for markedly increased amounts of the substance to  
achieve intoxication or desired effect or markedly diminished effect with 
continued use of the same amount of the substance
A. a strong desire or sense of compulsion to take alcohol
B.  difficulties in controlling alcohol-taking behaviour in terms 
of its onset, termination, or levels of use
C.  a physiological withdrawal state when alcohol use has 
ceased or been reduced, as evidenced by: the characteristic 
withdrawal syndrome for alcohol; or use of the alcohol with 
the intention of relieving or avoiding withdrawal symptoms
D.  evidence of tolerance, such that increased doses of alcohol 
are required in order to achieve effects originally produced 
by lower doses (clear examples of this are found in alcohol-
dependent individuals who may take daily doses sufficient 
to incapacitate or kill nontolerant users)
B. withdrawal: the characteristic withdrawal syndrome for the substance or the 
same (or a closely related) substance is taken to relieve or avoid withdrawal 
symptoms
C.
D.
the substance is often taken in larger amounts or over a longer period than 
was intended
there is a persistent desire or unsuccessful efforts to cut down or control 
substance use
E.
F.
G.
a great deal of time is spent in activities necessary to obtain the substance, 
use of the substance or recovering from its effects
important social, occupational or recreational activities are given up or 
reduced because of substance use
the substance use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been caused 
or exacerbated by the substance
E.  progressive neglect of alternative pleasures or interests 
because of alcohol use, increased amount of time necessary 
to obtain or take alcohol or to recover from its effects
F.  persisting with alcohol use despite clear evidence of overtly 
harmful consequences.
We have not re-evaluated diagnostic categories since at the time 
of writing these guidelines DSM-V is being developed and will be 
published in 2013. The criteria for the dependence syndrome are 
similar in both ICD and DSM classification systems (Table 2). In 
most recent trials either DSM-IV or ICD-10 is used, though in older 
trials definitions of ‘dependence’ were less precise. DSM-V may 
return to using the term ‘addiction’ to distinguish this syndrome 
from ‘dependence’ which would apply to those tolerant to 
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medication but not abusing or escalating its use. The criteria for the 
categories ‘harmful use’ (ICD-10) and ‘substance abuse’ (DSM-IV) 
differ, with the emphasis on negative social consequences of sub-
stance use in the DSM classification, and on the physical and mental 
health consequences in the ICD-10 classification. It is currently pro-
posed for DSM-V to combine substance abuse and dependence into 
one disorder: substance use disorder. Substance ‘misuse’ is a com-
monly used term in many studies and has been used in recent NICE 
guidance (NICE, 2011a, b). However it is not an official diagnostic 
term and may refer to harmful use, abuse or dependence. We have 
therefore used these more precise diagnostic terms wherever possi-
ble, but have had to use the term when describing studies where it is 
used and further discrimination is not possible.
We have not covered in depth how to safely prescribe the phar-
macotherapies described here, since guidance is constantly 
updated. The reader is recommended to consult current resources 
such as British National Formulary (BNF), Summaries of Product 
Characteristics (SPC) (http://www.medicines.org.uk/emc/). We 
also suggest seeking appropriate support and supervision from 
peers and clinical governance if required, since many of the medi-
cations described do not hold a licence for the indication under 
discussion in UK, though may in other countries.
Methodology
A consensus meeting was held on 8 December 2009 involving 
experts in the field of addiction and comorbidity. These included 
reviewers who gave brief presentations of their key area, with 
an emphasis on systematic reviews (e.g. Cochrane Database) 
and randomised controlled trials (RCTs) where possible, 
although inevitably much of the information presented did not 
come from these sources. This was followed by a discussion of 
the important issues to identify consensus and areas of uncer-
tainty regarding the quality of evidence and strength of recom-
mendations. A draft of this review of the literature, which was 
updated during writing with any subsequently published litera-
ture, was then circulated to all participants and other interested 
parties. Feedback was incorporated, wherever possible, into this 
final version.
Identification of relevant evidence
The range of disorders covered in these guidelines did not allow 
for a systematic review or meta-analysis of all possible data from 
primary sources. Existing systematic reviews and RCTs were 
identified from MEDLINE and EMBASE searches, from the 
Cochrane Database as well as from guidelines and identification 
by experts in the field.
Evidence categories and strength of recommendations
Categories of evidence for causal relationships (including treat-
ment) and strength of recommendations are given in Table 1 and are 
taken from Shekelle et al. (1999). The strength of recommendation 
reflects not only the evidence but also the importance of the study. 
For instance, it is possible to have methodologically sound (cate-
gory I) evidence about an area of practice that is clinically 
irrelevant or has such a small effect that it is of little practical 
importance, and therefore attracts a lower strength of recommenda-
tion. More commonly, however, it has been necessary to extrapo-
late from the available evidence leading to weaker levels of 
recommendation (B, C or D) based upon category I evidence state-
ments. For some of the treatments, the strength of the recommenda-
tion may refer to not using this treatment approach. Where 
recommendations are not strictly based on systematic evidence at 
all, but represent an important consensus (practical or ethical), we 
have indicated ‘S’ (standard of care). The recommendations are 
there to give clinicians options in using pharmacotherapeutic 
approaches. However, not all options may be appropriate for every 
individual or clinical situation, and consequently they should not be 
seen as prescriptive.
Treatment aims
There are several possible aims when planning treatment for sub-
stance use disorders, ranging from those pertinent to the individ-
ual, for example reduced risk of infection from stopping injecting, 
through to those concerning society, for example reduction in 
crime. We emphasise that a shared understanding of treatment 
aims between patient and prescriber are key, alongside the fact 
that adequate demonstrable planning with the patient concerning 
their goals is required by many commissioners and services. 
Clarity is important since the same pharmacotherapy may be used 
for substitution as well as withdrawal/detoxification, for example 
methadone or buprenorphine in opiate addiction.
These guidelines focus on pharmacotherapy which is primarily 
for those who are dependent rather than engaging in ‘harmful use’ 
or ‘abuse’. We have not reviewed psychosocial treatments or other 
forms of treatment, for example acupuncture. NICE has under-
taken several systematic reviews and meta-analyses in these areas, 
and there are other guidelines and Cochrane reviews available (e.g. 
Ferri et al., 2011; Knapp et al., 2007; White et al., 2011). There is 
limited evidence concerning the interaction between these two 
approaches or whether there is an optimal pharmacological–psy-
chosocial combination. For those patients who meet criteria for 
harmful use (ICD-10 criteria, Table 2) or abuse (DSM-IV criteria, 
Table 2) but do not meet criteria for a dependence syndrome, psy-
chosocial approaches are the mainstay of treatment, and pharmaco-
therapy currently has a more limited role compared with those with 
dependence. It may, of course, be appropriate to use pharmaco-
therapy to treat any comorbid psychiatric disorder. Pharmacological 
interventions for the substance use disorder itself are of most value 
in dependence, and are targeted at the following areas of patient 
management:
x withdrawal syndromesx relapse prevention and maintenance of abstinencex reduction of harms associated with illicit drug use by pre-
scribing a substitute drug or drugs (e.g. methadone main-
tenance treatment in which aims may include cessation of 
injecting, reduction or cessation of illicit heroin use, and 
reduction or cessation of other high-risk behaviours)x prevention of complications of substance use (e.g. use of 
thiamine to prevent Wernicke’s encephalopathy and 
Korsakoff’s syndrome)
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In this guideline, we have tried to indicate clearly the aims of 
each treatment. Goals should be set and agreed between the 
patient and prescriber. We have not included the pharmacological 
treatments used in management of severe acute intoxication or 
overdose. Such management usually takes place in Accident and 
Emergency departments.
Alcohol
Management of withdrawal and detoxification
Acute alcohol withdrawal, its associated risks and management includ-
ing settings and pharmacological management or ‘medically assisted 
withdrawal’, has been systematically reviewed for NICE guidelines, 
by groups led by Royal College of Physicians (NICE, CG100, 2010c) 
(Ia) and by Royal College of Psychiatrists (NICE, CG115, 2011a) (Ia) 
as well as by Cochrane (Amato et al., 2010; Minozzi et al., 2010) (Ia). 
The recommendations in both NICE guidelines are broadly in agree-
ment with our previous recommendations supporting the use of benzo-
diazepines. One difference, however, was that the CG100 guidelines, 
whose remit was management within a general medical inpatient set-
ting, recommended a ‘symptom-triggered’ regimen (see Hecksel et al. 
(2008) regarding issues of managing in general medical setting) (III). 
However, the CG115 guidelines emphasised that this approach was 
only for inpatients or residential settings if the appropriate level of 
monitoring was available. These NICE guidelines recommended a 
fixed-dose regimen for community-based withdrawal. A recent 
study not available for inclusion in either NICE guidelines reported 
that outpatient alcohol withdrawal could be managed effectively 
and safely using chlordiazepoxide either with a symptom triggered 
or a fixed-schedule regimen (Elholm et al., 2011). The median of 
total doses of chlordiazepoxide over 10 days were 725mg in symp-
tom triggered (range: 50 – 2800) and 875mg in fixed-schedule 
(range: 100 – 1900). In addition, the CG100 guidelines recom-
mended clomethiazole as an alternative for inpatients, although to 
be used cautiously. The CG115 guidelines did not recommend 
using clomethiazole in the community.
The use of anticonvulsants continues to receive attention, since 
reducing glutamate overactivity is now thought to be key in reduc-
ing risk of brain toxicity during withdrawal. Undergoing more 
than two detoxifications has been associated with poorer perfor-
mance on some cognitive tasks although a causal link has not been 
proven (Duka et al., 2004; Loeber et al., 2010). Krupitsky et al. 
(2007) (Ib) reported that a range of antiglutamatergic approaches 
such as memantine (NMDA antagonist), topiramate (AMPA/kain-
ate inhibitor) or lamotrigine (glutamate release inhibitor) were 
efficacious in treating alcohol withdrawal similarly to diazepam. 
A Cochrane review (Minozzi et al., 2010) (Ia) was cautious about 
anticonvulsants, stating that there was ‘insufficient evidence in 
favour of anticonvulsants for treatment of alcohol withdrawal’ 
although they seemed to have ‘limited side effects’ and ‘might be 
effective for some symptoms’, for example seizures. NICE, 
CG100, (2010c) (Ia) recommended using carbamazepine or ben-
zodiazepines, although in the UK there is less clinical experience 
in using anticonvulsants. NICE, CG115, (2011a) (Ia) guidelines 
did not comment on use of carbamazepine.
Due to concerns about carbamazepine’s safety and tolerabil-
ity, alternative anticonvulsants, for example oxcarbazepine, lev-
etiracetam, pregabalin, have been investigated. Studies may 
show benefits compared with placebo but no one anticonvulsant 
has emerged as preferential (e.g. Anton et al., 2009 (Ib); Barrons 
and Roberts, 2010 (Ia); Bonnet et al., 2010 (III); Di Nicola et al., 
2010 (IIb); Martinotti et al., 2010 (Ib); Richter et al., 2010 (Ib)). 
The role for anticonvulsants in alcohol withdrawal therefore still 
remains unclear. However, the finding that using carbamazepine 
during withdrawal was followed by longer time to eventual 
return to drinking than with using the benzodiazepine, lorazepam 
(Malcolm et al., 2002) (Ib), raises the question of whether ben-
zodiazepine withdrawal leaves the brain vulnerable to relapse. 
Consequently, determining how to measure impact on markers of 
neurotoxicity is critical to answer this important question.
Acamprosate has been shown to reduce the hyperglutamatergic 
state during alcohol withdrawal in animal models and may have 
neuroprotective potential (Mann et al., 2008) (IV). A clinical study 
showed acamprosate reduced glutamate levels in the brain 25 days 
after initiation of benzodiazepine-treated alcohol withdrawal 
(Umhau et al., 2010) (Ib). Starting acamprosate 8 days prior to 
detoxification and continuing for 15 days without other medication 
for withdrawal resulted in reduced arousal level measured with mag-
netoencephalography and improved decreased wake time after sleep 
onset and increased stage 3 and REM sleep latency (Boeijinga et al., 
2004 (Ib); Staner et al., 2006 (Ib)). Gual and Lehert (2001) (Ib) and 
anecdotally, clinicians who routinely use acamprosate during detox-
ification in addition to usual medication for alcohol withdrawal 
report no unwanted events and suggest acamprosate improves 
symptoms. However, a full randomised placebo-controlled trial has 
yet to be completed. Another small (n = 16 vs. 18) trial designed to 
see if giving acamprosate in addition to medication for alcohol with-
drawal rather than starting it at the end of the detoxification improved 
drinking outcomes, found no benefit in drinking outcomes, indeed 
this approach might worsen some (Kampman et al., 2009) (Ib).
There are a number of medications that may be useful not only in 
treating withdrawal but also in relapse prevention, and are further 
described in this section below. These include baclofen, some anti-
convulsants (e.g. topiramate) and gamma-hydroxybutyric acid 
(GHB or sodium oxybate; see Relapse Prevention, Other medica-
tions below), but there is limited evidence currently (Caputo and 
Bernardi, 2010; Leone et al., 2010 (Ia); Liu and Wang, 2011 (Ia)). 
Clearly if a medication can be used to treat withdrawal and reduce 
the risk of complications and prevent lapses/relapses during early 
abstinence, it may have advantages to patients who would otherwise 
have to wait until after detoxification before starting relapse preven-
tion medication.
Alcohol withdrawal-related seizures. Bråthen et al. (2005) 
(Ia) have produced consensus recommendations for diagnosis and 
management of alcohol-related seizures based on a systematic 
review of the evidence. They recommend longer-acting benzodi-
azepines, for example diazepam, or if not available lorazepam, 
since they are efficacious for primary and secondary seizure pre-
vention. They concluded that there is insufficient evidence for 
other pharmacological approaches.
Recommendations: management of alcohol withdrawal and 
detoxification. Although many alcohol-withdrawal episodes 
take place without any pharmacological support, particularly in 
those patients with a mild level of alcohol dependence, in the pres-
ence of symptoms medication should be given. Detoxification 
should be planned as part of a treatment programme to increase 
the likelihood of patients successfully altering their subsequent 
drinking behaviour. Early identification and treatment of alcohol 
dependence can reduce the level of complications.
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Treatment regimens
x Benzodiazepines are efficacious in reducing signs and 
symptoms of withdrawal (A); fixed-dose regimens are rec-
ommended for routine use with symptom-triggered dosing 
reserved for use only with adequate monitoring (D)x Carbamazepine has also been shown to be equally effica-
cious to benzodiazepines (A)x Clomethiazole is reserved for inpatient settings only after 
due consideration of its safety (A)
Seizures
x Benzodiazepines, particularly diazepam, prevent de novo 
seizures (A)x Anticonvulsants are equally as efficacious as benzodiaz-
epines in seizure prevention, but there is no advantage 
when combined (A)x In preventing a second seizure in the same withdrawal epi-
sode, lorazepam but not phenytoin has been shown to be 
effective (A)
Delirium
x Benzodiazepines, particularly those with longer half-life 
prevent delirium (A) and should be used for treatment (B)
Key uncertainties
x What is the role of acamprosate or carbamazepine and 
other anticonvulsants in alcohol detoxification – uncom-
plicated and complicated?x What is the appropriate regimen for maximum symptom 
control, reducing risk of complications, preventing neuro-
inflammation and brain damage?
Alcohol-related brain disorder
Wernicke–Korsakoff syndrome (WKS) is now considered to be a 
unitary disorder comprising acute Wernicke’s encephalopathy (WE) 
which proceeds in a proportion of cases to Korsakoff’s syndrome. 
Adequate assessment and diagnosis still remain a challenge despite 
WKS being well recognised as a complication of harmful alcohol 
use. Thiamine replacement is still the critical intervention for WKS, 
and increased vulnerability is associated with genetic susceptibility 
in association with poor diet (Sechi and Serra, 2007) (IV).
Acute – Wernicke’s encephalopathy. It has been suggested 
that a presumptive diagnosis of WE should be made for any 
patient with a history of alcohol dependence who shows one or 
more of the following: evidence of ophthalmoplegia, ataxia, acute 
confusion, memory disturbance, unexplained hypotension, hypo-
thermia, coma, or unconsciousness (Sechi and Serra, 2007) (IV). 
Alcohol or benzodiazepine or carbamazepine intoxication may 
complicate the presentation. Operational criteria for the diagnosis 
of WE have been proposed with only two of the classic triad (oph-
thalmoplegia, ataxia, confusion) and dietary deficiencies (Caine 
et al., 1997) (IV). Although they help in distinguishing the prob-
lem from other potentially coexisting conditions such as alcohol 
withdrawal or hepatic encephalopathy, they are not yet widely 
used. Patients commonly deemed ‘at risk’ of developing WE dur-
ing a hospital admission or a planned detoxification are those 
whose drinking has exceeded 15 units per day for a month or more 
and where there is evidence of recent weight loss or vomiting or 
diarrhoea or malnutrition or peripheral neuropathy or chronic ill-
health. This is based only on ‘expert opinion’, but derives also 
from the established causal relationship of WE to severe malnutri-
tion and hyperemesis of pregnancy.
Recent systematic reviews of the evidence for how best to treat 
WE have been completed for Cochrane (Day et al., 2004) (Ia) and 
NICE (2010c) (Ia). There is still insufficient evidence from RCTs. 
Nevertheless there is growing consensus for using parenteral regi-
mens in those with WE and also, importantly, for those at risk as 
described above (NICE, 2010c) (Ia). Our recommendations con-
cerning importance of identifying these two populations, particu-
larly those at risk, and their treatment have not changed from the 
previous BAP guidelines. Whether or not and, if so, for how long 
to give oral thiamine to apparently healthy but potentially mal-
nourished alcohol-dependent individuals remains unclear, with 
NICE (2010c) (Ia) not recommending ‘widespread use of thia-
mine’ in alcohol-dependent people ‘eating a normal diet’. We sug-
gest if there is any suggestion that such ‘healthy’ alcohol-dependent 
individuals may not have a healthy diet or have reduced thiamine 
levels, oral thiamine should be considered.
Chronic or persisting – Korsakoff’s syndrome. Alcohol-related 
brain disorders encompass a broad range of dysfunction including 
Korsakoff’s syndrome (Kopelman et al., 2009) (IV). Research is 
increasingly being focussed on prevention, and the roles of 
increased brain glutamate, oxidative stress and neuroinflammation 
give us a number of targets for the future (Thomson et al., 2012). 
Once cognitive impairment or Korsakoff’s syndrome is evident 
and adequate thiamine replacement has been given, little additional 
pharmacotherapy to ameliorate cognitive impairment has been 
shown to be effective. For Korsakoff’s syndrome, there has been 
little progress in finding an efficacious pharmacotherapy, with only 
a small trial of rivastigmine showing no effect published since the 
last guidelines (Luykx et al., 2008) (III). Maintaining abstinence is 
key, and pharmacotherapy may be used for this (see below).
Recommendations: alcohol-related brain disorder. A high 
index of suspicion must be maintained at all times regarding WE 
since it rarely presents with all signs and symptoms. The follow-
ing recommendations are based on uncontrolled trials and from 
empirical clinical practice.
x In healthy uncomplicated alcohol-dependent/heavy drink-
ers (i.e. those at low risk), oral thiamine >300 mg/day 
should be given during detoxification (D)x If patient is at high risk of WE (e.g. malnourished, unwell) 
prophylactic parenteral treatment should be given, using 
250 mg thiamine (one pair of ampoules Pabrinex®) i.m. or 
i.v. once daily for 3–5 days or until no further improve-
ment is seen (D)x If WE is suspected or established, parenteral thiamine 
(i.m. or i.v.) of  >500 mg should be given for 3–5 days (i.e. 
two pairs of ampoules Pabrinex® three times a day for 3-5 
days), followed by one pair of ampoules once daily for a 
further 3–5 days depending on response (D)
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Key uncertainties
x What is the appropriate dose, route and duration of thia-
mine administration in presumed or clinically obvious WE?x To determine thiamine requirements during different 
stages of a patient’s drinking, for example in those con-
tinuing to drink heavily, during alcohol withdrawal in oth-
erwise healthy patients.x To understand more about other neurobiological processes 
involved in WE.x How best to treat Korsakoff’s syndrome and manage the 
persisting symptoms long term?
Preventing lapse and relapse, promoting and 
maintaining abstinence
Since the last guidelines the debate about what is a reasonable or 
appropriate outcome regarding drinking behaviour continues. 
Abstinence is generally reported as ‘continuous complete absti-
nence’, cumulative abstinence or % time abstinent. There is no 
single definition of other drinking outcomes, nor is it clear which 
accrue health and social benefits. Relapse can be defined as five 
drinks in US studies (drink = 14 g alcohol = 8.1 UK units; note that 
the amount of alcohol in a ‘unit’ or ‘drink’ differs worldwide) in 
men and four drinks (6.5 units) in women on a single occasion, with 
any lesser episode of alcohol consumption categorised as a ‘lapse’. 
In other studies, controlled drinking is reported as mean daily self-
reported consumption of 5 units or less (men) or 3 units or less 
(women) and no single day exceeding 8 units (men) or 6 units 
(women). What level of alcohol drinking confers an acceptable low 
risk will depend on individual circumstances (Gmel et al., 2003). 
For those with cirrhosis and decompensated liver failure any drink-
ing, even small amounts, is likely to be harmful (Tilg and Day, 
2007). Complete abstinence gives them the best chance of recovery 
so they should be encouraged towards abstinence, though reduced 
drinking may be acceptable as an intermediate treatment goal in 
developing medicinal products for treatment of alcohol dependence 
(European Medicines Agency’s guidelines, 2010). In addition, for 
those who have lost control of their drinking, reductions maybe 
hard to achieve and maintain, so a period of abstinence is also gen-
erally advocated. For those that are unwilling or unable to become 
abstinent, reduced drinking may be an appropriate intermediate 
goal on the way to abstinence, although ideally clinical benefit 
should also be evident. For others with less adverse health conse-
quences or not dependent, some drinking may be acceptable.
Participants in the majority of trials are abstinent prior to start-
ing pharmacotherapy, and generally the trial’s aim is to maintain 
abstinence. Some studies have noted that having abstinence as a 
goal is associated with a good response (e.g. Anton et al., 2006; 
Mason and Lehert, 2010; Koeter et al., 2010) (Ib). In addition, all 
pharmacotherapies discussed here have been studied as an adjunct 
to psychosocial interventions, and use of medication alone is not 
currently advocated. Whether there is an optimal combination of a 
particular type of psychosocial intervention and pharmacotherapy 
has not been widely studied, so patients should engage with which-
ever psychosocial approach they find beneficial or is available.
When taking evidence from trials to UK practice, it is important 
to consider a trial’s inclusion/exclusion criteria and where they 
were conducted. In particular, recent trials of pharmacotherapy in 
US settings do not necessarily come to the same conclusion as 
those conducted in European studies (Garbutt, 2009). In US trials 
patients may be recruited via advertisement, may be less depend-
ent, able to stop drinking without medication, less anxious, and not 
want abstinence, which contrasts with European trials where 
patients are generally recruited from specialist alcohol services and 
tend to be highly dependent, require medically assisted alcohol 
withdrawal and a majority are aiming for abstinence. However, 
such differences can be used to inform clinicians what types of 
patients are more likely to benefit from that medication.
Reviewing the place of medication in relapse prevention, NICE 
(2011a) has recently recommended that ‘after a successful with-
drawal for people with moderate and severe alcohol dependence, 
consider offering acamprosate or oral naltrexone in combination 
with an individual psychological intervention (cognitive behav-
ioural therapies, behavioural therapies or social network and 
environment-based therapies) focused specifically on alcohol mis-
use’. In addition, ‘for harmful drinkers and people with mild alco-
hol dependence who have not responded to psychological 
interventions alone, or who have specifically requested a pharma-
cological intervention, consider offering acamprosate or oral nal-
trexone in combination with an individual psychological 
intervention (cognitive behavioural therapies, behavioural thera-
pies or social network and environment-based therapies) or behav-
ioural couples therapy’. We endorse the recommendation that 
pharmacotherapy should be the default position, such that the deci-
sion not to prescribe is made actively for those patients presenting 
with harmful alcohol use or abuse that have not benefited from 
psychosocial interventions and for everyone with dependence, 
rather than only thinking of medication for more complex patients. 
The range of medications are described below. We have considered 
a broader range of pharmacological approaches than NICE (2011a).
Acamprosate. Acamprosate acts as a functional glutamatergic 
NMDA antagonist, and since alcohol dependence and particularly 
withdrawal are associated with a hyperglutamatergic system, it 
can reduce this (Mann et al., 2008; Mason and Heyser, 2010). 
Acamprosate is generally well tolerated, with gastrointestinal dis-
turbance (e.g. nausea, diarrhoea) being the most common side-
effect reported (Mason and Heyser, 2010; NICE, 2011a) (Ia). It 
can be given safely to a wide number of patients with physical 
comorbidity, although with caution or even contraindicated in 
those with severe liver and renal impairment (see SPC).
There are a number of good-quality systematic reviews and 
meta-analyses of trials of acamprosate including those by 
Cochrane (Rösner et al., 2010a) (Ia), NICE (2011a) (Ia), Health 
Technology Board of Scotland (Slattery et al., 2003) (Ia), Swedish 
Board (Berglund et al., 2003) (Ia), and the Spanish Agency for 
Health Technology Assessment (Bouza et al., 2004) (Ia) in addi-
tion to those by Mann et al. (2004), Kranzler and van Kirk (2001), 
Mason and Ownby (2000), Rösner et al. (2008) and Mason and 
Heyser (2010) (Ia). These reviews broadly come to the same con-
clusion that compared with placebo, acamprosate is moderately 
effective in increasing the amount of abstinence after detoxifica-
tion; for example Rösner et al. (2010a) (Ia) report RR 0.86 (95% 
CI 0.81–0.91), and NICE CG115 (2011a) (Ia) report RR = 0.83 
(95% CI = 0.77–0.88). The ‘number needed to treat’ (NNT) was 
calculated as 9–11 (e.g. Rösner et al., 2010a; Slattery et al., 2003) 
(Ia). Notably, later systematic reviews and meta-analyses report 
smaller effect sizes due to three reasonably sized recent negative 
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studies conducted in the USA and Australia (COMBINE, Anton 
et al., 2006 (see below); Mason et al., 2006; Morley et al., 2006) 
(Ib). However, some of these studies included low-severity 
patients with few withdrawal symptoms, that is, patients who may 
be less likely to respond to acamprosate.
While the most potent consistent effect of acamprosate is to 
improve abstinence, some but not all meta-analyses or reviews 
have found evidence that acamprosate can reduce ‘heavy drinking’ 
in patients who have relapsed (Chick et al., 2003; NICE 2011a) 
(Ia) as was also found for naltrexone by Rösner et al. (2010b) (Ia).
When to start and how long to prescribe for? In most 
trials of acamprosate, patients were abstinent from alcohol for 
several days, and currently it is recommended that this drug 
should be started as soon as possible after detoxification. This 
recommendation was influenced by the UK study which did not 
find acamprosate to be superior to placebo; this might have been 
due to the greater mean length of time after detoxification that 
acamprosate was started compared with other studies (Chick 
et al., 2000) (Ib). A secondary analysis of COMBINE has shown 
that a longer period of pretreatment abstinence resulted in a poorer 
response with acamprosate (Gueorguieva et al., 2011) (Ib). Given 
this evidence and acamprosate’s potential neuroprotective effect, 
we recommend it should be started during detoxification, despite 
Kampman et al. (2009) (Ib) reporting in a preliminary trial that 
some drinking outcomes may worsen.
Currently the SPC recommends acamprosate be given for 1 
year. Mann et al. (2004) (Ia) reported from their meta-analysis that 
acamprosate’s effect size for abstinent rates increased with time 
from 1.33 at 3 months, to 1.5 at 6 months and 1.95 at 12 months. 
NICE (2011a) recommends medication should be prescribed for 6 
months but stopped if drinking persists after 4–6 weeks. 
Pragmatically it is sensible not to continue prescribing any medi-
cation without review if drinking behaviour is not changing.
The benefits of acamprosate in maintaining abstinence have 
been shown to persist for 3–12 months after stopping treatment, 
with a 9% lower risk to return to any drinking in patients who 
received acamprosate than those who received placebo (RR = 0.91; 
95% CI 0.87–0.96) and a 9% higher continuous abstinence duration 
(MD 8.92; 95% CI 5.08–12.77; Rösner et al., 2010a) (Ia). The NNT 
for an additional prevention of drinking until the post-treatment 
evaluation was estimated at NNTB 12.5 (95% CI 9.09–25.00).
Who to give it to? Given that many people do not respond to 
acamprosate, are there any predictors to guide the clinician? While 
acamprosate has been referred to as ‘anti-craving’, recent trials have 
failed to show such an effect (Richardson et al., 2008 (Ib)). One trial 
reported a slight anxiolytic effect (Chick et al., 2000) (Ib) and insom-
nia, common in the early weeks of abstinence, seems to be helped by 
acamprosate (Staner et al., 2006) (Ib). Recently secondary analyses of 
the COMBINE dataset suggest those with subsyndromal anxiety and/
or a significant past psychiatric history may particularly benefit from 
acamprosate, as do ‘very frequent drinkers’, but those who manage 
to stop drinking >14 days pretreatment may do worse (Gueorguieva 
et al., 2011; Mason and Lehert, 2010) (Ib). Mason et al. (2006) 
(Ib) had previously reported that acamprosate was effective in 
those motivated for abstinence. However, while individual studies 
may report post-hoc associations between clinical variables and 
outcome, meta-analyses of trials have not found robust predictors 
for ‘treatment-matching’. Verheul et al. (2005) (Ia) used data from 
seven European trials and reported that high physiological depend-
ence at baseline, negative family history of alcoholism, late age of 
onset, serious anxiety symptomatology at baseline, severe craving at 
baseline, and female gender did not predict response to acamprosate.
Since acamprosate’s proposed mechanism of action is to cor-
rect glutamate–GABA imbalance, it has been hypothesised that 
since those more severely dependent are more likely to have such 
an imbalance, they are more likely to respond to acamprosate. 
There is some supporting evidence, since Morley et al. (2010) (Ib) 
reported an interaction between dependence severity and acam-
prosate treatment, such that higher levels of dependence severity 
at baseline predicted a beneficial response to acamprosate. In 
addition, failure of the two US trials to find acamprosate effective 
would fit with this hypothesis, since participants were less 
severely dependent (COMBINE, Anton et al., 2006; Mason et al., 
2006) (Ib). However, evidence from meta-analyses has not been 
found in support of this (NICE, 2011a; Verheul et al., 2005) (Ia). 
Verheul et al. (2005) (Ia) indeed concluded that acamprosate is 
potentially effective for anyone with alcohol dependence. At the 
time of writing these guidelines, a large prospective study set up 
to define if there are any subgroups who respond to either acam-
prosate or naltrexone, ‘project PREDICT’ has yet to formally pub-
lish its results (Mann et al., 2009) (Ib).
Psychosocial intervention. Whether one psychosocial 
approach is preferable to another when prescribing acamprosate 
has not been investigated except in the COMBINE study, where 
acamprosate lacked efficacy with each of the three modes of psy-
chosocial support offered (Anton et al., 2006) (Ib). One study 
reported no additional benefit of minimal and brief psychosocial 
interventions to acamprosate (de Wildt et al., 2002). Nevertheless, 
we suggest that a patient should be advised to engage with what-
ever approach they find available and acceptable.
Naltrexone. Naltrexone is a non-selective opioid antagonist. 
There is growing evidence for a role of the endogenous opioid sys-
tem and its receptors in addiction (see Lingford-Hughes et al., 2010). 
The mu opioid receptor modulates dopaminergic cell firing in the 
ventral tegmental area, and therefore blocking the mu opioid recep-
tor with naltrexone prevents any increase in dopaminergic activity. 
Consequently, naltrexone reduces alcohol’s rewarding effects and 
also motivation to drink or ‘craving’ (Drobes et al., 2004; NICE, 
2011a) (Ia). A role of the endogenous opioid system in impulsive 
behaviour is being increasingly characterised, with reduced opioid 
activity associated with lower levels of impulsivity. Consistent with 
this, naltrexone has been shown be effective in some impulse-con-
trol disorders such as pathological gambling, in particular those with 
a family history of alcoholism (Grant et al., 2008) (Ib).
Naltrexone as an oral tablet is licensed in the USA and some 
European countries to improve drinking behaviour. Whilst not 
licensed in the UK, it can be used and NICE (2011a) recommended 
that oral naltrexone, or acamprosate, be offered to those who are 
moderately to severely dependent, and to those less dependent or 
drinking harmfully if failing to improve. Early trials used dose of 
50 mg/day, although more recent US studies have used 100 mg/
day. In the UK, 50 mg/day is more typically used, and it is unclear 
whether or how much extra benefit is accrued from higher doses.
There have been several meta-analyses and systematic reviews 
which broadly have the same conclusion that oral naltrexone sig-
nificantly reduces return to heavy drinking, probably by reducing 
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‘lapse to relapse’, but does not necessarily improve cumulative or 
continuous abstinence rates. The meta-analysis by NICE (2011a) 
(Ia) revealed that compared with placebo, naltrexone significantly 
reduced relapse to heavy drinking (RR = 0.83, 95% CI = 0.75–0.91). 
A Cochrane review found naltrexone reduced the risk of heavy 
drinking to 83% of the risk in the placebo group RR = 0.83 (95% CI 
0.76–0.90) and decreased drinking days by about 4%, MD -3.89 
(95% CI -5.75 to -2.04 (Rösner et al., 2010b)) (Ia). The most com-
mon side-effects are nausea and sedation (Rösner et al., 2010b) (Ia).
When to start and how long to prescribe for? Naltrexone 
can be used safely while someone is still drinking, but in trials for 
relapse prevention it is started soon after stopping drinking. Most 
trials conducted were for 3 or 6 months. One study has reported 
that those who had naltrexone for 24 weeks rather than 12 weeks 
had better drinking outcomes (Longabaugh et al., 2009 (Ib)). It is 
not clear if there is an optimal length of time; however, 6 months 
of treatment is reasonable, with stopping the medication if drink-
ing persists for 4–6 weeks. Early studies of naltrexone suggest its 
beneficial effects did not persist for 14 or 16 weeks after stopping 
(Anton et al., 2001; O’Malley et al., 1996) (Ib). However, more 
recent evidence from the COMBINE study reported continued 
benefit persisting for up to a year (Donovan et al., 2008) (Ib).
Who to give it to? As for acamprosate, naltrexone does not 
help everyone and post-hoc analyses of trials have been under-
taken to indicate who might respond. While several studies includ-
ing more severely dependent individuals have suggested that 
naltrexone may be less effective in this group (e.g. Krystal et al., 
2001; Morley et al., 2006, 2010) (Ib), meta-analyses have not sup-
ported this; indeed, the reverse has been found (e.g. NICE, 2011a) 
(Ia). Nevertheless, naltrexone has been shown to be beneficial in 
‘heavy drinkers’ as well as ‘dependent drinkers’ (see below). A 
beneficial response has been reported as more likely in those with 
a positive family history (Monterosso et al., 2001; Rohsenow et 
al., 2007; Rubio et al., 2005) (Ib). Gueorguieva et al. (2007, 2010) 
(Ib) applied their ‘trajectory modelling’ to several naltrexone tri-
als, including those that did not find in favour of naltrexone, and 
reported that naltrexone increased the probability of a lower risk 
trajectory such as abstainer or ‘nearly daily drinking’. There have 
been several secondary analyses of the COMBINE dataset. In the 
medical management condition, naltrexone improves outcome in 
‘type A’ (after Babor, less severe, later onset, weak/absent family 
history, less psychiatric comorbidity), but no such advantage was 
seen in type B alcoholics (Bogenschutz et al., 2009) (Ib). Afri-
can Americans may not respond as well to naltrexone, although 
benefit has been shown for American Indian and Alaskan natives 
(O’Malley et al., 2008; Ray and Oslin, 2009) (Ib).
Concerning gender, Greenfield et al. (2010) (Ib) reported no gen-
der differences in response to naltrexone in the COMBINE study. In 
comorbid cocaine/alcohol dependence, naltrexone (150 mg/day) 
resulted in reduced cocaine and alcohol use in men but not women; 
indeed, their cocaine use increased (Pettinati et al., 2008b) (Ib).
A functional polymorphism, Asp40 allele, of the mu opioid 
receptor gene has been shown to predict naltrexone treatment 
response in alcohol-dependent individuals (Anton et al., 2008; 
Kim et al., 2009; Oroszi et al., 2009; Oslin et al., 2003) (Ib), but 
its impact may be moderated by other efficacious treatment or 
patient variables such as motivation, since such an association has 
not always been found (Gelernter et al., 2007) (Ib).
The impact of depressive symptoms or depression on naltrex-
one’s effectiveness is not clear, with evidence from some trials 
suggesting their presence is associated with greater improvements 
(Kiefer et al., 2003; Krystal et al., 2008; Morley et al., 2010) (Ib). 
For further discussion about effectiveness of naltrexone in 
depressed patients, see Comorbidity section.
Naltrexone + psychosocial interventions. The interaction 
between a number of different psychosocial interventions and 
naltrexone has been investigated, with no clear advantage of one 
approach. Several studies have suggested cognitive behavioural 
therapy (CBT) has a beneficial interaction with naltrexone and to 
be superior to supportive therapy (Balldin et al., 2003) (Ib), moti-
vational enhancement therapy (Anton et al., 2005) (Ib), and equal 
to medical management (O’Malley et al., 2003) (Ib). Supportive 
therapy has been shown to be better than coping skills therapy 
(O’Malley et al., 1992) (Ib). In the COMBINE study, comparable 
outcomes resulted from combined behavioural intervention (CBI) 
alone, naltrexone, and the combination of CBI and naltrexone 
(Anton et al., 2006) (Ib). Broad spectrum treatment (BST) has 
been shown to result in better drinking outcomes than motiva-
tional enhancement therapy (MET) only with 24 rather than 12 
weeks of naltrexone (Longabaugh et al., 2009) (Ib). However, 
many people may not be able to or want to access such intensive 
or comprehensive psychosocial treatment. It is therefore of inter-
est that naltrexone has been shown to be effective with ‘medical 
management’ which involves regular but short meetings with a 
practitioner, often a nurse, monitoring compliance and supporting 
abstinence (Anton et al., 2006; O’Malley et al., 2003) (Ib).
Other opioid antagonists. There are injectable forms of nal-
trexone which have been designed to overcome poor adherence. 
An extended-release monthly injectable formulation of naltrexone 
(XR-NTX) is licensed in the USA and is being used in the UK by 
some for the treatment of alcohol dependence. In a 6 month trial, 
XR-NTX (380 mg monthly) significantly reduced the rate of 
heavy drinking compared with placebo (Garbutt et al., 2005) (Ib). 
A dose-dependent effect was apparent, since 190 mg monthly 
reduced the rate of heavy drinking, but not significantly. The 
effect was more pronounced in those who were abstinent for at 
least 4 days at the start compared with those who were still drink-
ing (O’Malley et al., 2007) (Ib). The effect of the injection is seen 
within 2 days (Ciraulo et al., 2008) (Ib). Side-effects are similar to 
those of the oral preparation and include nausea; however, injec-
tion site pain and reactions have been reported, possibly related to 
poor injection technique, and some required medical treatment 
(Garbutt, 2009). Unfortunately, no direct comparison between 
immediate-release oral naltrexone and extended-release injectable 
naltrexone is available, and it is not possible to make an evidence-
based benefit–risk assessment (Roozen et al., 2007).
An alternative oral medication is nalmefene, which is an opi-
oid antagonist with a differing pharmacological profile to naltrex-
one at the three opioid receptor subtypes (Bart et al., 2005). 
Nalmefene can be given safely in alcohol dependence and can 
significantly prevent relapse to heavy drinking (Mason et al., 
1994, 1999) (Ib). It may have a better safety profile than naltrex-
one with less risk of liver toxicity. Mason et al. (1999) (Ib) did not 
find a difference in reduction in drinking or side-effects between 
20 mg/day and 80 mg/day, and Anton et al. (2004) (Ib) reported 5 
mg, 10 mg and 20 mg/day were reasonably well tolerated. 
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European trials are being conducted in the hope of characterising 
the role and dose for nalmefene in treating alcohol dependence, 
and results are expected in the near future.
Opioid antagonists and ‘heavy drinking’. Due to naltrexone’s 
proposed mechanism of action in reducing the pleasurable effects 
of alcohol, naltrexone has also been investigated in those who are 
still drinking. In addition, an alternative strategy to daily dosing is 
to use opioid antagonists in a targeted way, that is ‘as needed’, to 
reduce heavy drinking. In alcohol dependence, naltrexone taken 
only when craving is effective in maintaining reduced drinking 
(Heinälä et al., 2001) (Ib). In male, but not female, heavy drinkers 
‘targeted’ naltrexone taken when drinking was imminent, rather 
than daily naltrexone or placebo, reduced ‘drinks per day’ by 
almost 20% (Kranzler et al., 2009) (Ib). With minimal psychoso-
cial intervention, nalmefene (10 mg or 40 mg) taken prior to 
‘imminent drinking’ has been shown to significantly reduce heavy 
drinking days, very heavy drinking days and total alcohol con-
sumption (Karhuvaara et al., 2007) (Ib).
Comparing acamprosate and naltrexone. There are four pub-
lished trials comparing acamprosate with naltrexone, of which 
two also studied them combined. The earlier European trials 
reported that naltrexone (50 mg/day) was superior to acamprosate 
(1998 mg/day) or placebo, and the combination conferred no 
additional benefit to naltrexone but improved outcomes compared 
with acamprosate (Kiefer et al., 2003; Rubio et al., 2001) (Ib).
A large nine-arm trial in the USA, COMBINE, examined whether 
acamprosate (3 g) or naltrexone (100 mg) individually or together 
provided any benefit in addition to standard ‘medical management’ 
or more intensive combined behavioral intervention (CBI) (Anton 
et al., 2006) (Ib). The primary outcomes were % days abstinent from 
alcohol and time to first heavy drinking day. While all groups 
showed improvements in drinking outcomes, naltrexone with medi-
cal management alone or in combination with CBI resulted in greater 
improvements than placebo or medical management alone, whereas 
acamprosate showed no evidence of additional efficacy in any com-
bination. Naltrexone or CBI added to medical management resulted 
in a similar level of improvement, with no additional benefit of all 
three together. An Australian trial where patients received either 
acamprosate (1998 mg) or naltrexone (50 mg/day) or placebo along-
side manualised compliance therapy found no superiority of either 
over placebo (Morley et al., 2006) (Ib). Another Australian trial 
reported that a combination of acamprosate and naltrexone with 
CBT resulted in the greatest benefit compared with either medication 
alone, with CBT or CBT alone (Feeney et al., 2006) (IIb).
In summary, taking into account the potential difference between 
European patient samples and the sample included in the COMBINE 
study, it appears there is no overall superiority of naltrexone over 
acamprosate that would apply to the UK patient population. From 
their review, Rösner et al. (2008) (Ia) concluded that ‘acamprosate 
was found to be more effective in preventing a lapse, whereas nal-
trexone was better in preventing a lapse from becoming a relapse’.
Disulfiram. Disulfiram has been used for many years to help 
people remain abstinent. Disulfiram blocks aldehyde dehydroge-
nase, causing accumulation of acetaldehyde if alcohol is con-
sumed, resulting in nausea, flushing, and palpitations. This deters 
people from drinking (Fuller and Roth, 1979) (Ib). Disulfiram 
also blocks dopamine-b-hydroxylase in the brain, so increasing 
dopamine and reducing noradrenaline, and this may contribute to 
its clinical effects in alcoholism or cocaine addiction (see later; 
Schroeder et al., 2010).
The fact that the disulfiram–alcohol reaction can have poten-
tially severe adverse consequences often makes practitioners cau-
tious of using disulfiram. However, recent studies report that 
disulfiram can be used safely in a wide range of patients, includ-
ing those with psychosis (see comorbidity section later) and hepa-
titis C (Martin et al., 2004) (III). For more information about the 
safety of disulfiram, see Chick (1999) and Malcolm et al. (2008). 
To optimise compliance, witnessing (now the preferred term to 
‘supervision’) disulfiram intake has been shown to be an impor-
tant contributor to effectiveness, since otherwise disulfiram is no 
better than basic support (Chick et al., 1992) (Ib).
Many of the trials of disulfiram were conducted some decades 
ago and were therefore not as rigorously undertaken as those for 
newer medications. In addition, due to the alcohol–disulfiram 
reaction, patients entering trials of disulfiram have to be aware 
they could be taking disulfiram. Systematic reviews of older trials 
report that disulfiram is no better than placebo in preventing lapse 
to drinking (NICE 2011a; Slattery et al., 2003) (Ia). More recent 
trials of disulfiram have compared it with newer medications such 
as naltrexone, acamprosate or topiramate (de Sousa and de Sousa, 
2004, 2005; de Sousa et al., 2008; Laaksonen et al., 2008) (Ib). 
When taking medication for 12 weeks, disulfiram has been shown 
to be superior to naltrexone or acamprosate in prolonging time to 
first drink and number of ‘heavy drinking days’ (Laaksonen et al., 
2008) (Ib). All medication was ‘supervised’ by someone. However, 
in a subsequent 12-week phase of targeted medication taken in ‘a 
craving situation’, there were no differences between disulfiram, 
naltrexone and acamprosate (Laaksonen et al., 2008) (Ib). Two 
open but randomised pragmatic trials of disulfiram in a private 
clinic in Mumbai reported that disulfiram (250 mg/day) was supe-
rior to either naltrexone (50 mg/day) or topiramate (150 mg/day) 
in lengthening time to relapse and maintaining abstinence (de 
Sousa and de Sousa, 2004, 2005; de Sousa et al., 2008) (IIa).
NICE (2011a) (Ia) recommended that disulfiram should be 
tried after acamprosate or naltrexone, or where the patient indi-
cates a preference for it. There is no evidence to guide how long to 
prescribe disulfiram, but clearly it can only be started once alco-
hol free for at least 24 hr. Patients must also be warned about 
potential for a reaction with alcohol for up to 7 days after stopping 
disulfiram. An open prospective study lasting 9 years reported that 
2 years of treatment with disulfiram or calcium carbimide resulted 
in overall abstinence rates of 50%; however, not all patients could 
take disulfiram or calcium carbimide so received ‘sham’ treat-
ment, and the authors emphasised the importance of its psycho-
logical ingredient (Krampe et al., 2006) (IIb)
While in the UK the usual daily disulfiram dose is 200 mg 
once a day, it can be given in higher doses. For instance, in trials 
with comorbid alcohol and cocaine dependence, 500 mg/day was 
used (Carroll et al., 1998) (Ib). In addition, disulfiram can be 
given in larger doses less frequently than daily, which might be 
advantageous if asking patients to attend a service and have their 
medication supervised or witnessed. However, Ulrichsen et al. 
(2010) (IIb) reported that 800 mg of supervised disulfiram given 
twice a week over 26 weeks was no better than just attending 
twice a week without taking disulfiram. Notably, over half of 
recruits failed to be randomised since some definitely wanted 
disulfiram and others failed to show up.
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Baclofen. Baclofen is a GABA-B agonist that is licensed for con-
trolling muscle spasms; it does not hold a licence for use in alcohol 
dependence, although it is being used by some clinicians. Preclini-
cal evidence demonstrated that GABA-B receptors are key modula-
tors of dopaminergic neuronal firing and baclofen can reduce 
ethanol self-administration. An Italian RCT of baclofen in cirrhotic 
alcohol-dependent patients wanting to be abstinent showed baclofen 
significantly increased the number maintaining abstinence com-
pared with placebo (71% vs. 29%; Addolorato et al., 2007) (Ib). By 
comparison, another RCT in the USA reported no superiority of 
baclofen over placebo in reducing ‘heavy drinking’ or increasing 
abstinence (Garbutt et al., 2010) (Ib). This difference in effective-
ness may relate to the fact that the cirrhotic patients tended to be 
more severely dependent, anxious, required medication for detoxi-
fication, and wanted sobriety, which contrasted with those in the US 
study. Baclofen reduced anxiety in both populations. It has there-
fore been suggested that those with greater anxiety and withdrawal 
symptoms are more likely to benefit from baclofen. In addition, the 
more comprehensive psychosocial treatment in the US study for 
both groups may have confounded differences in outcome, whereas 
there was less available in the Italian study.
Both of these studies used baclofen 10 mg tds (total 30 mg/d). 
However, secondary analysis of a trial suggests that 20 mg tds 
may be superior to 10 mg tds (Addolorato et al., 2011) (Ib). This 
would be consistent with other studies of baclofen in metham-
phetamine, cocaine and nicotine dependence, where higher doses 
of 60 mg/day and 80 mg/day have been studied. Of note, a high-
profile case report detailed a patient taking up to 270 mg/day to 
control his alcohol consumption and craving before reducing to a 
lower ‘maintenance’ level (Ameisen, 2005).
Baclofen is generally well tolerated and can be safely given to 
patients with liver impairment (Leggio et al., 2010), where a lower 
dose may be sufficient. However baclofen-induced hepatitis in an 
alcohol-dependent patient has been reported (Macaigne et al., 
2011). There are reports of reversible psychiatric disturbance 
when higher (120 mg/day, 275 mg/day) doses are used (see Dore 
et al., 2011; Leo and Baer, 2005).
Anticonvulsants
Topiramate. Topiramate is an anticonvulsant with multiple 
pharmacological actions. Its use in substance use disorders includ-
ing alcohol dependence has recently been reviewed (de Sousa, 
2010; Johnson and Ait-Daoud, 2010; Shinn and Greenfield, 
2010). Topiramate does not currently hold a licence for such use.
In RCTs, topiramate (up to 300 mg/day) has been shown to 
improve the percentage of heavy drinking days, harmful drinking 
consequences, physical health and quality of life (Johnson et al., 
2004, 2007, 2008) (Ib). Unlike other medication trials that start 
with abstinence, here topiramate was started in some patients 
while they were still drinking but aiming for abstinence.
There have been two trials comparing naltrexone and topira-
mate. Starting after detoxification, the number of alcohol-depend-
ent patients that remained abstinent over 12 weeks was significantly 
greater in those receiving topiramate (titrated to 300 mg/day) com-
pared with either naltrexone or placebo (Baltieri 
et al., 2008) (Ib). No differences were found between naltrexone 
and placebo. Notably, a greater number in the topiramate group 
engaged with Alcoholcs Anonymous (AA) than in the other groups. 
In a 6-month open randomised trial, both naltrexone (50 mg/day) 
and topiramate (titration to 200 mg/day, then increased to 400 mg/
day if still craving or drinking; mean dose during study was ~200 
mg/day) were equally effective, with almost half maintaining absti-
nence (Flórez et al., 2011) (Ib). In one study, topiramate was less 
efficacious than disulfiram (de Sousa et al., 2008; see above) (IIb).
However, trials of topiramate have reported some problematic 
side effects compared with placebo, such as paraesthesia (50.8% 
vs. 10.6%), ‘taste perversion’ (23.0% vs. 4.8%), anorexia (19.7% 
vs. 6.9%), and difficulty with concentration (14.8% vs. 3.2%) 
(from Johnson et al., 2007) (Ib). Such adverse events resulted in 
12% of patients in the topiramate group dropping out, and people 
with alcohol dependence may be particularly susceptible to par-
aesthesia (Luykx and Carpay, 2010). This adverse event profile 
has likely limited clinicians using topiramate. Many of these prob-
lematic side effects are related to fast titration to high doses, and a 
slow titration to 300 mg/day over 6–8 weeks has been advocated 
(Johnson and Ait-Daoud, 2010). However 300 mg/day may still 
be too high for some patients.
Pregabalin. Pregabalin (flexible dosing 150–450 mg/day; 
average 275.8 + 95.6 mg/day) has been shown to result in similar 
abstinent or heavy drinking days as naltrexone (50 mg/day) (Mar-
tinotti et al., 2010) (Ib). Pregabalin was well tolerated; however, 
one person (3.2%) withdrew from the study due to confusion.
Specific serotonin reuptake inhibitors. Since serotonergic 
dysfunction has been implicated in alcohol dependence, particu-
larly in early onset, trials have investigated the effect of specific 
serotonin reuptake inhibitors (SSRIs) in harmful alcohol use, 
abuse and dependence. However, in those without comorbid 
depression, their use cannot be recommended. There is no ade-
quate evidence that they improve outcomes and in type 2 alcohol-
ics (early onset, positive family history, impulsive/antisocial 
personality traits) receiving psychosocial interventions, they have 
been shown to worsen outcomes (Chick et al., 2004; Kranzler 
et al., 1996; Pettinati et al., 2000) (1b).
More recently, SSRIs have been conceptualised as reducing 
stress-induced relapse, but adding sertraline (100 mg) to naltrex-
one (50 mg) does not further improve drinking outcomes com-
pared with naltrexone alone (Farren et al., 2009; O’Malley et al., 
2008) (Ib). These patients were not depressed, and a more recent 
study suggests this combination may be beneficial in depressed 
alcoholics (Pettinati et al., 2010; see comorbidity section) (Ib). An 
open study with only 11–12 patients per group compared escitalo-
pram (20 mg/day) alone with naltrexone (50 mg/day) or with 
gamma hydroxybutyric acid (GHB) (75 mg/kg) or with naltrexone 
and GHB (Stella et al., 2008) (IIb). Improvements were seen in all 
groups, with the smallest effect seen in escitalopram alone, and 
with the triple combination being the most effective after 6 months.
Other medications. There are a number of trials of other phar-
macotherapies in alcoholism, although these are often small, 
open, single studies or not placebo-controlled. For example, 
antagonising dopaminergic activity with newer generation anti-
psychotics such as aripiprazole has shown some limited efficacy 
(Anton et al., 2008; Martinotti et al., 2009). GHB, a GABA-B 
agonist which also acts on GHB receptors in the brain and is 
used to treat narcolepsy, has also shown efficacy in treating alco-
hol withdrawal and relapse prevention (see review by Addolor-
ato et al., 2009). It has a licence in some European countries, but 
concerns about its abuse potential currently limits its use in the 
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UK (Leone et al., 2010) (Ia); however, the advent of a new solid 
formulation (Alcover) may make this less of an issue (see Chick 
and Nutt, 2012). Finally, the 5HT3 antagonist, ondansetron, has 
shown promise, particularly in early onset alcoholism (Johnson, 
2010). The mechanistic concepts behind these and other approaches 
to addiction treatments are discussed in Nutt et al., 2012.
Recommendations: preventing relapse, maintaining abstinence
x Acamprosate can be used to improve abstinence rates (A). 
It should be continued if the person starts drinking, since 
there is evidence that acamprosate reduces alcohol con-
sumption (A), at least for a period to assess whether there 
is overall patient benefit attributable to acamprosate.x Naltrexone can be used to reduce risk of lapse becoming a 
relapse, but there is less evidence to support its use in 
maintaining abstinence (A). Naltrexone may therefore be 
a better choice if someone is ‘sampling’ alcohol regularly 
but wishes to be abstinent.x For acamprosate and naltrexone there is no consistent evi-
dence to suggest which types of patient will respond, and 
relapse prevention medication should be offered to/con-
sidered for everyone who is alcohol dependent wanting to 
be abstinent (A).x Disulfiram is effective if intake is witnessed. Disulfiram 
can be offered as a treatment option for patients who 
intend to maintain abstinence, and for whom there are no 
contraindications (B).x Baclofen should be considered if a patient wants to be absti-
nent, has high levels of anxiety and has not benefited from or 
is unable to take acamprosate, naltrexone or disulfiram (C).x SSRIs should be avoided, or used with caution in type 2 
alcoholism (B).
Key uncertainties
x Who is likely to benefit from which pharmacotherapy?x Is there a role for prescribing medication such as opioid 
antagonists to alter drinking behaviour in harmful alcohol 
drinking or alcohol abuse rather dependence?x What is the role of sodium oxybate in managing alcohol 
withdrawal and relapse prevention?x How long to continue the prescription, particularly if the 
patient has resumed drinking?x Are any particular forms of psychosocial intervention bet-
ter than others in the context of pharmacotherapy?
Opioid dependence
Opioid maintenance treatments
Methadone maintenance treatment: MMT
Background. Methadone, a mu opioid receptor agonist with 
a much longer half-life than heroin, is the most widely used and 
researched treatment for heroin dependence. Despite its widespread 
use, longer-term methadone maintenance continues to be dis-
puted. Opinions and practice are strongly influenced by political/
social context. There are a number of updated systematic reviews 
recently published, and a technology appraisal of both methadone 
and buprenorphine maintenance treatments was completed by 
NICE in 2007 (TA114) (NICE, 2007c) (Ia). This considered 31 
systematic reviews and 27 RCTs, dated up to 2005, the majority 
of which concerned methadone maintenance. Studies were based 
in a variety of settings, and the quality of studies included was 
moderate to good. Most studies were of fixed-dose regimes with 
supervised consumption, although some later studies were of flex-
ible dosing regimes. The doses used in the studies ranged from 20–
150 mg daily. The main outcome measures of interest were retention 
in treatment and reduction in use of illicit opioid drugs. Since the 
publication of the NICE technology appraisal, there have been three 
new or updated Cochrane reviews, comparing methadone main-
tenance treatment (MMT) with no opioid replacement treatment 
(Mattick et al., 2009) (Ia); comparing buprenorphine maintenance 
treatment (BMT) with placebo and with MMT (Mattick et al., 2008) 
(Ia); and comparing agonist treatment alone with agonist treatment 
plus psychosocial treatment (Amato et al., 2011a) (Ia).
The research evidence remains firmly based on programmes 
with supervised consumption, whereas in practice, many treat-
ment programmes provide methadone without supervision of con-
sumption. Methadone is available in oral (liquid and tablet) 
formulations and as an injectable preparation. The injectable prep-
aration is considered in the section below on injectable opioid 
maintenance treatment. Tablet formulations are not recommended 
in recent UK treatment guidelines because of the risk of injection 
of crushed tablets and increased risk of diversion (Department of 
Health, 2007). However, studies of the effectiveness of oral main-
tenance therapy do not address different formulations, probably 
because the dangers of misuse and diversion are low in treatment 
programmes in which consumption is supervised.
Goals of treatment. The goals of treatment are initially reten-
tion in treatment and the reduction of illicit drug use and of associated 
risks and harms, including reductions in heroin use (by self-report and 
by analysis of urine or hair samples), injecting, mortality, criminal 
activity and use of other drugs, and improved physical and psycho-
logical health. Maintenance is in itself a treatment; however it is often 
a stage in a long-term care plan with the ultimate goal of abstinence.
Effectiveness. Compared with no opioid replacement, MMT 
appears significantly more effective for retaining patients in treatment 
and for the reduction of heroin use (six RCTs), but not significantly 
more effective in reducing criminal activity (three RCTs); there was a 
trend towards reduction in mortality (four RCTs) (Mattick et al., 2009) 
(Ia). However, it was discussed that the RCTs were not suitable to 
measure the effects on morbidity, mortality and criminality, and that 
large-scale cohort studies show substantial effects on these outcomes. 
The impact of opioid substitution treatment on HIV infection has been 
assessed in a Cochrane review (Gowing et al., 2011). This concluded 
that oral substitute treatment reduces drug-related behaviours with a 
high risk of HIV transmission, but has less effect on sex-related behav-
iours (IIa). Overall, although the number of well-conducted RCTs of 
methadone maintenance treatment is small, the findings are supported 
by many observational studies (Marsch, 1998) (I).
Dosing. Methadone doses ranging from 60–100 mg daily are 
more effective than lower doses (<39 mg) in retaining patients in 
treatment and in reducing use of heroin and cocaine during treat-
ment (Faggiano et al., 2003) (Ia). There are risks associated with 
methadone induction, and starting doses should be significantly 
lower (see Department of Health, 2007, and section on compari-
son of methadone and buprenorphine below).
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Additional therapies. The optimal mode of delivery of 
methadone is unknown. The majority of research studies are 
based on supervised consumption, so the advantages of super-
vision over unsupervised dosing are therefore not established. 
Many programmes involve substantial additional therapies, rang-
ing from regular counselling to integrated programmes including 
family therapy, psychiatric care and help with employment. An 
updated Cochrane review (Amato et al., 2011a) examined the 
effectiveness of agonist maintenance treatment combined with a 
specific psychosocial treatment versus the effectiveness of agonist 
maintenance treatment alone (with standard counselling). Thirty 
four RCTS were included, with a total of 3777 subjects. An ear-
lier version of this review showed a reduction in heroin use with 
addiction of a psychosocial treatment, but the updated version 
with added studies found no evidence of reduction in heroin use 
or number of patients abstinent at the end of follow-up. There is 
no clear evidence of enhancement of agonist maintenance treat-
ments by specific psychosocial treatments (IIa).
Buprenorphine maintenance treatment: BMT
Background. Buprenorphine is a long-acting mu opioid 
receptor partial agonist with improved safety over methadone. 
BMT is a more recently established approach than methadone, 
but there is a growing evidence base supporting equivalent effec-
tiveness to methadone in maintenance treatment. A Cochrane 
review compared buprenorphine maintenance with placebo and 
with MMT (Mattick et al., 2008) (Ia). This review included 24 
studies, all RCTs. In addition, the NICE technology appraisal of 
methadone and buprenorphine, referred to in the section on MMT, 
was published in 2007 (NICE, 2007c) (Ia). The goals of BMT are 
the same as those of MMT: the reduction of illicit drug use and 
associated risks and harms.
Effectiveness. Compared with no opioid agonist replace-
ment, BMT is more effective in retaining patients in treatment 
at low, medium and high doses, but only medium (8–15 mg) and 
high (>15 mg) doses are effective in suppressing heroin use (Mat-
tick et al., 2008) (Ia). In this systematic review buprenorphine 
was also compared with MMT, and appeared to be less effec-
tive in retaining patients in treatment than medium or high-dose 
methadone. However, this may relate to slower induction prac-
tice (described in the section on buprenorphine and methadone 
below). In summary, buprenorphine maintenance is an effective 
treatment for opioid dependence (Ia). A discussion of the advan-
tages and disadvantages of MMT and BMT compared with each 
other is provided in a separate section below.
Dosing. Doses of 8–16 mg buprenorphine are superior to 
lower doses (Ia), 16 mg is superior to 8 mg (Ib), and doses of 
12–24 mg are preferable for maintenance treatment (IV).
Comparison of methadone maintenance and buprenorphine 
maintenance treatments
Effectiveness. The Cochrane meta-analysis conducted to 
evaluate the outcomes for MMT versus BMT (Mattick et al., 
2008) (Ia) consisted mostly of studies of fixed-dose regimes 
for methadone and buprenorphine, but this does not reflect clini-
cal practice in many settings. In addition, most studies were 
done with buprenorphine and not with the combination of 
buprenorphine and naloxone. However, eight studies were 
included that reported flexible dosing, five of which were double-
blind studies. A meta-analysis of these five studies showed lower 
rates of retention of patients for BMT RR 0.83 (95% CI 0.72–
0.95) compared with MMT. The total number of patients in these 
pooled studies was 788, with very little heterogeneity (I2=19.0%, 
p=29). However, over half of the patients in the pooled analysis 
were accounted for by one study n=405 (Mattick et al., 2003) (Ib). 
During this study, conducted between 1996 and 1998, patients 
were inducted onto BMT much more slowly than is now stand-
ard clinical practice. The authors note that the small difference in 
retention rates between BMT and MMT developed in the first 2 
weeks of treatment, with the retention curves essentially parallel 
thereafter. There was no significant difference between MMT and 
BMT on heroin use as confirmed by urinalysis.
Evidence from large representative population samples is also 
informative when making clinical choices between buprenorphine 
and methadone for maintenance. Burns et al. (2009) (III) reported 
on treatment retention rates from the extensive health database in 
New South Wales, Australia. Retention in treatment was better for 
patients maintained on methadone (69% of patients remained in 
continuous treatment at 3 months, 57% at 6 months, and 44% at 1 
year) than buprenorphine (39% at 3 months, 29% at 6 months, and 
21% at 1 year). The hazard ratio of a patient leaving treatment 
with BMT compared with MMT was 1.89 (1.79–1.99: p < 0.001). 
Patients commencing on BMT were more likely to switch medica-
tions at least once (p < 0.001) and have multiple treatment epi-
sodes (p < 0.001) than those on MMT. However, the authors note 
that during this time buprenorphine was a novel treatment, 
whereas methadone maintenance was a well-established practice 
and induction with buprenorphine was often not performed prop-
erly (first dose after withdrawal symptoms occurred followed by 
fast titration to an effective dosage).
Safety. The Australian health database described above 
was analysed with data from the Australian National Deaths 
Index to investigate mortality for individuals on opioid replace-
ment therapy (Degenhardt et al., 2009) (III). The time period 
studied captured 1644 deaths when patients and clinicians had 
a choice between BMT and MMT. Induction onto methadone 
treatment was significantly more hazardous with a crude mor-
tality ratio (CMR) of 26.3 compared with buprenorphine treat-
ment (CMR 2.5: relative risk 0.09, p = 0.04). However, cessation 
CMR was also high (17.3 both groups) and with higher drop-out 
rates for BMT, the overall standardised mortality ratio (SMR) 
was equal (7.3). Again it is possible that both these differences 
could be accounted for by too gentle induction regimes for 
buprenorphine.
In a study of the prevalence of corrected QT (QTc) interval 
prolongation during methadone and buprenorphine treatment, 
4.6% of subjects on methadone had corrected QT intervals > 500 
ms, 15% > 470 ms and 28.9% > 450 ms. All subjects on buprenor-
phine had QTc < 450 ms. There was a positive dose-dependent 
association between QTc interval and methadone dose. All eight 
patients with QTc > 500 ms were prescribed 120 mg or more of 
methadone (Anschersen et al., 2009) (III). Further information, 
debate and guidance is available elsewhere (e.g. Department of 
Health, 2007; Krantz et al., 2009).
The NICE technology appraisal of buprenorphine and metha-
done (NICE, 2007c) (Ia) acknowledges the effectiveness of both 
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MMT and BMT. The authors recommend that the choice of drug 
should be determined on a case-by-case basis, taking into account 
a person’s history of opioid dependence, their commitment to a 
particular management strategy, and the risk benefits of each 
treatment. If both treatments are suitable, the NICE recommenda-
tion is to choose methadone; this recommendation is influenced 
by the current superior performance of methadone in cost-effec-
tiveness analyses.
Summary. Both buprenorphine maintenance and methadone 
maintenance are effective treatments for individuals dependent on 
opioids. There is strong evidence that MMT increases the likeli-
hood of a patient remaining in treatment. However, methadone 
maintenance appears to be a more risky treatment during induc-
tion. In addition, the risk of cardiac effects (prolonged QTc inter-
val) appears higher with methadone, although this risk appears to 
be mainly associated with high-dose (>100 mg/day) methadone 
only, and the risk of related adverse events is not known. This 
may be of particular interest for patients who are prescribed other 
drugs that might prolong the QTc interval, such as antipsychotics. 
Further research is needed with more rapid induction regimes for 
buprenorphine treatment to see whether this removes some of the 
difference in retention rates in the early stages of treatment.
Buprenorphine with naloxone. Buprenorphine is also available 
as a sublingual tablet combined with naloxone in a 4:1 ratio (Sub-
oxone®). The active ingredient in sublingual administration is just 
buprenorphine as the naloxone is not very well absorbed, and 
open-label trials show that the product is free from opioid antago-
nist effects on sublingual administration (Amass et al., 2004) (Ib). 
This product has been used in successful studies in maintenance 
and detoxification (Amass et al., 2004; see Ling et al., 2010) (I), 
including in adolescents and young people (Woody et al., 2008) (I).
If the tablet is misused by crushing and used by intravenous 
injection or intranasally, the naloxone is also active and will cause 
opioid withdrawal symptoms in opioid users. The product is 
therefore intended to discourage injection without interfering with 
effectiveness with sublingual administration. There is evidence 
from naturalistic setting post-dispensing surveillance studies that 
diversion of buprenorphine/naloxone does occur, but that it is less 
prevalent than diversion of buprenorphine alone (McCormick 
et al., 2009; Mammen and Bell, 2009) (III)). There is evidence 
that the buprenorphine/naloxone combination is less likely to be 
injected than buprenorphine alone, although some individuals do 
inject it (Degenhardt et al., 2009) (III).
Slow-release oral morphine. A small number of short-term 
cross-over studies (in special populations, e.g. patients intolerant 
to methadone) of slow-release oral morphine (SROM) have been 
published. These show similar efficacy to methadone, but no 
long-term data are available (Bond et al., 2011; Eder et al., 2005; 
Mitchell et al., 2004; Winklbaur et al., 2008) (Ib). However, expe-
riences in Austria show that SROM is frequently abused and dom-
inates the black market (Beer et al., 2010).
Dihydrocodeine. A single RCT from the UK of dihydrocodeine 
(30 mg equivalent to 2.5 mg methadone) and methadone showed 
dihydrocodeine had a similar treatment retention rate to metha-
done. There was no difference in other measured outcomes, but 
there was a lot of switching in the dihydrocodeine group to metha-
done (Robertson et al., 2006) (Ib).
Injectable opioid maintenance treatment
Background. Injectable opioid treatment (IOT), also known 
as heroin-assisted treatment (HAT), has a long history, which 
is remarkable for variations between national jurisdictions. It 
was used in many parts of the UK during the twentieth century, 
although many had commented on the lack of evidence underpin-
ning treatment. This lack of evidence was reflected in our previous 
BAP guidelines, which stated that IOT could be a possible second-
line approach for those resistant to methadone to improve recruit-
ment and retention (Lingford-Hughes et al., 2004). During the past 
few years a number of studies have expanded the evidence base 
considerably (Ferri et al., 2011) (Ia). In addition to the main find-
ings below, it is of note that study reports contain detailed descrip-
tion of what constitutes optimised oral treatment, and that patients 
randomised to optimised oral treatment also show improvement 
over baseline, in a group often selected for treatment resistance.
Goals of treatment. The general goals of treatment are 
those of other forms of substitute prescribing for treatment of 
opioid dependence; namely, the reduction of illicit heroin use, 
of injecting and other risk behaviours, and of associated harms. 
The focus differs from oral methadone maintenance in terms of 
selection of patients. Because there is considerable evidence sup-
porting oral methadone maintenance, the use of injectable drugs 
has been considered mainly for those who have failed to benefit 
from optimal oral treatment, or who have not been attracted to or 
retained in treatment by oral methadone maintenance programmes 
(though see Haasen et al., 2010 below) (Ib).
Effectiveness: injectable diamorphine. Several open-label 
RCTs of on-site diamorphine provision compared with oral metha-
done have added to the literature base in recent years (Haasen et 
al., 2007 (Ib); March et al., 2006 (Ib); Oviedo-Joekes E, et al., 2009 
(NAOMI) (Ib); Strang et al., 2010 (RIOTT) (Ib); van den Brink 
et al., 2003 (Ib)). The findings of these studies are consistent across 
the different treatment contexts. There is increased retention in IOT/
HAT compared with control groups; reductions in self-reported 
illicit heroin use, and improved outcomes in terms of quality of 
life or health outcome measures. One study reported improved 
outcomes in relation to reduced consumption of alcohol (Haasen 
et al., 2009) (Ib). The Cochrane review by Ferri et al. (2011) (Ia) 
concluded that evidence suggested heroin alongside methadone 
for long-term, treatment refractory opioid users reduced illicit sub-
stance use and criminal activity and possibly reduced mortality and 
increased retention in treatment. However, due to the higher rate of 
serious adverse events, injectable heroin is an option for those that 
have failed previous maintenance treatments.
A number of the studies have reported longer-term follow-up 
outcomes – the study from the Netherlands demonstrates contin-
ued retention at 4 years of 55.7% (95% CI: 47.6–63.8%), and 
response according to the multifactorial dichotomous measure 
was significantly better for patients continuing 4 years of HAT 
compared with patients who discontinued treatment: 90.4% ver-
sus 21.2% (difference 69.2%; odds ratio (OR) = 48.4, 95% CI: 
17.6–159.1). Those who continued HAT treatment also had fewer 
health problems and were more likely to have stopped illicit drug 
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and excessive alcohol use (Blanken et al., 2010) (III). The German 
study also demonstrates improved long-term retention (Verthein 
et al., 2008) (III).
Inclusion criteria are typically those who have failed on oral 
opioid treatment, although the recent German study (Haasen et al., 
2010) (Ib) included a group that was not currently on oral treat-
ment. Controlled studies are now necessary to examine whether 
diamorphine treatment could be considered as one of several 
options in treating severely opioid-dependent patients, regardless 
of previous maintenance treatment experience.
Research reports also include cost utility analyses. The study 
in the Netherlands (Dijkgraaf et al., 2005) (Ib) analysed costs of 
addiction treatment, other health treatment, law enforcement and 
victim costs and found increased quality-adjusted life years 
(QALYs) per patient-year and a cost saving in the diamorphine 
group. However, the outcomes reported remain limited by a rela-
tive reliance on self-reported illicit drug use, with only two studies 
including biological measures. The illicit drug outcome in the 
German trial included urine and hair data but supplemented with 
self-report where these were not available. The recently reported 
UK study, RIOTT, had a reduction in urine tests positive for illicit 
heroin as the primary outcome measure.
Some studies provide data about the frequency of serious 
adverse events (Rehm et al., 2001, 2005) (III), with a lower mor-
tality rate among the treatment group in a Swiss study compared 
with mortality of Swiss opioid users in the general population.
Effectiveness: injectable methadone. The UK study, 
RIOTT (Strang et al., 2010) (Ib), included an arm in which par-
ticipants were randomised to receive injectable methadone. These 
subjects did not show the benefits demonstrated in the injectable 
heroin arm. Previous studies comparing injectable heroin and 
methadone have been observational studies without randomisa-
tion; this is the first randomised comparison.
Effectiveness: injectable hydromorphone. The North 
American study included an arm in which participants received 
hydromorphone to inject, rather than diamorphine. Results 
were equivalent, and the place of oral hydromorphone is being 
evaluated in a follow-up trial. (SALOME, Oviedo-Joekes et al., 
2010) (Ib).
Recommendations: opioid maintenance treatment for opioid 
dependence
Methadone maintenance treatment
x MMT is an appropriate treatment option for opioid-
dependent patients. It is effective in reducing heroin use, 
injecting, and sharing of injecting equipment (A).x MMT is more effective at doses in the range 60–120 mg 
than at lower doses. Following safe induction of metha-
done treatment (see Department of Health Guidelines), 
consideration should be given to higher maintenance 
doses (A).
Buprenorphine maintenance treatment
x BMT is an appropriate treatment option for opioid-depend-
ent patients. It is effective in reducing heroin use (A).
x Buprenorphine should be prescribed at doses of 8 mg or 
higher when used for maintenance treatment (B), and pref-
erably at doses over 12 mg (D).x Where concerns over diversion are paramount, buprenor-
phine/naloxone combinations may be preferred (B).
Choice of methadone or buprenorphine maintenance 
treatment
x Both methadone and buprenorphine are effective treat-
ments. Opioid-dependent patients should be offered 
either medication, guided by patient choice and safety 
considerations. (A).
Additional therapies
x MMT or BMT should be provided in conjunction with psy-
chosocial interventions such as regular counselling (B).
Injectable opioid maintenance treatments
x Highly supervised injectable diamorphine maintenance 
treatment should be considered for patients who have 
failed to respond to optimised MMT or BMT (B).x We do not recommend injectable methadone treatment at 
present, although further studies are warranted (C).
Key uncertainties – opioid maintenance treatment for opioid 
dependence
x How does BMT compare with MMT when high doses and 
faster induction are used?x How significant is the difference in safety of induction of 
methadone and buprenorphine treatment?x What is the clinical significance of the differences in car-
diac effects of methadone and buprenorphine?x Is there a role for injectable opioid maintenance treatment 
for people with severe opioid dependence who have not 
already tried oral MMT or BMT?
Management of withdrawal from opioid drugs
Background. There are good-quality systematic reviews of the 
main pharmacotherapeutic approaches: methadone at tapered doses 
(Amato et al., 2005) (Ia), buprenorphine tapering (Gowing et al., 
2009a) (Ia) and symptomatic treatment with α2 adrenergic agonists 
(Gowing et al., 2009b) (Ia). There is also a small number of small 
RCTs of SROM and one of dihydrocodeine. In addition, there is a 
systematic review of studies addressing the role of psychosocial 
treatments in supporting pharmacological treatment regimes for 
withdrawal (Amato et al., 2011b) (Ia). The main outcomes studied 
are severity of withdrawal symptoms, completion of withdrawal 
and adverse effects of the withdrawal regimen. With a wide variety 
of pharmacotherapeutic options, patient choice can help to guide a 
clinical decision. In 2007, a NICE clinical guideline on opioid 
detoxification was published (NICE, 2007b) (Ia).
Goals of treatment. The goals of treatment are to alleviate 
withdrawal symptoms and to complete withdrawal without 
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adverse effects. In evaluating the outcome of the withdrawal pro-
cess, it is important to distinguish the outcome of withdrawal itself 
from longer-term measures such as continued abstinence from 
heroin. Heroin dependence is often a chronic relapsing disorder.
Effectiveness: methadone at tapered doses. The Cochrane 
review by Amato et al., (2005) (Ia) considered 20 studies includ-
ing methadone versus adrenergic agonists (11 studies), methadone 
versus other opioids (five studies) and methadone versus anxiolyt-
ics (two studies). Methadone at tapered doses is effective in reduc-
ing withdrawal symptoms. Comparing methadone with any other 
pharmacological treatment for opioid withdrawal, there was no 
difference in treatment completion (14 studies, RR 1.08, 95% CI 
0.95–1.24) or abstinence at 1 month follow-up (two studies, RR 
1.17, 95% CI 0.72–1.92). The withdrawal symptoms experienced 
differed according to the medication used and the detoxification 
programme followed. Gowing et al. (2009a) (Ia) reported there 
was a trend towards more successful completion with buprenor-
phine compared with methadone (see below).
Effectiveness: buprenorphine. In the Cochrane review by 
Gowing et al. (2009a) (Ia), buprenorphine appeared equivalent to 
methadone at tapered doses in reducing the severity of withdrawal 
symptoms. The withdrawal symptoms may resolve more quickly 
with buprenorphine. There was a trend for better completion rates 
with buprenorphine (four studies, RR 1.18, 95% CI 0.93–1.49). 
Buprenorphine was better than α2 agonists at ameliorating with-
drawal symptoms. Buprenorphine was associated with lower 
mean peak withdrawal scores (four studies, SMD -0.45, 95% CI 
-0.64 to -0.25, p < 0.001) and lower mean overall withdrawal 
scores (two studies, SMD -0.59, 95% CI -0.79 to -0.39). Comple-
tion of detoxification was more likely with buprenorphine than α2 
agonists (10 studies, RR 1.64, 95% CI 1.31–2.06).
Effectiveness: D2 adrenergic agonists. Withdrawal symptoms 
and withdrawal completion rates are similar for α2 adrenergic ago-
nists and methadone at tapered doses (Cochrane review of 24 stud-
ies including 21 RCTs: Gowing et al., 2009b) (Ia) but α2 adrenergic 
agonists appear inferior to buprenorphine in alleviation of with-
drawal symptoms and in withdrawal completion. Nevertheless, they 
are effective and may be an appropriate choice for patients who 
prefer not to have an opioid drug. Lofexidine is preferable to cloni-
dine because of its more favourable side-effect profile: in particular, 
lofexidine causes hypotension less frequently than clonidine.
Effectiveness: slow release oral morphine. A randomised, 
double-blind, double dummy, parallel group design study com-
pared SROM with methadone for detoxification from opioid 
maintenance treatment. Subjects had a tapered dose reduction of 
SROM or methadone over 16 days. Completion rates were 51% 
(SROM) versus 49% (methadone) (difference between groups 
95% CI -12% to 16%). There was no significant difference in 
craving or signs and symptoms of withdrawal (Madlung-Kratzer 
et al., 2009) (Ib).
Additional therapies or approaches. A Cochrane review 
(Amato et al., 2011b) (Ia) of 11 studies of five different psychoso-
cial interventions and two detoxification medications (buprenor-
phine and methadone) found adding any psychosocial treatment 
to any detoxification treatment showed benefit in terms of reduced 
drop-outs (six studies, RR 0.71, 95% CI 0.59–0.85), use of opiates 
during treatment (four studies, RR 0.82, 95% CI 0.71–0.93) and at 
follow-up (three studies, RR 0.66, 95% CI 0.53–0.82) and clinical 
absences during the treatment RR 0.48 (95%CI 0.38–0.59).
Recommendations: management of withdrawal from  
opioid drugs
x There is a robust evidence base for three approaches to opi-
oid detoxification: methadone at tapered doses, buprenor-
phine, or an α2 adrenergic agonist (usually lofexidine) (A).x The choice of agent will depend on what treatment patients 
are already receiving, for example methadone or buprenor-
phine and individual preference. However, if short duration 
of treatment is desirable, or in patients with mild or uncertain 
dependence, α2 adrenergic agonists may be preferable (A).x SROM is not recommended for opioid detoxification (B).x Ultra-rapid detoxification is not recommended (A).x Pharmacological management of withdrawal should be 
supported by psychosocial treatment (A).
Key uncertainties
x The comparative effectiveness of buprenorphine versus 
methadone.x Optimal treatment regimens for management of with-
drawal using buprenorphine need to be established.
Opiate dependence: relapse prevention and 
maintaining abstinence
There has been very little investigation of the role of pharmaco-
therapy in relapse prevention or maintaining abstinence compared 
with alcohol or stimulants. Naltrexone is the only pharmacother-
apy that has received much attention, but one trial of baclofen (60 
mg/day) in abstinent opioid addicts showed promise in promoting 
abstinence, reducing withdrawal and depressive symptoms 
(Assadi et al., 2003).
Oral naltrexone. A good-quality systematic review by Cochrane 
(Minozzi et al., 2011 (Ia)) and a NICE technology appraisal (NICE, 
2007d) (Ia) have been recently published of naltrexone maintenance 
treatment to support maintenance of abstinence from opioid drugs in 
formerly dependent patients following detoxification. Naltrexone is 
prescribed for oral use as a 50 mg tablet. The studies on which these 
guidelines are based have been of patients prescribed the oral prepa-
ration. However, since the mid-1990s, naltrexone subcutaneous 
implants and intramuscular depots have been developed, although 
they are not yet licensed in the UK as pharmacological products.
The Cochrane reviewers (Minozzi et al., 2011) (Ia) concluded 
that there was no significant difference in treatment retention for 
people treated with naltrexone with or without adjunctive psy-
chosocial therapy compared with placebo with or without psy-
chosocial therapy (six studies, RR 1.43, 95%CI 0.72–2.82). 
There was a significant reduction in illicit heroin use as assessed 
by urinalysis (six studies RR 0.72; 95% CI 0.58–0.90) but the dif-
ference was not statistically significant when comparing 
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the studies of naltrexone versus placebo only. Naltrexone with 
psychosocial treatment showed reduced re-incarceration rates 
compared with psychosocial treatment alone (two studies RR 
0.47, 95%CI 0.26–0.84) but the sample size was small.
The NICE technology appraisal (NICE, 2007d) (Ia) considered 
the Cochrane review together with 13 RCTs and three non-ran-
domised comparative studies. None of the studies were conducted 
in the UK, the studies were of poor to moderate quality, and ran-
domisation was not adequately reported in the RCTs. The degree 
of supervision of medication in the studies was variable. Nine of 
the RCTs studied the effectiveness of strategies to improve reten-
tion on naltrexone, such as incentive vouchers, psychosocial thera-
pies and pharmaceutical agents. The main outcomes reported were 
retention in treatment, relapse rates and re-incarceration rates. 
Given that outcomes for retention and abstinence were likely to be 
higher in clinical practice than reported in the RCTs, as in practice 
treatment is targeted at highly motivated people seeking absti-
nence, NICE concluded that naltrexone is an appropriate treatment 
option in detoxified formerly opioid-dependent people who have 
high motivation and with adequate supervision.
Naltrexone implants and injectable sustained release 
naltrexone. An RCT of 56 patients given a 6-month naltrexone 
implant versus usual aftercare found naltrexone was associated 
with significantly fewer days of heroin use in the 6-month follow-
up period (Kunøe et al., 2009) (Ib). In an RCT of 60 patients, 
Comer et al. (2006) (Ib) found improved retention in treatment for 
injectable sustained-release naltrexone compared with placebo, 
and that retention was higher for those given higher dose naltrex-
one. Superior effects on abstinence from illicit drugs were not 
demonstrated. An RCT of 70 patients reported that a naltrexone 
implant significantly reduced relapse to heroin use and resulted in 
higher blood naltrexone levels compared with oral (Hulse et al., 
2009) (Ib). In a comparison of two separate trials (one of oral 
naltrexone and one of injectable sustained-release naltrexone), 
Brooks et al. (2010) (IIb) concluded that patients with severe 
baseline heroin use showed better outcomes when treated with 
oral naltrexone and intensive psychosocial therapy (behavioural 
naltrexone therapy), while those with less severe baseline heroin 
use showed better outcomes with injectable naltrexone. However, 
these conclusions are uncertain as they are drawn from a compari-
son of the interventions in two separate, though concurrent, trials 
(Brooks et al., 2010) (IIb). Others have reported that many patients 
did not accept a second injection (Kunøe et al., 2010), and plasma 
levels of naltrexone implants have been shown not to remain at 
the targeted levels for the intended time (Hulse et al., 2009).
Concerns have been raised whether naltrexone is associated 
with higher mortality due to suicide or overdoses. One study 
reported that risk of death appeared low during naltrexone treat-
ment; however, it was higher post-treatment compared with meth-
adone (Gibson and Degenhardt, 2007) (III). Studies using the 
implant have shown reduced opioid overdoses (Hulse et al., 2005) 
(III)) and similar mortality to methadone (Ngo et al., 2008) (III)).
Recommendations: naltrexone for treatment of opioid 
dependence
x Oral naltrexone treatment should be considered for for-
merly opioid-dependent people who are highly motivated 
to remain abstinent (D).
Key uncertainties
x How can naltrexone be used most effectively?x What is the role for injectable or depot naltrexone?x Is there a role for other pharmacotherapies?
Benzodiazepine dependence
Background
These guidelines address two differing patient populations: the 
‘therapeutic dose’ users, which includes patients who have been 
prescribed benzodiazepines usually on a long-term basis for a dis-
order such as anxiety or insomnia but who do not abuse their pre-
scription, and the other patients who misuse their prescription 
and/or use illicit benzodiazepines, often in high doses. This may 
include benzodiazepines purchased via the internet (Levine, 
2007). Individuals in either category may be dependent. Abuse of 
benzodiazepines is often associated with other substance abuse 
(e.g. to ‘come down’ from stimulants or to enhance the effect of 
opioids). It is important to establish the presence or absence of 
dependence to help determine whether pharmacological treatment 
is appropriate. Problems consistent with ICD-10 or DSM-IV 
dependence criteria in addition to physiological withdrawal symp-
toms should be elicited. Use patterns in high-dose abusers include 
once-daily dosing to maximise effect, seeking euphoric or seda-
tive effects, escalating dosages, ‘binge’ use and very high self-
reported doses. The withdrawal syndrome can be severe.
The literature and evidence base on the management of ‘thera-
peutic dose’ dependence is far more extensive and systematic than 
for the management of benzodiazepine dependence in illicit, high-
dose users. Transferring the management principles from the 
‘therapeutic dose’ literature to illicit drug users is affected not only 
by the differing clinical picture, but also by the need to avoid 
abuse and diversion of any prescribed medication (Fenton et al., 
2010; Seivewright, 2000).
Management of benzodiazepine dependence 
in ‘therapeutic dose’ users
Management often takes place in primary care and can include 
minimal interventions, gradual dose reduction and gradual dose 
reduction with additional psychological or pharmacological treat-
ments. A stepped approach can be considered, moving through 
minimal interventions to gradual dose reduction and then addi-
tional therapies aimed at specific symptoms. Minimal or brief 
interventions include GPs sending a letter advising patients of the 
need to reduce their benzodiazepine prescription, and provision of 
booklets on self-help strategies. In primary care populations, min-
imal interventions were more effective than routine care in achiev-
ing cessation of benzodiazepine use (three studies, OR = 4.37, CI 
2.28–8.40) increasing the success rates from 5% to 22% (Parr 
et al., 2008)(1a))
Gradual dose reduction alone. Dose-reduction schedules fre-
quently last several weeks, although there is wide variation from 
abrupt discontinuation to discontinuation over a year or more (Oude 
Voshaar et al., 2006a) (Ia). Gradual dose reduction is preferable to 
abrupt discontinuation of benzodiazepine (Denis et al., 2006) (Ia). 
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Switching from a short half-life benzodiazepine to a long half-life 
benzodiazepine before gradual taper does not receive much support 
(Denis et al., 2006 (Ia); Murphy and Tyrer, 1991 (Ib)), but may be 
useful if reduction of short half-life benzodiazepine causes prob-
lematic withdrawal symptoms. In primary care patients who had 
failed to cease benzodiazepine use with minimal intervention, grad-
ual dose reduction was more effective than routine care in achieving 
cessation of use (51% vs. 15%) (Oude Voshaar et al., 2003) (1b). At 
15-month follow-up 36% of those who received gradual dose 
reduction were abstinent based on benzodiazepine prescription 
data, compared with 15% of those who received routine care (Oude 
Voshaar et al., 2006b) (Ib). The British National Formulary contains 
advice on gradual benzodiazepine reducing regimes (see BNF).
Gradual dose reduction and additional 
psychological therapies
Additional psychological therapies increase cessation rates com-
pared with both routine care (three studies, OR = 3.38, CI 1.86–
6.12) and gradual dose reduction alone (seven studies, OR = 1.82, 
CI 1.25–2.67) (Parr et al., 2008) (Ia). The psychological interven-
tions employed in these studies generally included some form of 
group CBT. Compared with gradual dose reduction alone, addi-
tional psychological intervention seemed particularly beneficial 
in patients using benzodiazepines for insomnia and panic disorder 
(1b). In a primary care study Baillargeon et al. (2003) (Ib) reported 
that 77% of patients with chronic insomnia withdrew from benzo-
diazepines with gradual dose reduction and group CBT compared 
with 38% with gradual dose reduction alone (OR = 5.3, CI 1.8–
16.2). The effect persisted at 12-month follow-up. Morin et al. 
(2004) (Ib) found similar results in their study of older adults with 
chronic insomnia. Patients who received gradual dose reduction 
plus CBT were more likely to be benzodiazepine-free after the 
initial intervention (85%), compared with those who received 
gradual dose reduction alone (48%) or CBT alone (54%). For 
panic disorder patients attempting to stop benzodiazepines, suc-
cessful discontinuation was significantly greater in the gradual 
dose reduction plus CBT group, than the gradual dose reduction 
alone group (76% vs. 25%, p < 0.005) (Otto et al., 1993) (Ib). A 
pilot study of CBT delivered via the internet for cessation of ben-
zodiazepine use found good acceptability amongst participants 
but limited take-up (Parr et al., 2011) (IIb).
Gradual dose reduction plus additional pharmacotherapy has 
shown no benefit compared with gradual dose reduction alone in 
a meta-analysis (14 studies, OR = 1.30, CI 0.97–1.73) (Parr et al., 
2008) (Ia). The 14 studies involved 11 different pharmacothera-
pies. Four of the pharmacotherapies showed significant effects on 
benzodiazepine discontinuation rates in single studies (1b). 
Garfinkel et al. (1999) (IIb) reported discontinuation rates of 77% 
with the addition of melatonin compared with 25% with gradual 
dose reduction alone. Rickels et al. (1999) (Ib) added sodium val-
proate, trazodone or placebo to a benzodiazepine taper. At 5 weeks 
post-taper, 79% of sodium valproate and 67% of trazodone, but 
only 31% of placebo patients were benzodiazepine free. These 
differences were not maintained at 12 weeks post-taper. Adjunctive 
paroxetine in patients without major depression increased discon-
tinuation rates compared with gradual dose reduction alone (46% 
vs. 17%) (Nakao et al., 2006) (Ib). However, in patients in primary 
care with depression, adding paroxetine to gradual dose reduction 
did not increase benzodiazepine discontinuation rates above 
gradual dose reduction and placebo, with two-thirds in each group 
ceasing benzodiazepine use. In both groups depressive ratings 
improved with no significant effect of paroxetine, but paroxetine 
did have a beneficial effect on anxiety symptoms (Zitman and 
Couvée, 2001) (Ib). Within the meta-analysis the odds ratio for 
these two paroxetine studies was significant (OR = 1.73, CI 1.01–
2.96) (Parr et al., 2008) (Ib).
Two studies of imipramine with conflicting results were not 
reported in the meta-analysis. In patients with generalised anxiety 
disorder and long-term benzodiazepine use, imipramine increased 
discontinuation rates compared with placebo (83% vs. 37%, p < 
0.01). Buspirone also increased discontinuation rates but non-sig-
nificantly compared with placebo (68% vs. 37%, p < 0.06) (Rickels 
et al., 2000)(1b). However, in patients with panic disorder and 
long-term benzodiazepine use, imipramine or buspirone did not 
significantly increase discontinuation rates (Rynn et al., 2003) (Ib).
Flumazenil (a benzodiazepine antagonist) reduced withdrawal 
symptoms and craving compared with an oxazepam taper over 8 
days in benzodiazepine-dependent patients. Flumazenil-treated 
patients also had greater abstinence rates post detoxification 
(Gerra et al., 2002) (Ib). A flumazenil infusion has also been 
shown to be a safe and effective treatment for benzodiazepine 
withdrawal (Hood et al., 2009) (III).
Management of benzodiazepine dependence 
in high-dose and/or illicit drug users
There is little evidence to guide practitioners in the management 
of this often difficult-to-treat population. Patients should be 
assessed to determine why they are using benzodiazepines, and 
alternative treatment strategies employed for problems such as 
anxiety and insomnia. The presence of alcohol or other illicit drug 
abuse or dependence should be determined.
Benzodiazepine abuse is frequent amongst heroin users and 
those in opioid substitution treatment (Gelkopf et al., 1999; 
Gossop et al., 1998; Jaffe et al., 2004). Ongoing current benzodi-
azepine use is associated with concurrent poorer clinical outcomes 
in this population (Darke et al., 2010) (III). Prescribing of benzo-
diazepines during opioid substitution treatment is common, 
despite a lack of research to support this (Reed et al., 2011) (III). 
Such prescribing can often slip into de facto maintenance despite 
the lack of evidence for this. Use of benzodiazepines in combina-
tion with opioids is associated with increased opioid toxicity and 
performance deficits (Lintzeris et al., 2006; Nielsen et al., 2007) 
(III). A history of prescription of benzodiazepines was associated 
with mortality in Scottish patients receiving methadone in pri-
mary care (McCowan et al., 2009) (III).
Vorma et al. (2002) (Ib) evaluated gradual dose reduction with 
CBT versus an unspecified standard withdrawal regime in high-
dose benzodiazepine users. There was no significant difference in 
discontinuation rates (13% experimental group vs. 27% control 
group, OR 0.4 (0.1–1.5), p = 0.20). Over half the users in each group 
were able to reduce their dose by > 50% (54% vs. 59%). Reductions 
to therapeutic dose levels were maintained (Vorma et al., 2003) 
(Ib)). McGregor et al. (2003) (Ib) conducted an RCT of fixed grad-
ual dose reduction (5–10 mg reduction per day) versus symptom-
triggered diazepam taper methods during inpatient benzodiazepine 
withdrawal treatment in 44 high-dose benzodiazepine users. There 
were no significant differences in abstinence rates (27% gradual 
dose reduction vs. 18% symptom triggered). Both groups showed a 
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reduction in benzodiazepine dosage of 86% to around 14 mg which 
was maintained at 1 month post-discharge. Liebrenz et al. (2010) 
have proposed the need to evaluate agonist substitution treatment in 
high-dose benzodiazepine dependence, where individuals have not 
been able to undergo withdrawal. However, they recognise this 
needs to be balanced against the risks, particularly in regard to nega-
tive effects on cognition and memory.
In an open study in methadone-maintained benzodiazepine-
dependent patients, clonazepam was substituted for their benzo-
diazepine of choice. Patients were then either detoxified from 
or maintained on clonazepam, and outcome measured was self-
reported illicit benzodiazepine use. Illicit benzodiazepine use 
was reduced in the maintenance group compared with the 
detoxification group (Weizman et al., 2003) (III). Wickes et al. 
(2000) (III) described five case studies of clobazam mainte-
nance in methadone-maintained patients with mixed results. 
Clobazam was reported by the patients as being less sedating 
than diazepam.
Other small studies in benzodiazepine-dependent methadone-
maintained patients have examined community reduction and con-
tingency management. McDuff et al. (1993) (III) reported that 12 
out of 22 patients misusing primarily alprazolam completed an 
outpatient reduction procedure which averaged 7.8 weeks. 
Contingency management with rewards for benzodiazepine-free 
urines showed some success. However, results were not main-
tained at the end of the contingency phase (Stitzer et al., 1982) (III).
In clinical practice some services have used carbamazepine 
for inpatient benzodiazepine detoxification in opioid depend-
ence, particularly when the benzodiazepine use has been illicit. 
There is some evidence to support carbamazepine in attenuating 
the withdrawal symptoms from benzodiazepines (Di Costanzo 
and Rovea, 1992; Garcia-Borreguero et al., 1991; Schweizer 
et al., 1991) (IIb).
In practical terms for illicit drug users, there should be an 
extended assessment of their benzodiazepine use, dependence and 
needs with resistance to requests for immediate prescriptions. 
Opioid treatment should be optimised in opioid-dependent benzo-
diazepine users and benzodiazepine needs reassessed after this has 
been achieved. Much benzodiazepine use – even apparently 
dependent benzodiazepine use – resolves if this strategy is fol-
lowed. Benzodiazepines should be detected in serial drug screens. 
If a benzodiazepine prescription is to be issued, there should be a 
clear treatment plan outlining the goals and time frame of treatment. 
A single, long-acting benzodiazepine should be prescribed and initi-
ated on a daily dispensing basis. There is no need to match the high 
self-reported illicit doses. Prescribing need only be moderate dose, 
often far lower than claimed usage even in the presence of concerns 
about withdrawal seizures (Williams et al., 1996) (III). Doses 
greater than 30 mg diazepam equivalent per day should rarely be 
prescribed (Department of Health, 2007). Reduction schedules 
should be negotiated at the outset. In high-dose users, reducing to a 
‘therapeutic’ benzodiazepine dose level may be an appropriate first 
aim (McGregor et al., 2003; Vorma et al., 2002, 2003) (Ib), because 
of the high relapse or drop-out rates with detoxification. Once this 
has been achieved and there is sufficient psychosocial stability, fur-
ther reductions or detoxification can occur. For drug users on ‘main-
tenance’ benzodiazepine prescriptions, the treatment should be 
reviewed, including medication compliance with drug screening, 
and ideally a gradual dose reduction plan put in place.
Z-drugs - zaleplon, zolpidem and zopiclone
There is limited evidence on the prevalence of Z-drug abuse and 
dependence, although dependence has been reported (Hajak et al., 
2003; Jaffe et al., 2004; Victorri-Vigneau et al., 2007) (III). In case 
of dependence, withdrawal should include tapering of dose as 
with benzodiazepines. Broader guidance about their use is also 
available from NICE (NICE, TA77 (Ia)).
Recommendations: benzodiazepine dependence
Establishing the presence or absence of physiological withdrawal 
symptoms and the dependence syndrome is important in deter-
mining whether pharmacological treatment is appropriate.
Management of benzodiazepine dependence in ‘therapeutic 
dose’ users
x In early/mild dependence minimal interventions such as 
advisory letters, other information provision or General 
Practitioner advice should be offered (A).x Where dependence is established, gradual dose reduction 
of prescribed benzodiazepine is recommended (A).x Switching from a short half-life benzodiazepine to a long 
half-life benzodiazepine before gradual taper should be 
reserved for patients having problematic withdrawal 
symptoms on reduction (D).x Additional psychological therapies increase the effective-
ness of gradual dose reduction particularly in individuals 
with insomnia and panic disorder. Consideration should be 
given to targeted use of these interventions (B).x Additional pharmacological therapies do not appear to 
increase the effectiveness of gradual dose reduction. 
However, use of additional pharmacotherapy such as anti-
depressants, melatonin, valproate, and flumazenil should 
be considered on an individual basis (C).
Management of benzodiazepine dependence in high-dose 
and/or illicit drug users
x Maintenance prescribing in illicit drug users cannot be 
recommended on the basis of existing evidence, 
although it may reduce illicit benzodiazepine use in 
some patients (D).x Carbamazepine may be used instead of benzodiazepines to 
control withdrawal symptoms (C).x Doses greater than 30 mg diazepam are rarely necessary, 
and this is sufficient to prevent benzodiazepine withdrawal 
symptoms including withdrawal seizures in very high-
dose benzodiazepine users (D).x Drug screens should be monitored for benzodiazepine and 
other drug use (D).x Reduction of high-dose use to a therapeutic dose level 
may be a useful therapeutic objective in some dependent 
users (D).x Clinicians should remember the potential risks of benzodi-
azepine prescribing in patients co-dependent on alcohol 
and/or opioids (D).
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Key uncertainties
x What is the optimal speed or duration of gradual dose 
reduction?x Is a stepped care model from simpler to more complex 
interventions for benzodiazepine detoxification helpful?x Can additional psychological interventions be delivered 
effectively by alternatives to face-to-face contact?x In illicit drug users, is there a role for benzodiazepine ago-
nist maintenance therapy?x Do modified detoxification strategies for high-dose users 
(e.g. partial reduction and stabilisation at therapeutic dose 
prior to completing reduction) work?
Stimulant drugs: cocaine (including crack), 
methamphetamine and amphetamine
Research on pharmacotherapy for stimulant drugs has focused 
mainly on the treatment of dependent users of the various forms of 
cocaine and amphetamine. Treatment goals are usually the man-
agement of withdrawal and the maintenance of abstinence, 
although the value of substitution treatment with harm reduction 
goals is also considered. Overall, the evidence supporting phar-
macological treatment is weak.
Management of withdrawal from stimulant drugs
Amphetamine. A Cochrane review identified four studies from 
which it was concluded that neither mirtazapine nor amineptine 
were significantly effective in treating amphetamine withdrawal 
(Shoptaw et al., 2009) (Ia). Concerning mirtazapine, one RCT sug-
gested that mirtazapine may reduce hyperarousal and anxiety 
symptoms associated with amphetamine withdrawal (Kongsakon 
et al., 2005) (Ib). However a more recent study failed to find any 
benefit of mirtazapine over placebo (Cruickshank et al., 2008) (Ib).
Cocaine. In a double-blind placebo-controlled trial of amanta-
dine, propranolol and both in combination, for treatment of 
patients with severe cocaine withdrawal symptoms, 119 patients 
were randomly allocated to the four treatment groups (Kampman 
et al., 2006) (Ib). None of the three active treatments (propranolol, 
amantadine or their combination) was significantly more effective 
than placebo in promoting abstinence from cocaine. Among 
patients highly adherent to study medication, propranolol treat-
ment was associated with better treatment retention and higher 
rates of cocaine abstinence compared with placebo.
Cocaine dependence: preventing relapse, 
maintaining abstinence
Psychostimulant drugs. Recently a Cochrane review has been 
published regarding efficacy of psychostimulant drugs for treat-
ment of cocaine dependence (Castells et al., 2010) (Ia). Sixteen 
studies were included, with a total of 1345 patients. Drugs inves-
tigated included dextroamphetamine, mazindol, methylphenidate, 
modafinil and bupropion, methamphetamine and selegiline. Psy-
chostimulant drugs did not improve treatment retention or reduce 
cocaine use. There was a statistical trend in favour of 
psychostimulant drugs in improving sustained abstinence from 
cocaine. Considering all outcomes for individual drugs, only the 
proportion of patients achieving sustained abstinence from 
cocaine was higher with dextroamphetamine, bupropion and 
modafinil at a statistical trend of significance.
Dopamine agonists. Dopamine agonists (amantadine, bro-
mocriptine and pergolide) have been investigated in 17 ran-
domised studies with 1224 participants, with urine tests for 
cocaine use and retention in treatment as the main outcomes of 
interest. A meta-analysis (Amato et al., 2011c) (Ia) found no sig-
nificant difference between interventions. In a study of patients 
with severe cocaine withdrawal symptoms, amantadine was not 
found to be effective in retaining patients in treatment either alone 
or in combination with propranolol (Kampman et al., 2006) (Ib). 
The evidence does not support the use of dopamine agonists.
Anticonvulsants. A Cochrane review included 17 trials with a 
total of 1194 patients (Minozzi et al., 2008) (Ia). Overall, anticon-
vulsants were not found to be effective in improving treatment 
retention, in reducing use of cocaine or craving for cocaine. Anti-
convulsants studied included carbamazepine (six studies), tiagabine 
(three studies), lamotrigine and valproate (one study each) for 
which no significant differences in outcomes were found compared 
with placebo (1b). There were three studies of gabapentin and two 
of phenytoin in which placebo was superior to anticonvulsant (1b). 
Topiramate (one study) may be beneficial in patients capable of 
achieving some level of abstinence (Kampman et al., 2004) (1b).
Disulfiram. Initial studies of the effectiveness of disulfiram for 
patients dependent on both cocaine and alcohol were thought to 
reflect efficacy for alcohol dependence (Carroll et al., 1998, 2000) 
(Ib), but later studies showed an independent effect on cocaine 
use. Disulfiram reduced cocaine use in a placebo-controlled trial 
when given with either interpersonal psychotherapy (IPT) or 
CBT. A combination of disulfiram with CBT was most effective in 
reducing cocaine use for those patients who were not alcohol 
dependent. Disulfiram appears to reduce the rewarding effects of 
cocaine use (Baker et al., 2007) (III). Other trials of disulfiram 
have been based on patients with concurrent alcohol dependence 
or opioid dependence (maintained on methadone or buprenor-
phine); for those with concurrent alcohol and cocaine dependence, 
a combination of disulfiram and naltrexone was most likely to 
result in three consecutive weeks of abstinence from alcohol and 
cocaine (Pettinati et al., 2008a) (Ib).
Antidepressants. A range of antidepressant drugs has been 
investigated for treating cocaine dependence or problematic use, 
including desipramine (17 trials, 75–300 mg); fluoxetine (five tri-
als, 20–60mg); nefazodone (<400 mg) and ritanserin (10 mg) (two 
trials each); bupropion (three trials, 300 mg) and one trial each 
with imipramine (150–300 mg), buspirone (30 mg), gepirone 16 
mg), paroxetine (20 mg), citalopram (20 mg), venlafaxine (<150 
mg), selegiline (20 cm2 patch containing 1.0 mg/cm2), tryptophan 
(8 g/day), sertraline (110 mg) and imipramine (150–300 mg). 
Some 37 randomised studies with (3551 participants) have been 
meta-analysed (Pani et al., 2011) (Ia). Studies of patients with 
concurrent opioid dependence were studied separately, but yielded 
similar results. Desipramine performed no better than placebo in 
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terms of retention in treatment, although there was a non-signifi-
cant trend in favour of desipramine in terms of cocaine-free 
urines. One trial favoured imipramine over placebo in terms of 
clinical self-report, and one trial suggested that fluoxetine main-
tained people in treatment. However, there was no significant 
effect when selecting studies using operationally defined diagnos-
tic criteria. Pani et al. (2011) concluded that the evidence did not 
support the efficacy of antidepressants. There has since been a 
small open trial of reboxetine which showed some improvement 
but also adverse effects (Szerman et al., 2005) (III). In summary, 
there is no evidence to support the use of antidepressants for 
cocaine dependence (1a).
Antipsychotic drugs. A meta-analysis and systematic review 
included seven small studies (293 participants), with risperidone, 
olanzapine and haloperidol (Amato et al., 2007) (Ia). No signifi-
cant differences were found for any of the efficacy measures com-
paring any antipsychotic drug with placebo. The studies of 
haloperidol and olanzapine were too small to give conclusive 
results (Amato et al., 2007).
Baclofen. Initial studies demonstrating reduced craving and 
cocaine use in patients with high baseline cocaine use have not 
been supported by a multicentre RCT of baclofen (60 mg/day) in 
an 8-week programme for severely dependent users (Kahn 
et al., 2009) (1b). The effectiveness of baclofen at higher doses is 
unknown (see alcohol section), as is effectiveness as a relapse pre-
vention agent in patients already cocaine-abstinent.
Cocaine vaccine. Cocaine vaccines are in development: high 
levels of anti-cocaine antibodies can sequester cocaine and facili-
tate inactivation. The cocaine vaccine has been studied in metha-
done-maintained opioid-dependent patients. Only 38% achieved 
target levels of IgG, but there were significantly more cocaine-
free urines in these patients. The blockade achieved was only 
short term, and further work on the vaccine is required (Martell 
et al., 2009) (Ib).
Amphetamine dependence: preventing 
relapse, maintaining abstinence
Antidepressants. Randomised double-blind trials have investi-
gated fluoxetine, amlodipine, imipramine and desipramine. 
Fluoxetine may decrease craving in the short term, and imipra-
mine may increase adherence to treatment in the medium term. 
No reduction in amphetamine use or other benefits were identified 
(Srisurapanont et al., 2001) (Ia).
Dexamphetamine. Substitute prescribing with  dexamphet-
amine or methylphenidate for treatment of amphetamine depen-
dence has been reported as possibly beneficial in small studies 
(Elkashef et al., 2008) (IV). Descriptive studies (see Lingford-
Hughes et al., 2004) suggest benefits in terms of reduction in 
amphetamine use and in injecting; however, all are small, and five 
are retrospective and rely on self-reported outcomes. In one pilot 
RCT (Shearer et al., 2001) (Ib) 41 long-term dependent amphet-
amine users were randomised to dexamphetamine (up to 60 mg) 
or weekly counselling only. Reductions in use were seen in both 
groups without discernable differences, but the study lacked 
power.
Modafinil. Shearer et al. (2009) (Ib) studied 80 methamphet-
amine-dependent subjects allocated randomly to modafinil (200 
mg/day) (n = 38) or placebo (n = 42) under double-blind condi-
tions. There were no differences in methamphetamine abstinence, 
craving or severity of dependence, although medication-compliant 
subjects tended to provide more ‘clean’ urine samples over the 
10-week treatment period (p = 0.07). There were significant reduc-
tions in systolic blood pressure (p = 0.03) and in weight gain (p = 
0.05) in modafinil-compliant subjects compared with placebo.
Methylphenidate and aripiprazole. Tiihonen et al. (2007) (Ib) 
compared aripiprazole (15 mg/day), slow-release methylpheni-
date (54 mg/day), and placebo in 53 individuals with intravenous 
amphetamine dependence over 20 weeks. Patients who received 
methylphenidate had significantly fewer amphetamine-positive 
urine samples than patients who had received placebo (OR = 0.46, 
95% CI 0.26–0.81). In contrast, aripiprazole patients had signifi-
cantly more amphetamine-positive urine samples than the placebo 
group (OR = 3.77, 95% CI 1.55–9.18). The study was terminated 
early because of these effects of aripiprazole.
Disulfiram. Because of its potential in treating cocaine depen-
dence, the effect of disulfiram on amphetamine use was studied in 10 
subjects (Sofuoglu et al., 2008) (IIb) where it was found to enhance 
the subjective effects of dextroamphetamine, including anxiety, sub-
jective ‘high’ feeling, ‘bad drug effects’ and ‘drug liking’.
Naltrexone. One RCT reported that naltrexone (50 mg/day) sig-
nificantly increased the number of amphetamine-negative urines 
compared with placebo (Jayaram-Lindström et al., 2008) (Ib).
Recommendations: stimulant drugs
x There is no convincing evidence supporting the use of 
pharmacological treatment for amphetamine and cocaine 
abuse and dependence. Psychosocial interventions such as 
CBT and contingency management remain the mainstay 
of treatment (S).x We do not recommend the use of dopamine agonists, anti-
depressants or anticonvulsants (A).x Disulfiram is not yet an established treatment for cocaine 
use, but clinicians should be alert to further studies as the 
current small evidence base is of interest (C).x There is no clear evidence to support substitute prescrib-
ing of dexamphetamine for treatment of cocaine or 
amphetamine dependence, but definitive studies are war-
ranted and clinicians should be alert to further studies (D).
Key uncertainties
x When to use pharmacological strategies?x Which are optimal psychosocial interventions?x Is there a role for disulfiram, and if so, what is the appro-
priate dose?
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x Is there a role for baclofen at higher doses, or in relapse 
prevention?x Is there a role for naltrexone?x Is there a role for propranolol?
‘Club’ drugs
Ecstasy (MDMA)
Ecstasy dependence is rare, and there are no specific trials exam-
ining it. Depressive symptoms in MDMA users may lead to an 
antidepressant being prescribed, but it is likely to be ineffective in 
many (see comorbid section).
A MixMag 2009 Survey revealed that 19% (227/1197) MDMA 
users had ever been prescribed antidepressants, 9.5% (113/1180) 
had ever taken MDMA while on antidepressants and 8.8% in the 
last 12 months. This is of concern due to risks of interaction, 5HT 
syndrome, as well as poor efficacy. As for other comorbid disor-
ders, the advice is to delay diagnosis of depressive disorder until 
2–4 weeks abstinent.
Recommendations: Ecstasy
x There is absence of any evidence for a role for pharmaco-
therapy in treating Ecstasy dependence or withdrawal. 
Psychosocial approaches are recommended (S).x Assessment of whether the individual has a depressive dis-
order should occur in absence of Ecstasy use (S).
Key uncertainties
x Whether long-term use incurs any impact on neurotrans-
mitter systems, for example the serotonergic system, that 
could be prevented or ameliorated with pharmacotherapy?
Gamma-hydroxybutyric acid (GHB) and its precursors
Pharmacological treatments for users of gamma-hydroxybutyric 
acid (GHB) and its precursor drugs gamma-butyrolactone (GBL) 
and 1,4-butanediol are currently directed at management of the 
withdrawal syndrome. This is similar to that of alcohol, but 
sometimes with particularly marked neuropsychiatric symptoms 
and autonomic instability that can be life-threatening. For a com-
prehensive review of GHB abuse, dependence and withdrawal, 
see Gonzalez and Nutt, (2005), McDonough et al. (2004) and 
Wojtowicz et al. (2008) and the case series of 19 patients under-
going GBL withdrawal (Bell and Collins, 2011) (III). Some 
patients have required urgent intensive care as a result of severe 
delirium, seizures and rhabdomyolysis. Currently there are no 
clear predictors of who might develop such difficulties, and so 
facilities to admit patients for acute medical care should always 
be available.
The majority of case reports are with benzodiazepines but high 
initial doses (40–120 mg diazepam in first 24 h, sometimes more) 
are usually needed (Bell and Collins, 2011; McDonough et al., 
2004). There are case reports of the use of other sedative agents, 
mainly pentobarbital, in patients resistant to treatment with benzo-
diazepines (McDonough et al., 2004; Schneir et al., 2001; Sivilotti 
et al., 2001) (III). A recent study reported a titration and tapering 
procedure in 23 moderate to severe GHB-dependent inpatients 
whereby pharmaceutical GHB replaced illicit GHB, which was 
then tapered over 1 week (de Jong et al., 2012) (III). Patients 
experienced low withdrawal symptoms and none developed psy-
chosis or delirium. Given that GHB/GBL have GABA-B agonist 
activity, baclofen may be used in withdrawal in much the same 
way that benzodiazepines are used in alcohol withdrawal, particu-
larly as it is much safer than barbiturates (see case report 
LeTourneau et al., 2008) (III). Bell and Collins (2011) have 
reported a case series of 19 patients treated for withdrawal from 
GBL, most of whom were outpatients. They used high-dose diaz-
epam (mean dose in the first 24 h 75 mg) together with baclofen 
(10 mg tds). Sixteen patients completed withdrawal, although sev-
eral had lapses to GBL use during treatment. One patient devel-
oped delirium that required admission to an inpatient detoxification 
unit. Insomnia, anxiety and depression were common persisting 
symptoms for some weeks after withdrawal.
Recommendations: GHB/GBL
x Planned outpatient withdrawal from GHB/GBL should be 
approached with caution and particular attention given to 
previous withdrawals, comorbid dependence (particularly 
to benzodiazepines), physical and psychiatric health and 
social support (S).x Successful management of withdrawal has been achieved 
using high-dose benzodiazepine regimes, either alone or 
in conjunction with baclofen. This approach is the treat-
ment of choice at present (C).x Although outpatient treatment is possible, there are sev-
eral case reports of severe withdrawal syndromes with 
life-threatening complications. Consideration should 
therefore be given to inpatient admission for management 
of withdrawal and ability to admit patients for acute medi-
cal care should always be available (S).
Key uncertainties
x What is the optimal assessment and treatment regimen to 
prevent complications of withdrawal?x What are the indicators for suitability for inpatient or out-
patient withdrawal?x What is the potential utility of GHB/sodium oxybate in 
managing withdrawal?
Cannabis
Dependence on cannabis is third behind that to tobacco and alco-
hol in terms of population prevalence, with up to 1% of the 
European population meeting criteria (Wittchen et al., 2011). 
Research related to pharmacological treatment of cannabis abuse 
and dependence focuses mainly on alleviation of withdrawal 
symptoms to aid quit attempts (Budney et al., 2004; Cui et al., 
2001; Hart, 2005). The symptoms are primarily emotional and 
behavioural, although appetite change, weight loss, and physical 
discomfort are also reported. An assessment scale for cannabis 
withdrawal has recently been developed by Allsop and colleagues 
(2011). Pharmacological approaches and studies have recently 
been reviewed (van den Brink, 2012).
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Treating cannabis withdrawal
Oral tetrahydrocannabinol (THC or dronabinol). There are 
two small randomised, double-blind placebo-controlled trials of 
oral tetrahydrocannabinol (THC) (Budney et al., 2007; Haney 
et al., 2004) (Ib) which reduced withdrawal symptoms, including 
reduction in sleep problems and anxiety. Doses ranged from 30–
90 mg daily. Reductions in craving and depressed mood were 
greater with higher doses.
Haney et al. (2008) compared oral THC (60 mg) with placebo, 
with lofexidine (2.4 mg) and with a combination of THC and lofex-
idine treatment under laboratory conditions with mixed results. The 
combination of lofexidine and oral THC produced the most robust 
improvements in sleep and decreased withdrawal symptoms, crav-
ing, and relapse. In a more recent, larger study (Levin et al., 2011) 
(Ib) 156 cannabis-dependent adults were enrolled in a randomised, 
double-blind, placebo-controlled, 12-week trial of dronabinol 20 
mg twice a day or placebo started after 1 week of abstinence. There 
was no significant difference between treatment groups in the pro-
portion of participants who achieved 2 weeks of abstinence. 
Dronabinol was well tolerated, improved treatment retention and 
provided better relief from withdrawal symptoms than placebo.
Lithium carbonate. There are two small open-label studies of 
the use of lithium carbonate (Bowen et al., 2005; Winstock et al., 
2009) (IIb) that suggest potential benefit in alleviating cannabis 
withdrawal and a RCT is underway.
Anticonvulsants. No clear benefit has been found in two small 
randomised double-blind placebo controlled trials of divalproex 
sodium. Haney et al. (2004) found it reduced craving, but 
increased ratings of irritability, anxiety and tiredness, whereas 
Levin et al. (2004) found no benefit (Ib).
Antidepressant drugs. The antidepressant drugs bupropion, 
fluoxetine and mirtazapine have been tested in placebo-controlled 
trials. In two studies of bupropion (Carpenter et al., 2009 (106 sub-
jects); Haney et al., 2001 (10 subjects)) (Ib) no benefit was found, 
and bupropion worsened irritability, sleep disturbance and depressed 
mood. Riggs et al. (2007) (III) found no benefit from fluoxetine in 
depressed adolescents with substance use disorders. In a small pla-
cebo-controlled laboratory study of mirtazapine, Haney et al. 
(2010) found mirtazapine improved sleep and food intake but not 
other withdrawal symptoms or relapse to cannabis use.
To date there appears to be no substantial evidence for antide-
pressant prescribing to aid cannabis withdrawal. Depressed mood is 
more common in cannabis users and therefore clinicians are likely 
to consider antidepressant use. It is possible however that prescrib-
ing some antidepressants such as SSRIs and bupropion may exac-
erbate anxiety and insomnia in the early stages of withdrawal.
Cannabinoid receptor antagonists. A study of rimonabant 
was discontinued because of significant medication side effects 
(Montebello R, personal communication). It is unknown whether 
other antagonists would have a similar effect.
Baclofen. In a small human laboratory study of baclofen in can-
nabis intoxication, withdrawal and relapse (Haney et al., 2010), 
baclofen decreased craving for tobacco and cannabis in a dose-
dependent fashion, but had little effect on mood during abstinence 
and did not decrease relapse. Baclofen also worsened cognitive 
performance.
Buspirone. In a single controlled trial of buspirone (50 partici-
pants), there was a significant difference in favour of buspirone in 
terms of negative urine drug screens achieved (McRae-Clark 
et al., 2009) (Ib).
Hypnotic medications. Sleep difficulties are commonly 
reported by people attempting to quit cannabis use. Some practi-
tioners use a low-dose benzodiazepine to aid sleep in the short 
term during cannabis withdrawal, although there is a risk of abuse 
and dependence. A laboratory study of extended-release zolpidem 
(Vandrey et al., 2011) demonstrated that zolpidem attenuated the 
effects of cannabis withdrawal on sleep architecture, and improved 
sleep efficiency but not sleep latency.
Recommendations: cannabis withdrawal
x At present there is no clear evidence base for pharmaco-
logical treatment of cannabis withdrawal and no pharma-
cological treatment can be recommended (D).x We do not recommend the use of antidepressant drugs for 
the treatment of cannabis withdrawal (D).
Key uncertainties
x Which pharmacotherapeutic approaches for the manage-
ment of cannabis withdrawal should be given priority, for 
example, oral THC, lithium, buspirone?x What are the optimal dose, dosing frequency, and partici-
pant characteristics for the use of oral THC?x What are the risks and benefits of short-term hypnotic pre-
scribing (such as benzodiazepines or zolpidem)?x Are combination medication regimens aimed at individual 
symptoms helpful?x What might be the role of cannabinoid receptor-specific agents?x What is the clinical utility of psychometrically validated 
scales for assessing the symptomatology and severity of 
cannabis withdrawal?x Which approaches are most helpful for those with comor-
bid mental illness, physical health and other substance use 
disorders such as co-occurring cigarette smoking?x What is role of medication in preventing relapse?
Polydrug use
In clinical practice, it is common for patients to abuse or even to 
have developed dependence on more than one drug. One approach 
is to apply evidence-based treatments for each drug simultane-
ously or sequentially. However, it would be helpful to have a clear 
evidence base for a treatment strategy for polydrug users, so we 
have examined treatment studies including patients who were 
using more than one drug in the month prior to starting treatment.
Opioids and cocaine
Comparison of methadone and buprenorphine maintenance. 
Cocaine reduces serum methadone concentration (Tennant and 
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Shannon, 1995), and although some patients may respond to an 
increase in methadone dose, the cocaine use itself should be addressed. 
Three RCTs have compared methadone with buprenorphine mainte-
nance treatment for patients using both opioids and cocaine. One RCT 
(Schottenfeld et al., 2005) (Ib) found that methadone at an average 
dose of 80 mg was superior to buprenorphine average dose 15 mg, 
whereas two studies showed no difference between the two treatments 
in opioid or cocaine-free urines at 26 weeks (Strain et al., 1994) and 24 
weeks (Schottenfeld et al., 1997) (Ib).
Use of two drugs for treatment of opioid dependence and 
cocaine use. There have been a number of randomised placebo-
controlled trials adding a treatment for cocaine use to methadone or 
buprenorphine treatment. These have been largely negative in terms 
of reducing cocaine use. These include adding bupropion to metha-
done maintenance (Margolin et al., 1995) (Ib), desipramine to meth-
adone or buprenorphine (Kosten et al., 2003; Oliveto et al., 1999) 
(Ib), and gabapentin to methadone (González et al., 2007) (Ib).
By contrast, significant reductions in cocaine use have been 
found in two studies of disulfiram (250 mg/day) combined with 
methadone maintenance (Petrakis et al., 2000) (Ib) and buprenor-
phine maintenance (George et al., 2000) (Ib). A more recent dou-
ble-blind, placebo-controlled RCT of disulfiram for treatment of 
cocaine abuse in methadone-stabilised patients found increasing 
cocaine use in patients treated with low-dose disulfiram (62.5 mg 
or 125 mg daily) and decreasing cocaine use only in patients given 
high-dose disulfiram (250 mg; Oliveto et al., 2011) (Ib).
Two studies adding tiagabine to methadone maintenance treat-
ment (González et al., 2003, 2007) (Ib) have found significant 
reductions in cocaine use at 12-week follow-up. One study of 
bupropion and/or contingency management added to methadone 
showed significant reductions in cocaine use at 25 weeks only in 
the group receiving methadone plus bupropion plus contingency 
management (Poling et al., 2006) (Ib).
There is a published 24-week phase RCT of a cocaine vaccine 
in methadone maintenance patients (Martell et al., 2009) (Ib). 
Five vaccinations were given over 12 weeks; 38% of patients 
achieved high IgG levels with significant reduction in cocaine 
use, although this treatment would be expected to remain effective 
for 2 months only.
Opioids and alcohol
A systematic review of the effect of methadone maintenance treat-
ment on alcohol consumption (Srivastava et al., 2008) (Ia) exam-
ined 15 studies: three found an increase, three found a decrease, 
and nine found no difference in the alcohol consumption. Nava 
and colleagues (2008) (IIb) compared high-dose methadone (200 
mg) with high-dose buprenorphine (32 mg) in an open RCT of 218 
patients over 1 year. Those on buprenorphine reported less craving 
and lower alcohol consumption than those on methadone. There is 
evidence from the studies of cocaine and opioid users described 
above that disulfiram reduces alcohol consumption in conjunction 
with methadone if patients are prepared to stop drinking alcohol.
Opioids and benzodiazepines
Studies mainly examine detoxification from both substances in 
inpatient settings but there are no RCTs. de Wet and colleagues 
(2004) (III) reported that opioid patients using benzodiazepines 
experienced more severe withdrawal symptoms, including opioid-
specific withdrawal symptoms, than users of opioids alone during 
inpatient detoxification. A pilot study of 27 patients comparing 
buprenorphine plus carbamazepine with oxazepam plus carba-
mazepine (Schneider et al., 2000) (III) showed similar completion 
rates for both groups but superior symptom relief in the buprenor-
phine/carbamazepine group.
Reed and colleagues (2007) (IIb), in a preliminary study of 
patients undergoing inpatient detoxification, found superior com-
pletion rates and less severe withdrawal symptoms in opioid and 
benzodiazepine-dependent patients where buprenorphine was 
used for management of withdrawal rather than methadone. 
Kristensen and colleagues (2006) (IIb) compared a buprenorphine 
and valproate regime with a clonidine and carbamazepine regime 
in an open-label study of inpatient detoxification from both opi-
oids and benzodiazepines. Earlier symptom relief was achieved 
with the buprenorphine/valproate combination.
Studies in community settings are limited. A study of benzodi-
azepine detoxification for those regularly using benzodiazepines, 
mostly alprazolam, reported 12 out of 22 methadone patients were 
successful (McDuff et al., 1993) (IIb). Weizman and colleagues 
(2003) (III) compared detoxification from benzodiazepines using 
clonazepam with clonazepam maintenance treatment in patients 
engaged in a methadone maintenance programme. Low-dose 
maintenance appeared more successful than detoxification in pre-
venting illicit benzodiazepine use (66 patients followed for 1 year).
Alcohol and cocaine
This is a common comorbidity and challenging to treat.
Naltrexone. Naltrexone appears ineffective in reducing either 
alcohol or cocaine use in alcohol and cocaine users when used at 
daily doses of 50 mg (Hersh et al., 1998; Schmitz et al., 2004) (Ib) 
or 100 mg (Schmitz et al., 2009) (Ib). Higher doses of naltrexone, 
such as 100 mg/day and 150 mg/day, may have beneficial effects 
in combined dependence, particularly in men (McCaul, 1996; 
Oslin et al., 1999; Pettinati et al., 2008b) (Ib). Those with higher 
severity of cocaine but not alcohol dependence were less likely to 
achieve abstinence from cocaine (Ahmadi et al., 2009). Early ben-
efit at 2 months was lost at 6 months (McCaul, 1996) (Ib). Schmitz 
et al. (2009) found no differences between naltrexone (100 mg/
day) and placebo added to contingency management. Poor com-
pliance and engagement in treatment is consistently found.
Disulfiram. Disulfiram at daily doses of 250–500 mg appears to 
improve treatment retention and duration of abstinence from both 
alcohol and cocaine (Carroll et al., 1998) (Ib) with a sustained 
response at 12 months for cocaine, but not alcohol (Carroll et al., 
2000) (Ib). The effect of disulfiram on reducing cocaine is inde-
pendent of its effect on alcohol consumption, although those that 
did best stopped or reduced their drinking.
Naltrexone/disulfiram combination. Pettinati et al. (2008a) 
(Ib) conducted an RCT of disulfiram (250 mg/day) alone, naltrex-
one (100 mg/day) alone, disulfiram/naltrexone in combination, 
and placebo (208 patients). Medication adherence was low in all 
groups. Patients taking disulfiram either alone or in combination 
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were more likely to abstain from alcohol and cocaine. Patients 
taking the combination of disulfiram and naltrexone were the 
most likely to achieve three consecutive weeks abstinence from 
alcohol and cocaine. All medications were well tolerated, with no 
serious adverse events.
Recommendations:
Opioids and other harmful substance use, abuse or 
dependence
x There is currently inadequate evidence to favour either 
MMT or BMT for patients who use both opioids and 
cocaine or alcohol. Either treatment is appropriate for the 
management of the opioid dependence (A).x Disulfiram may be helpful for patients committed to absti-
nence from alcohol (D).x There is no evidence to support adding bupropion, desip-
ramine, amantadine or gabapentin to methadone or 
buprenorphine maintenance treatment to reduce cocaine 
or alcohol use in opioid-dependent cocaine or alcohol 
users (B).x Benzodiazepine withdrawal and opioid withdrawal can be 
carried out concurrently in an inpatient setting (B).x Buprenorphine is superior to methadone for relief of opi-
oid withdrawal symptoms when opioid and benzodiaze-
pine withdrawal is carried out concurrently in an inpatient 
setting (B).
Alcohol and cocaine
x Disulfiram should be considered for patients with concur-
rent alcohol and cocaine abuse/dependence (C).x A combination of disulfiram and naltrexone may be con-
sidered for patients with concurrent alcohol and cocaine 
abuse/dependence (D).
Key uncertainties
x The appropriate dose response of disulfiram remains to be 
established.x What is the potential of tiagabine as a treatment for cocaine 
and opioid dependence?x The potential of a cocaine vaccine needs further study.x Is high-dose buprenorphine superior to high-dose metha-
done in terms of reduction of craving for alcohol and of 
alcohol consumption?x There is inadequate evidence to guide the management of 
benzodiazepine withdrawal in opioid-dependent patients 
in community settings.
Nicotine dependence
Nicotine dependence is recognised in ICD-10 and DSM-IV as a 
psychiatric disorder. The defining features include failed attempts 
to abstain, powerful urges to use nicotine, and withdrawal symp-
toms on cessation. An estimated 80% of cigarette smokers are 
classifiable as dependent by DSM-IV criteria, and the treatment of 
nicotine dependence has been investigated in a large number of 
well-conducted RCTs. There are high-quality systematic reviews 
(Moore et al., 2009; Stead et al., 2008) (Ia) and treatment guide-
lines (USDHHS, 2008; West et al., 2000).
The main harmful effects of nicotine dependence arise from 
long-term health effects of tobacco constituents other than nico-
tine, and this is particularly true for smoking cigarettes. The ben-
efits and sustainability of reductions in cigarette consumption are 
uncertain; therefore the primary goal of treatment is permanent 
cessation of smoking. An abstinent period of 6 months or longer is 
widely regarded as an acceptable marker for successful cessation, 
in that it permits a quite accurate prediction of permanent cessa-
tion: relapse after this time is estimated at around 50% over a life-
time (West et al., 2005). However, there has been more recent 
interest in the use of nicotine replacement products for patients 
attempting to reduce their cigarette consumption (Nicotine 
Assisted Reduction in Smoking) prior to planning a specific quit 
attempt, as well as for those who are ready to quit. In this strategy, 
the long-term goal remains permanent cessation, but a short-term 
goal may be to reduce smoking by at least 50%, with a review of 
the quitting goal after 3 months.
Nicotine replacement therapy
Nicotine replacement therapy (NRT) consists of products that 
allow smokers to obtain therapeutic doses of nicotine without 
other toxins, to provide a partial substitute for smoking and to aid 
smoking cessation. Nicotine from the product binds to nicotinic 
acetylcholinergic receptors in the central nervous system in a 
dose-dependent manner. This reduces urges to smoke and nicotine 
withdrawal symptoms, and partially blocks the rewarding effect 
of a cigarette if a lapse occurs.
Products and dosing. A variety of nicotine replacement prod-
ucts are available. These include nicotine-containing gum (2 mg 
and 4 mg), transdermal patches (varying doses), inhalator/inhaler, 
nasal spray (0.5 mg per dose, usually administered two doses at a 
time), sublingual tablet, mouth-spray, lozenge and now electronic 
cigarettes (though these are not typically seen as anti-smoking 
devices). These products have differing rates of delivery of nico-
tine. Transdermal patches provide the slowest delivery. The nasal 
spray and electronic cigarette provides the fastest delivery (tmax 
is around 10 min), although the gum, inhalator, lozenge, mouth-
spray and sublingual tablet typically achieve peak levels within 30 
min of use. In many countries, including the UK, products may be 
used singly or in combination (usually of the transdermal patch 
plus a faster-acting product). In some countries, such as the USA, 
combination use is not permitted, according to the label.
When used with a quit attempt, NRT should be started on, or 
up to 2 weeks prior to, the target quit date. It should be used for a 
minimum of 8 weeks, and then as long as is necessary. As 
described above, NRT can be used with the goal of smoking 
reduction, where there is a long-term goal of smoking cessation: 
the aim is to reduce cigarette consumption by at least 50%, and the 
quitting goal should be reviewed after 3 months.
Clinical effectiveness. All the above forms of NRT can help 
people who make a quit attempt to increase their chances of suc-
cessfully stopping smoking. From the findings of a Cochrane 
review (Stead et al., 2008) (Ia) based on 111 trials with over 40,000 
participants, NRTs have been estimated to increase the rate 
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of quitting by 50–70%. There is evidence (from six trials) that 
combining a nicotine patch with a rapid-delivery form of NRT 
(nicotine combination therapy) is more effective than a single type 
of NRT (nicotine monotherapy). Pooled evidence from four trials 
indicates that starting a nicotine patch for a brief period before the 
target quit date significantly increases the rate of cessation com-
pared with initiating the patch on the quit day. Indirect compari-
sons of a large number of trials showed no difference in success 
rates between regimes involving abrupt cessation of nicotine patch 
use and those in which tapered doses of nicotine patch were used.
A further systematic review (Moore et al., 2009) (Ia) concen-
trated on studies of NRT used in patients who aim to reduce smok-
ing but have no short-term goal to quit smoking. Seven RCTs 
were included, with a total of 2767 patients. The longer-term quit 
rate was approximately doubled in those who had received NRT 
compared with those who had used placebo. Most of the evidence 
comes from trials with regular behavioural support and monitor-
ing. There is evidence that NRT can be effective when given with-
out behavioural support (Hughes et al., 2011). However, general 
population studies have produced mixed findings (West and 
Fidler, 2011; West and Zhou, 2007) (IIb).
Dosing. In highly dependent smokers there appears to be a sig-
nificant benefit of 4 mg gum compared with 2 mg gum (from four 
trials), but only marginal evidence of a benefit from higher doses 
of patch (from seven trials) (Stead et al., 2008) (Ia).
Safety. NRT delivers pure nicotine, which is just one of the com-
ponents smokers already obtain from cigarettes. NRT does not pose a 
cancer risk and is safe in patients with stable coronary heart disease 
(Stead et al., 2008) (Ia). It is effective in helping smoking cessation in 
patients with chronic obstructive pulmonary disease (van der Meer et 
al., 2001) (Ia). NRT may present some risk to the foetus (Lumley et 
al., 2009) (Ia), but this may be less harmful to the foetus than smoking 
during pregnancy (see section on pregnancy). A minority of smokers 
transfer dependence from cigarettes to NRT. Such patients would 
probably resume smoking if they could not continue NRT use.
Additional therapies and context of treatment. Additional 
behavioural support improves overall success rates but does not 
appear to be required for NRT to be effective (Stead et al., 2008) 
(Ia). There is some evidence to suggest that abstinence rates are 
lower in those who buy NRT over the counter in comparison with 
those who obtain NRT by prescription (West and Fidler, 2011) (III).
Specific patient groups. NRT has not yet been shown to be 
effective in adolescents (two small trials, see Grimshaw and Stan-
ton, 2006) (Ia).
Antidepressants
There are several reasons to believe antidepressants might help 
in smoking cessation. Nicotine withdrawal may produce depres-
sive symptoms or precipitate a depressive episode; nicotine may 
have antidepressant effects that maintain smoking, and antide-
pressants may substitute for this effect; and some antidepres-
sants may have a specific effect on neural pathways (e.g. 
inhibiting monoamine oxidase) or receptors, (e.g. blockade of 
nicotinic-cholinergic receptors) underlying nicotine addiction 
(Hughes et al., 2007) (Ia).
The atypical antidepressant bupropion has been well studied 
and is licensed as an aid to smoking cessation. It has dopaminergic 
and adrenergic actions, and also appears to act as an antagonist at 
the nicotinic acetylcholinergic receptor (Fryer and Lukas, 1999). 
Bupropion is produced as a sustained release tablet formulation. 
Results of a meta-analysis of 49 trials (Hughes et al., 2007) (Ia) 
show bupropion to be more effective than placebo in promoting 
continuous abstinence from smoking. This effect appears to be 
independent of its antidepressant action, and the effect is also 
independent of the patient’s history of depression.
In their meta-analysis and Cochrane review, Hughes and col-
leagues (2007) (Ia) considered the following antidepressant drugs 
in addition to bupropion: nortriptyline; SSRIs including fluoxe-
tine, paroxetine and sertraline; monoamine oxidase inhibitors; 
venlafaxine; and St John’s Wort. There was clear evidence for 
effectiveness of nortriptyline and bupropion, and both are well tol-
erated. No significant effects were found for fluoxetine, paroxe-
tine, sertraline, the monoamine oxidase inhibitor moclobemide, or 
for venlafaxine. There were no long-term trials of St John’s Wort.
Anxiolytic drugs
Anxiolytic drugs have also been of interest to aid smoking cessa-
tion. The rationale for this is that anxiety symptoms are present in 
nicotine withdrawal, and that smoking is a behaviour that is some-
times used to relieve anxiety. In a meta-analysis and Cochrane 
review, Hughes and colleagues found one trial each for diazepam, 
meprobamate, metoprolol and oxprenolol, and two trials for bus-
pirone (Hughes et al., 2000) (Ia). No trial showed a significant 
effect in helping smokers to quit, but confidence intervals were 
wide. The authors conclude that the role for anxiolytic drugs can-
not be ruled out on current evidence.
Nicotine receptor partial agonists
Nicotine receptor partial agonists may help people to stop smok-
ing by a combination of counteracting withdrawal symptoms (act-
ing as an agonist) and reducing smoking satisfaction (acting as an 
antagonist, see Nutt et al., 2012). In the review and meta-analysis 
by Cahill et al. (2011) (Ia), 11 trials of varenicline were identified. 
Varenicline at standard dose increased the chances of successful 
long-term smoking cessation between two- and threefold com-
pared with placebo or bupropion. Varenicline has been found in 
direct and indirect comparisons in RCTs to be more effective than 
bupropion or nicotine patches (Cahill et al., 2011; NICE, 2007e) 
(Ia). It has also been associated with higher success rates in rou-
tine clinical practice (Brose et al., 2011) (III). It is unclear whether 
varenicline is more effective than optimised NRT (for example 
patches plus a faster-delivery form of NRT). Lower-dose regi-
mens of varenicline also increased success rates, while reducing 
the incidence of adverse events (the most common being nausea). 
Limited evidence suggests that varenicline may have a role to play 
in relapse prevention. There have been reports of possible serious 
adverse events, including depressed mood, agitation and suicidal 
thoughts, but their relationship to varenicline has not been sub-
stantiated (Gunnell et al., 2009; Tonstad et al., 2010) (III). 
Varenicline has not been established as safe in pregnancy, breast-
feeding or adolescence. There is evidence that a very low-cost 
partial agonist which is available in some parts of Europe, cyti-
sine, is effective in aiding cessation (West et al., 2011).
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Nicotine vaccines
Nicotine vaccines are currently in development. These induce 
antibodies which bind to the nicotine molecule to prevent it enter-
ing the brain, and are intended as relapse prevention adjunctive 
treatment, rather than a cessation treatment. Data to date are sug-
gestive of efficacy, but there is currently insufficient evidence for 
them to be recommended for use.
Recommendations: nicotine
x NRT, varenicline, bupropion, nortriptyline and cytisine are 
all effective in aiding smoking cessation. Prescriptions for 
one of these should be offered to all smokers (A).x Optimal results can be expected with either varenicline or 
combination of NRT patch plus a faster-acting form of 
NRT (A).x All smokers should also be encouraged to use behavioural 
support where this is available (for example in the UK 
National Health Service all smokers should have access to 
a trained stop-smoking practitioner), but unwillingness to 
use behavioural support should not preclude prescribing 
pharmacotherapy (A).x All pharmacotherapies can safely be used in patients with 
stable cardiac disease (A).x NRT should be considered to aid smoking reduction as a 
prelude to quitting in smokers not ready to make a quit 
attempt but willing to reduce (A).x Although effectiveness is not established in these patient 
groups, NRT can be considered on an individual basis for 
pregnant women and for young people under 18 (D).x Nortriptyline and cytisine are very low-cost, effective 
medications that may be of particular value in low to mid-
dle income countries (D).
Key uncertainties
x It is not clear whether varenicline is more effective than 
combination of NRT patch and a faster acting product.x The benefits of combining multiple treatments need to be 
evaluated.x There is uncertainty about whether NRT bought over the 
counter is currently proving effective in some 
populations.x It is not clear whether cytisine is more or less effective 
than varenicline under a similar dosing schedule.
Pregnancy
In pregnancy, the general principles of best practice need to apply 
to the foetus as well as to the woman. There are a number of 
sources of evidence and good practice to guide practitioners 
despite the difficulties, ethical and otherwise, of conducting RCTs 
in this population. We focus here on pharmacotherapy, and the 
reader is directed elsewhere for broader management issues, for 
example NICE clinical guideline on pregnancy and complex 
social factors which included women who misuse alcohol and/or 
drugs (NICE, 2010b) (Ia), the Confidential Enquiries into 
Maternal Deaths reports (Centre for Maternal and Child Enquiries 
(CMACE), 2011), NICE guidance on antenatal and postnatal 
mental health (NICE, 2007a) (Ia) and smoking (NICE, 2010a) 
(Ia), and the Cochrane review on improving pregnancy outcomes 
by pre-pregnancy health promotion (Whitworth and Dowswell, 
2009) (Ia). There are also Cochrane reviews of psychosocial inter-
ventions and opioid agonist maintenance treatment for pregnant 
women (Minozzi et al., 2008; Terplan and Lui, 2007) (Ia).
Problems with the evidence base include the facts that much 
comes from the USA and no RCTs were conducted in the UK, 
polysubstance misuse is the norm in the UK, numbers in RCTs are 
small, and the high prevalence of nicotine use as a potential 
confounder.
Assessment and antenatal care
Enabling pregnant substance users to access antenatal care is vital. 
In 2006–2008, 11% of all maternal deaths were in substance mis-
users (CMACE, 2011) and 44% of substance-misusing women 
received no/little antenatal care. Some 31% of maternal deaths 
from suicides were in substance misusers. Assessment tools such 
as T-ACE, TWEAK or AUDIT C have been shown to have the 
highest sensitivity for identifying prenatal risk of drinking (Burns 
et al., 2010).
Early information-sharing between the GP, maternity and 
addiction services is essential. All women who are substance users 
should have integrated specialist care that includes professionals 
in addiction, child safeguarding, specialist midwifery and obstet-
rics (CMACE, 2011; NICE, 2010b).
Women who are substance users and who attend drug treat-
ment programmes are likely to have better antenatal care and bet-
ter general health than those who do not engage with treatment 
services. Addiction services should fast-track pregnant women 
into treatment and engage substance-misusing partners 
(Department of Health, 2007).
Opioids
Opioid dependence is associated with increased maternal and 
neonatal complications. Maintenance treatment with an opioid 
substitute can prevent the adverse effects on the foetus of repeated 
withdrawals and periods of intoxication. The UK guidelines on 
clinical management of harmful drug use or abuse or dependence 
cover general management strategies for pregnant opioid-
dependent women (Department of Health, 2007).
Methadone. MMT in pregnancy is associated with improved 
compliance with antenatal care, reduced maternal morbidity and 
improved neonatal outcomes (Burns et al., 2007; Fajemirokun-
Odudeyi et al., 2006; Kandall et al., 1999) (IV). The most appro-
priate methadone dose in pregnancy is still debated. Some 
practitioners favour higher doses to limit illicit drug use and coun-
teract the increased methadone clearance in pregnancy, which 
may necessitate a dose increase in the third trimester (Drozdick 
et al., 2002; Wolff et al., 2005). Others favour lower doses to try 
to reduce the incidence of neonatal abstinence syndrome (NAS) 
(Dashe et al., 2004) or using the lowest doses compatible with 
stability (Dryden et al., 2009). Splitting the daily dose in the third 
trimester can be a helpful strategy (III). A recent systematic review 
and meta-analysis did not find an association between high or 
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low-dose maternal MMT and severity of NAS (Cleary et al., 
2010) (III). A prospective study of pregnant women prescribed up 
to 110 mg/day of methadone did not find an association between 
methadone dose and measures of NAS (Gray et al., 2010 (III)). 
However, a recent retrospective cohort study found a dose–
response relationship between maternal methadone dose at deliv-
ery and NAS (Cleary et al., 2011).
Buprenorphine. There is increasing experience with buprenor-
phine during pregnancy. Improvements in perinatal outcomes 
were similar for methadone and buprenorphine in a prospective 
observational study (Lejeune et al., 2006 (III)). Of note, buprenor-
phine combined with naloxone is contraindicated in pregnancy 
(BNF, SPC), so all studies have used buprenorphine. In a Cochrane 
review of maintenance opioid agonist treatments in pregnancy 
(Minozzi et al., 2008 (Ia)) two studies compared methadone (at 
doses between 40–100 mg/day) with buprenorphine (at doses 
between 8–24 mg/day) (Fischer et al., 2006; Jones et al., 2005) 
(Ib). Comparing methadone with buprenorphine there was no dif-
ference in maternal treatment drop-out rates (two studies), NAS 
(two studies), use of heroin (one study) or APGAR scores (one 
study). Kakko et al. (2008) (III) found that buprenorphine was 
associated with lower levels of NAS and increased birth weight. A 
recent multicentre international RCT of buprenorphine and meth-
adone in 175 pregnant opioid-dependent women (the MOTHER 
study) found that babies of mothers treated with buprenorphine 
had less severe neonatal abstinence symptoms requiring less med-
ication and shorter stays in hospital (Jones et al., 2010) (1b).
Slow-release oral morphine. In a RCT comparing methadone 
with SROM there was no difference in maternal or neonatal out-
comes for methadone and SROM except reduced maternal heroin 
use in the third trimester with morphine (Fischer et al., 1999) (IIb).
Detoxification. Detoxification or withdrawal has been thought 
to be risky in the first trimester due to risk of miscarriage and in 
the third trimester due to the risk of foetal stress and premature 
labour. If it has to be undertaken, the second trimester is preferred. 
A reduction of 2–3 mg of methadone every 3–5 days has been 
suggested, as long as illicit opiate use is not continuing (Depart-
ment of Health, 2007). A slow reduction in the third trimester may 
be undertaken (Department of Health, 2007). Any potential bene-
fit from dose reductions must be balanced against the risk of 
decreased methadone doses leading to relapse to illicit drug use.
Recommendations: opioids and pregnancy
x Methadone and buprenorphine (not buprenorphine/nalox-
one) maintenance treatment improves maternal and foetal 
outcomes, and substitution treatment should be offered to 
pregnant opioid-dependent women (B).x The choice of medication should be based on individual 
need and preference following full assessment, and the 
dose of methadone prescribed should be that which main-
tains clinical stability (C).x Buprenorphine may be associated with less NAS (B).x Detoxification should be avoided in the first trimester, is 
preferred in the second and only with caution in third tri-
mester (S).
Key uncertainties
x Can psychosocial interventions enhance outcomes in com-
bination with substitution treatment?x Are the findings for generally similar outcomes with 
methadone and buprenorphine maintained with larger 
studies?
Stimulants
A Cochrane review of psychosocial interventions for pregnant 
women examined nine trials of contingency management or 
motivational interviewing (Terplan and Lui, 2007) (Ia). The 
majority of women used opiates and cocaine. Contingency 
management may increase treatment retention but there is no 
clear effect on drug abstinence. There was no evidence to sup-
port motivational interviewing. RCTs focussing on obstetric 
and neonatal outcomes are needed. The Department of Health 
guidelines recommend offering psychological approaches 
including family intervention to pregnant women misusing 
stimulants (Department of Health, 2007). Substitute prescribing 
is not recommended.
Recommendations: stimulants and pregnancy
x There is not enough evidence to make any recommenda-
tions except ‘stop’ and use psychosocial interventions and 
not pharmacotherapy for relapse prevention (S).
Key uncertainties
x What psychosocial intervention is most effective in 
pregnancy?
Nicotine
All pregnant women who smoke or who have stopped in the last 
2 weeks should be referred to smoking cessation services 
(NICE, 2010a). A Cochrane review (Lumley et al., 2009) (Ia) 
found smoking cessation interventions reduced smoking in late 
pregnancy (RR 0.94, 95% CI 0.93–0.96), reduced low birth 
weight (RR 0.83, 95% CI 0.73–0.95), and preterm birth (RR 
0.86, 95% CI 0.74–0.98) plus increased mean birth weight by 
39.26 g (95% CI 15.77–62.74 g). There were no significant dif-
ferences for very low birth weight or perinatal mortality. 
Financial incentives to women to quit smoking were more 
effective than other interventions (RR 0.76, CI 0.71–0.81). 
Self-help smoking cessation interventions for pregnant smokers 
are effective (OR 1.83 95% CI 1.23–2.73) (Naughton et al., 
2008) (Ia).
Pharmacotherapy. NRT should be considered if smoking ces-
sation interventions without NRT have failed (NICE, 2010a). 
However, there is mixed evidence for the effectiveness of NRT in 
pregnancy, so it is not as effective as in the general population 
(Lumley et al., 2009; Oncken et al., 2008) (Ib). Bupropion and 
varenicline should not be prescribed to pregnant or breast-feeding 
women (NICE, 2010a).
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Recommendations: nicotine and pregnancy
x Psychosocial interventions should be offered since they 
are effective (A).x Offer NRT after risk–benefit analysis if other interven-
tions have failed (B).
Key uncertainties
x Are financial incentives to stop smoking in pregnancy 
effective in a UK setting?
Alcohol
There is much controversy regarding how much alcohol is ‘safe’ 
to drink in pregnancy (Carson et al., 2010; NICE, 2008; O’Leary 
et al., 2007); however, there is no evidence of a threshold level of 
alcohol consumption during pregnancy above which alcohol is 
harmful to the baby. NICE (2008) states “in the absence of clear 
evidence of a threshold it would appear that drinking no more than 
1.5 units/day is not associated with harm to the baby but there 
remains a possibility that there is an increased miscarriage rate in 
association with alcohol consumption although the evidence is 
limited and of poor quality”. There is limited evidence that binge 
drinking, as defined by drinking five or more standard drinks in a 
single episode, may be associated with neuro-developmental harm 
to the baby (NICE, 2008). UK government advice is currently not 
to drink during pregnancy or when trying to conceive (Department 
of Health, 2008). If a woman chooses to drink, they should drink 
no more than ‘1–2 units once or twice a week’ and that binge 
drinking (> 7.5 units) on a single occasion may be harmful 
(Department of Health, 2008; NICE, 2008). In addition, a man is 
also recommended not to drink excessively to improve fertility.
Detoxification. We and others recommend the use of benzodi-
azepines for alcohol detoxification during pregnancy (e.g. Latt 
et al., 2009; Lingford-Hughes et al., 2004; Rayburn and Bogen-
schutz, 2004; TIP, 2006) (IV), preferably in an inpatient setting 
under specialist supervision (NICE, 2011a). Either chlordiazepox-
ide or diazepam can be used.
Relapse prevention. No relapse prevention medication has 
been evaluated in pregnancy suitable for a systematic Cochrane 
review (Smith et al., 2009) (Ia), and existing studies of pharmaco-
logical interventions in alcohol treatment exclude pregnant 
women. The BNF advises to avoid acamprosate in pregnancy and 
to avoid disulfiram in the first trimester. Naltrexone is licensed in 
UK to prevent relapse in opioid dependence and the BNF says it 
can be used if ‘benefit outweighs risk’. In the USA, advice is to 
avoid any of these medications unless ‘potential benefit outweighs 
risks’ (TIP, 2009) (IV). In addition, appropriate birth control is 
recommended while on these medications.
There is therefore little research evidence for the efficacy or 
the safety of pharmacological treatments in pregnancy or breast 
feeding, and these are best avoided.
Recommendations: alcohol and pregnancy
x Women and men are advised not to drink alcohol when 
trying to conceive (S).
x Pregnant women with symptomatic withdrawal should be 
offered medical cover for their detoxification, ideally as an 
inpatient (D).x Starting relapse prevention medication should be avoided, 
although if already successfully established on relapse 
prevention medication, patients’ needs should be assessed 
on a case-by-case analysis (D).
Key uncertainties
x What are the risks of alcohol withdrawal versus the risks 
of benzodiazepine exposure to foetus, and does any tri-
mester carry more risk than at other times?x Risk of medication such as acamprosate, naltrexone or 
disulfiram versus risk of excessive drinking and its conse-
quences in pregnancy and breast feeding.
Comorbidity
Symptoms of psychiatric disorders such as depression, anxiety 
and psychosis are the rule rather than the exception in patients 
misusing drugs and/or alcohol. In addition, these psychiatric dis-
orders increase the risk of harmful substance use, abuse or depend-
ence, and patients may be physically unwell. Such patients are 
often the most challenging to engage and treat, and their prognosis 
is frequently poor. The number of placebo-controlled trials is 
small, and although increasing steadily there remains little evi-
dence to guide treatment, particularly in the adolescent or old age 
populations. There are now national guidelines to guide treatment 
of comorbidity in UK (NICE, 2011a, 2011b) (Ia), in Australia 
(Mills et al., 2009) (IV) as well as management within relevant 
BAP guidelines (see for example those for ADHD (not covered in 
these guidelines), schizophrenia, bipolar disorder at www.bap.
org.uk) (IV). We therefore concentrate on the psychopharmacol-
ogy of treating such comorbid disorders. As previously discussed, 
all studies include a psychosocial intervention.
While it is common to refer to a patient’s psychiatric disorder 
or substance use disorder as primary or secondary, this may have 
limited use clinically. It is important to establish whether sub-
stance use may be contributing to their psychiatric problems. Such 
an assessment may be appropriate at every meeting, particularly if 
there are changes in their psychiatric presentation. While remov-
ing or minimising the contribution of harmful substance use is an 
important aim, it is often not achieved. In addition, misplaced 
attribution of the psychiatric disorder purely to substance use can 
occur, and may result in the patient achieving abstinence but not 
being reassessed, or never having their psychiatric problems ade-
quately addressed because they never achieve abstinence. 
Pragmatically, both disorders may have to be treated concurrently, 
although improvement in one does not necessarily result in 
improvement in the other.
The literature contains a wide variety of types of studies and 
outcomes, but few RCTs or even trials, with many being case 
series. Most do not use ‘intention to treat’ analysis and have small 
samples (e.g. n = 16–100) and short duration (days to weeks). In 
some studies, the primary outcome measure is the psychiatric dis-
order, with secondary outcomes being substance related, and nei-
ther the goal regarding substance use, for example reduction or 
abstinence, nor the extent and nature of psychosocial interven-
tions is discussed. Reductions in psychiatric symptoms, for 
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example depression, can be reported although patients did not 
necessarily have a diagnosis of depression.
In the following sections we primarily focus on studies where 
the impact of the medication on substance use outcomes is 
reported from the perspective of pharmacotherapy for the psychi-
atric disorder as well as for substance use disorder. Some pharma-
cotherapy has not been studied in patients with a comorbid 
psychiatric disorder. However, such absence of evidence due, in 
part, to difficulties in studying this population and lack of ‘pharma’ 
interest in conducting such large-scale trials should not deter pre-
scribing, given its potential effectiveness.
Assessment
It is important to distinguish between substance-induced and sub-
stance-related psychiatric disorders. While it is advisable to allow 
at least 2 weeks of abstinence before making diagnosis of a psychi-
atric disorder, this is often impractical. A complete substance his-
tory should be obtained, including nicotine and so-called ‘legal 
highs’ as well as drugs bought off the internet, with urinalysis and 
blood tests. To establish how a patient’s substance use and other 
psychiatric disorder are linked, the order of onset of their psychiat-
ric disorder and substance use, family history and effect of previous 
treatments of comorbid psychiatric disorder should be determined.
Bipolar disorder
The limited evidence is presented in several systematic reviews 
and guidelines available, including BAP bipolar guidelines 
(Goodwin et al., 2009 (IV); NICE, 2011b (Ia), TIP, 2006 (IV); 
Spanish (Casas et al., 2008) (IV) and Australian guidelines (Mills 
et al., 2009) (IV); and comprehensive reviews by Vornik and 
Brown (2006) and Tiet and Mausbach (2007)).
After nicotine, the most commonly abused substance is alco-
hol. The majority of bipolar disorder patients report using sub-
stances, including alcohol, to reduce anxiety (e.g. Bizzarri et al., 
2007). Given the overlap between and increased risk of mania and 
harmful alcohol use, abuse or dependence, detoxification from 
alcohol may be needed early in treatment of mania alongside 
mood stabilisation. Trials are generally conducted in a depressive 
or mixed phase, or maintenance phase.
Treating bipolar disorder. Existing standard pharmacological 
approaches appear effective in comorbid bipolar disorder and 
there is no robust evidence for better efficacy of any one particular 
pharmacological approach. Compliance may be affected by warn-
ings about not drinking alcohol when taking a mood stabiliser. 
There is evidence for the use of carbamazepine, valproate and 
antipsychotics for improving alcohol-related outcomes.
The combination of lithium and valproate has been compared 
with lithium alone in two trials. Patients with BPD I and alcohol 
dependence completed a few days of stabilisation on lithium, after 
which valproate or placebo was added for 24 weeks (Salloum et al., 
2005) (Ib) The lithium plus valproate group had a significantly 
lower proportion of heavy drinking days (p = 0.02) and a trend 
toward fewer drinks per heavy drinking day (p = 0.055) than the 
lithium plus placebo group, although manic and depressive symp-
toms improved equally in both groups. In the other trial, patients 
with BPD I or II and alcohol, cannabis or cocaine abuse 
or dependence entered a 6-month stabilisation ‘open’ phase with 
lithium and valproate, followed by a blinded 6-month ‘mainte-
nance’ phase comparing this combination with lithium alone (Kemp 
et al., 2009) (Ib). Only 31 of the 145 patients were randomised in 
the maintenance phase, and the combination was not superior in 
improving any of their chosen outcome measures including ‘time 
to treatment’ for a mood episode or time to discontinuation with 
medication. However, in those that entered the maintenance phase, 
substance use was reduced so that more than half were no longer 
abusing alcohol or cannabis or cocaine. The combination of lithium 
and valproate resulted in greater improvements in drinking out-
comes. Therefore both trials suggest a combination of lithium and 
valproate may be better than lithium alone for substance abuse; 
however, the combination is not superior in improving mood.
In two open-label studies, Brown and colleagues reported that 
the addition of lamotrigine improved mood – depression and 
mania – and reduced cocaine craving and use (Brown et al., 2003, 
2006) (Ib).
Quetiapine has been the most-studied antipsychotic, with 
mixed results. An open trial of add-on quetiapine (flexible dosing, 
mean dose 229 mg/d) in patients with bipolar disorder and cocaine 
dependence reported ‘substantial improvement in psychiatric 
symptoms and cocaine cravings’ (Brown et al., 2002) (IIb). 
Further analysis of this trial examined those who had alcohol 
craving at baseline, of which about half were dependent or abused 
alcohol, and reductions in craving and alcohol consumption were 
seen (Longoria et al., 2004). An RCT comparing quetiapine (303 
+ 152 mg/day) with risperidone (3.1 + 1.2 mg/day) reported that 
both medications improved psychiatric symptoms and stimulant 
cravings (Nejtek et al., 2008) (Ib).
An RCT of add-on quetiapine (600 mg/day) found no improve-
ment in alcohol use or craving in those with bipolar disorder and 
alcohol abuse or dependence (Brown et al., 2008) (Ib). An open 
trial that included patients with alcohol dependence and bipolar 
disorder (n = 10), or schizoaffective disorder (n = 2) and/or bor-
derline personality disorder (n = 10) found that quetiapine alone 
improved psychiatric symptoms, and decreased alcohol consump-
tion and craving (Martinotti et al., 2008) (IIb). A double-blind 
placebo-controlled trial reported no benefit of quetiapine (400 
mg/day, up to 800 mg/day) as an adjunct to lithium or divalproex 
in reducing number of heavy drinking days, nor improvement in 
bipolar disorder (Stedman et al., 2010) (Ib).
In an open-label study of 20 patients with bipolar disorder or 
schizoaffective disorder, a switch to aripiprazole resulted in 
improved depression, mania and BPRS scores as well as reduction 
in cocaine and alcohol craving, and amount spent on alcohol, but 
not cocaine use (Brown et al., 2005) (IIb).
Relapse prevention medication in bipolar disorder: alcohol.  
A secondary analysis of the trial (Petrakis et al., 2005) (Ib) com-
paring disulfiram and naltrexone alone and in combination with 
placebo, in patients with a psychiatric comorbidity, compared 
those with psychosis spectrum, of which the majority (73%) had 
bipolar disorder, with the remaining non-psychotic participants 
(Petrakis et al., 2006b) (Ib). There was no significant difference 
between the psychotic and non-psychotic groups in retention or 
compliance; however, the ‘psychotic group’ complained about 
more side effects, drank more heavily and had less abstinence, but 
responded more to either naltrexone or disulfiram. In the ‘psy-
chotic group’, placebo resulted in little change in their frequency 
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of heavy drinking days (12/84); however, there was a significant 
reduction in drinking with naltrexone (3/84), disulfiram (4/84) and 
the combination (6/84). There was no difference between the medi-
cations. Despite improvement in drinking, there was no significant 
change in psychiatric symptoms rated with PANSS.
There is evidence that naltrexone can reduce number of drink-
ing days from a pilot RCT where it was added to a CBT pro-
gramme aimed at bipolar disorder and alcohol dependence, 
delivered over 16 weeks alongside usual medication (Brown et al., 
2009) (Ib).
An RCT in those with bipolar disorder and alcohol dependence 
compared acamprosate with placebo in addition to their mood-
stabilising medication (Tolliver et al., 2012) (Ib). While acampro-
sate showed no benefit in drinking related outcomes, the study 
was small (n = 30), of short duration (8 weeks), and levels of 
alcohol drinking were low with more abstinent than drinking days 
at baseline. However, acamprosate was well tolerated and had no 
adverse effects on mood. An anxiety disorder was present in about 
75% of the group and associations with increased depressive 
symptoms and greater alcohol consumption were reported 
(Prisciandaro et al., 2011, 2012). Anticonvulsants and antipsy-
chotics were associated with greater alcohol use and lithium with 
lower alcohol consumption.
Relapse prevention medication in bipolar disorder: 
cocaine. Carbamazepine has been shown to result in a trend 
towards fewer cocaine-positive urines and reduction in depression 
in a group of patients with a mix of bipolar disorder and depres-
sive disorders (Brady et al., 2002) (Ib).
Recommendations: bipolar disorder
x Treat different phases of bipolar disorder as recommended 
in guidelines, for example NICE, BAP; however, assess 
contribution of substance use to hypomania or mania and 
consider if medically assisted withdrawal is required (S).x Review pharmacotherapy for bipolar disorder particularly if 
only on lithium, and consider adding sodium valproate (D).x Offer naltrexone to help patients reduce their alcohol con-
sumption (C).x Offer acamprosate if naltrexone has not been effective to 
help patients remain abstinent (D).x Consider disulfiram if patient wants abstinence and acam-
prosate and naltrexone have failed. The patient must be 
able to understand the risks of taking disulfiram and have 
their mood monitored (D).
Key uncertainties
x What is the best pharmacological approach for patients 
with comorbid bipolar disorder, in manic, depressive or 
maintenance phases?x What is the best pharmacological approach for their 
comorbid harmful substance use, abuse or dependence?
Schizophrenia
Managing substance use in patients with schizophrenia is a sig-
nificant challenge, and there are still limited empirical data to 
guide clinicians. The debate continues about the influence of sub-
stances, particularly cannabis, on causing schizophrenia de novo, 
increasing vulnerability and increasing relapse rates. There is 
some evidence to suggest that vulnerability to psychosis and sub-
stance use may be shared, rather than substances being taken to 
ameliorate psychotic symptoms or overcome side-effects of medi-
cation (Chambers et al., 2001). Nicotine is the most commonly 
abused substance, with up to 85% of patients with schizophrenia 
smoking cigarettes. Alcohol is the next most commonly abused 
substance, followed by cannabis. With the introduction of restric-
tions on smoking, more patients are being offered nicotine substi-
tution and cessation programmes. Recent comprehensive and 
systematic reviews have described some of the challenges and 
management (Lubman et al., 2010; San et al., 2007; Wobrock 
and Soyka, 2009), and see other guidelines (Barnes et al., 2011; 
Mills et al., 2009; NICE, 2011b). A recent Cochrane review con-
cluded that there was no good evidence for effectiveness of any 
one particular psychosocial treatment in psychotic spectrum dis-
orders comorbid with substance abuse (Cleary et al., 2008) (Ia). 
Of note, a recent trial in the UK showed that integrated motiva-
tional interviewing and CBT in addition to standard care was no 
better than standard care alone in improving psychiatric or sub-
stance use outcomes (Barrowclough et al., 2010) (Ib). Another 
trial in the Netherlands found that training parents in ‘motiva-
tional interviewing and interaction skills’ focused on reducing 
cannabis use resulted in reduced cannabis use in their young adult 
offspring with schizophrenia compared with routine family sup-
port (Smeerdijk et al., 2011). However, there were no differences 
in the patients’ general level of functioning and in reducing par-
ents’ stress and sense of burden. Throughout these guidelines we 
have used the terminology to describe antipsychotics as in the 
original paper, that is, typical or atypical or first or second-gener-
ation antipsychotic (FGA, SGA).
The importance of reducing substance abuse is illustrated by a 
prospective study that followed-up patients with schizophrenia 
and found much of the improvements in reducing relapse rates in 
patients compliant with their antipsychotic medication were 
diminished by substance abuse (Hunt et al 2002). Analysis of the 
CATIE study revealed that, compared with non-users, illicit drug 
users tended to stop their antipsychotic, and the advantage of 
olanzapine seen in non-users was attenuated (Swartz et al., 2008) 
(Ib). Significantly poorer outcomes were seen in those with mod-
erate/severe drug use (Kerfoot et al., 2011) (Ib). This reinforces 
‘the need for concurrent substance abuse treatment’.
The majority of studies covering schizophrenia comorbid with 
harmful substance use, abuse or dependence are still not prospec-
tive RCTs but rather retrospective surveys, open trials or case series. 
We will focus on reports published since the last guidelines in 2004.
With regard to treating schizophrenia itself, recent evidence 
from CUtLASS1 and CATIE trials indicates that FGA are not 
inferior to SGA (Barnes et al., 2011) (IV). This has had a large 
impact on recommendations suggesting FGA were appropriate as 
‘first line’ rather than favouring SGA over FGA, as happened after 
the introduction of many SGA (Barnes et al., 2011) (IV). The lack 
of extrapyramidal side effects of many SGAs may be now out-
weighed by their effects on physical health and associated impact 
on morbidity and mortality. Substance abuse also impacts 
adversely on physical health, and therefore reducing its impact, 
such as stopping smoking, is likely to have significant health 
benefits.
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Treating schizophrenia
Oral medication. There is some evidence from older stud-
ies that typical antipsychotics or FGA do not reduce harmful 
substance use, abuse or dependence, and it is hypothesised that 
substances of abuse may be used to overcome extrapyramidal side 
effects and possible consequences of hypodopaminergia such as 
low mood and blunted affect (see review by Siris, 1990). However 
as described above, more recent trials report that SGA may not be 
superior to FGA for treating schizophrenia and similarly it is not 
clear in comorbidity. 
There have been several trials comparing olanzapine with halo-
peridol. Green et al. (2004) (Ib) reported the substance use data 
from a double-blind randomised trial comparing olanzapine with 
haloperidol in patients in their first episode of schizophrenia. 
Patients who were abusing substances (alcohol, cannabis, other) 
were less likely to respond to either antipsychotic, and were less 
likely to complete treatment with haloperidol. At 12 weeks, olan-
zapine but not haloperidol, was associated with a reduced response 
with regard to their psychotic symptomatology in those abusing 
alcohol compared with those not abusing alcohol. No data regard-
ing substance use at the 2 year end point was reported (Green et al., 
2006). In other small trials, no clinically meaningful differences 
were found, (Sayers et al., 2005; Smelson et al., 2006) (Ib).
Similarly, in observational studies and case notes reviews of 
other SGAs some benefits for them over FGAs have been reported, 
but these are of uncertain clinical value; for example, Scheller-
Gilkey et al. (2003) (III) found reduced use of alcohol but not 
other drugs. In a retrospective case notes review, Petrakis et al. 
(2006a) (III) found that the severity of substance use and sub-
stance-related problems had declined by follow-up in patients 
receiving atypical (olanzapine, quetiapine, risperidone) but not 
conventional antipsychotics, whether ‘maintained’ or ‘switched 
to’, but this was not significant.
With tobacco the situation might be different, in that Stuyt 
et al. (2006) (III) studied inpatients with dual-diagnosis of schizo-
phrenia or schizoaffective disorder who were not allowed to 
smoke; about half of those on risperidone or ziprasidone stated 
that they were not going to smoke on discharge, whereas all those 
on olanzapine or depot said they intended to.
The CATIE study (Swartz et al., 2008) (Ib) found that although 
olanzapine led to less ‘all cause discontinuation’ in those not using 
illicit drugs, there was no difference in those abusing illicit drugs. 
By contrast, alcohol use and abuse in the absence of illicit sub-
stance use had little effect on time to discontinuation, since these 
patients tended to be older and more stable. They concluded by 
reinforcing the need for concurrent substance use disorder treat-
ment. In an open uncontrolled trial in patients with schizophrenia, 
switching to quetiapine was associated with improvements in psy-
chiatric symptoms and substance abuse (Potvin et al., 2006) (IIb).
In small studies, oral risperidone has been shown to be supe-
rior to ‘typical antipsychotics’ (Smelson et al., 2002) (IIb) or 
worse than clozapine in terms of substance use-related outcomes 
(Green et al., 2003) (III). Olanzapine showed a trend for a greater 
effect in reducing cocaine use, while risperidone resulted in more 
craving for cannabis (Akerele and Levin, 2007) (IIb). In young 
adults with a recent diagnosis of schizophrenia, no differences 
were reported between olanzapine and risperidone in subjective 
well-being, cannabis craving or reduction in number of joints 
smoked (van Nimwegen et al., 2008) (Ib).
Given that preclinical studies suggested that partial agonists at 
the DRD2/3 may have potential to treat substance use disorders, 
there was interest in aripiprazole, which has similar pharmacol-
ogy. In six of 10 patients with schizophrenia and cocaine depend-
ence who completed an 8-week trial of aripiprazole, reductions 
were seen in cocaine and alcohol craving, cocaine-positive urines 
and psychotic symptoms (Beresford et al., 2005; see also section 
on stimulants) (IIb).
Depot medication. Open, pilot trials of depot flupenthixol 
have shown that it was well tolerated in patients with schizophre-
nia and alcohol dependence or cocaine abuse, and resulted in 
improvements in cocaine and alcohol use but not necessarily psy-
chiatric symptoms (Levin et al., 1998; Soyka et al., 2003) (IIb). 
In an open, randomised study, injectable risperidone was shown 
to be statistically superior to zuclopenthixol-depot regarding 
improvements in substance abuse and schizophrenia symptoms 
(Rubio et al., 2006) (Ib).
Clozapine. Although case reports and surveys (Green et al., 
2003; Kim et al., 2008) (III) suggest that clozapine is beneficial 
for schizophrenia with substance use disorders, there are still no 
prospective randomised studies. A review of patients with schizo-
phrenia discharged on clozapine found that there was no differ-
ence in time to readmission between those with and without a 
substance-use disorder, suggesting clozapine is beneficial in the 
abusing group (Kelly et al., 2003) (III). In a naturalistic survey, 
patients on clozapine stayed in the community longer despite 
drinking as much alcohol as patients on risperidone at baseline; 
however, no alcohol data were collected during follow-up period 
(Kim et al., 2008) (III). Clozapine has also been shown to result 
in fewer relapses to substance abuse compared with other antipsy-
chotics (8% vs. 40%), but there was no difference in improvement 
in psychiatric symptoms (Brunette et al., 2006) (III).
Summary. There is currently insufficient evidence to recom-
mend one antipsychotic over another or FGA versus SGA when 
treating schizophrenia with comorbid harmful substance use, 
abuse or dependence, either in relation to superiority in reducing 
substance use or improving psychiatric symptoms.
Relapse prevention medication in schizophrenia: alcohol. 
There have been a number of trials of alcohol relapse-preven-
tion medication in patients with schizophrenia, but there are 
none for illicit substances of abuse. Smoking cessation is dis-
cussed below.
A placebo-controlled RCT of naltrexone reported fewer drink-
ing days, fewer heavy drinking days and less craving with naltrex-
one without improving psychosis, although importantly not 
worsening it either (Petrakis et al., 2004) (Ib). A prospective open 
study found similar benefits (Batki et al., 2007) (IIb). In Petrakis 
et al. (2006b) naltrexone was also found to be of benefit, although 
only a few patients had schizophrenia.
With disulfiram, Mueser et al. (2003) and Petrakis et al. (2005, 
2006b) (Ib) have reported benefits in reducing alcohol consump-
tion with limited adverse events, despite its theoretical propensity 
to increase psychosis through its blockade of dopamine-beta-
hydroxylase. For information about the safety of disulfiram see 
Chick (1999) and Malcolm et al. (2008).
There is one study comparing the effects acamprosate 
with placebo on cognitive functioning in 30 patients with schizo-
phrenia (Ralevski et al., 2011) (Ib). There were no adverse effects, 
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including on cognitive functioning, and drinking improved in 
both groups.
There are only case reports of baclofen (25 mg tds; Agabio et al., 
2007) (III) and acamprosate (666mg tds; Tek et al., 2008) (III) reduc-
ing alcohol consumption in single patients with schizophrenia.
Relapse prevention medication in schizophrenia: opioids. 
There is very little information on illicit opioid use. One open 
study in heroin-dependent patients with comorbid schizophrenia 
found those on olanzapine remained longer in treatment and 
revealed more negative urine analyses for illicit drugs compared 
with those on haloperidol treatment (Gerra et al., 2007) (II). 
Higher doses are generally needed for methadone-maintained 
patients with psychiatric comorbidity, with enrolment and stabili-
sation in such programmes having a beneficial effect on their psy-
chiatric symptoms (Tenore, 2008) (IV). The potential interaction 
between methadone and antipsychotics, for example on QTc inter-
val, will need to be considered.
Relapse prevention medication in schizophrenia: nicotine. 
Patients have high rates of smoking, which contributes to their 
higher rates of physical morbidity and mortality. However, 
recently there have been changes with restrictions on smoking in 
public places and hospitals, and the general health of patients with 
schizophrenia is receiving more attention. Whilst many patients 
with schizophrenia do quit smoking with pharmacological support 
from NRT or bupropion, quit rates are less than half of those seen 
in the general population.
An early RCT found that nicotine transdermal patches resulted 
in limited numbers stopping smoking, but those on atypical antip-
sychotics fared better than those on typical antipsychotics (George 
et al., 2000) (Ib). Tidey et al. (2002) (IIb) found that a nicotine 
patch (21 mg) did not further improve quit rates achieved with 
contingency management.
As an adjunctive to psychological support, bupropion has been 
shown to aid smoking cessation, to be safe and well tolerated, and 
there is some evidence to suggest that those on atypical antipsy-
chotics are more likely to be able to quit (George et al., 2002; 
Weiner et al., 2001) (Ib).
Two RCTs have reported that combining bupropion SR or pla-
cebo with high-dose transdermal nicotine patch resulted in higher 
abstinence rates than nicotine substitution alone (Evins et al., 
2007; George et al., 2008) (Ib). The combination was safe and 
well tolerated. Evins et al. (2007) found equivalent outcomes 
between those on typical and atypical antipsychotics. However, in 
both studies longer-term abstinence after the treatment period was 
no different between the groups, so it may be that longer treatment 
and support should be considered.
One pilot trial of galantamine (a cholinesterase inhibitor) 
reported that it had no effect on reducing smoking and nicotine 
dependence (Kelly et al., 2008) (Ib). One suggested reason why 
patients with schizophrenia smoke is to derive benefits from nico-
tine on cognition. A small prospective study of varenicline was 
undertaken to explore possible beneficial effects on cognition and 
smoking (Smith et al., 2009) (IIb). After 9 weeks, improvements 
in some cognitive tasks were seen, with a reduction in smoking 
also apparent without adverse psychiatric consequences. A pre-
liminary study of mecamylamine (a nicotinic receptor antagonist) 
found that it increased the number of cigarettes smoked (McKee 
et al., 2009) (IIb).
A Cochrane review of smoking cessation in schizophrenia 
concluded that bupropion increased smoking abstinence rates. 
However, it did not find any evidence for benefit from NRT (Tsoi 
et al., 2010) (Ia). Of the psychosocial interventions, only contin-
gency management could be supported.
Recommendations: schizophrenia
x The negative impact of harmful substance use, abuse or 
dependence on patients with schizophrenia requires that 
their substance use is assessed and treatment is also 
focussed on any harmful substance use, abuse or depend-
ence (S).x Antipsychotic medication should be optimised following 
existing guidance, for example NICE, BAP (D).x Clozapine should be considered in patients with persisting 
harmful substance use, abuse or dependence, since it has 
been reported to reduce substance use and improve psy-
chosis, but these data are still preliminary (D).x Medication for patients’ substance misuse should be con-
sidered, such as optimising opioid substitution, use of 
alcohol relapse prevention such as naltrexone or acampro-
sate, and smoking cessation using bupropion or vareni-
cline (D).
Key uncertainties
x Prospective RCTs with substance-use related outcomes 
investigating antipsychotic medication in comorbid schiz-
ophrenia are required.x Prospective RCTs investigating relapse prevention medi-
cation for alcohol misuse or nicotine are required.
Depression
Opioids and depression. Depressive symptoms are very com-
mon in opioids addicts, with about half meeting criteria for major 
depression: this may motivate them to present for treatment for 
opioid dependence. Often other substances such as alcohol and 
cocaine contribute to their depressed mood. Despite this comor-
bidity there is evidence that such patients do well in opioid treat-
ment and certainly no worse than non-depressed patients (Ngo 
et al., 2011; Nunes et al., 2004) (III). Higher doses may be needed 
for methadone-maintained patients with depression, and enrol-
ment and stabilisation in such programmes alone is likely to have 
a beneficial effect on their psychiatric symptoms (Tenore, 2008) 
(IV). This may be a direct effect of opioid agonism on the reward 
pathway as well as secondary consequences on their chaotic life-
style. Buprenorphine may have advantages over methadone in 
treating depressed opioid addicts due to its kappa antagonism, 
although this has not been shown consistently (Dean et al., 2004 
(IIb); Gerra et al., 2006 (III)). Nevertheless, in about 10–20%, 
depression will persist (Nunes et al., 2004) (IV).
Studies of comorbid opioid dependence and depression are in the 
meta-analysis by Nunes and Levin, (2004 (Ia)) and also in a compre-
hensive review (Nunes et al., 2004) (IV). Conclusions were similar 
to those for alcohol and depression (see below), with antidepressants 
not being robustly superior for mood or substance use over placebo. 
The meta-analysis by Torrens et al. (2005) (Ia) considered seven 
studies, all of which were of methadone-maintained patients, but no 
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significant difference in opioid use was reported by any study. 
However the meta-analysis using data from two studies of doxepin 
and imipramine was just significant (OR = 3.65, 95% CI 1.10–
12.16). Only one study involving imipramine reported improvement 
in depression, and the meta-analysis using data from two studies of 
imipramine and sertraline showed no significant effect on mood 
(OR = 2.27, 95% CI 0.39–13.19). Kosten et al. (2004) (Ib) found 
that desipramine in combination with either methadone or buprenor-
phine did not improve mood in opioid and cocaine-dependent 
patients, and indeed the depressed desipramine/buprenorphine 
group had least improvement in opiate-free urines. A recent trial 
reported depressive symptoms improved in addicts starting on 
buprenorphine and addition of escitalopram showed no advantage in 
terms of depressive or opiate outcomes (Stein et al., 2010) (Ib).
Overall, antidepressant treatment within methadone mainte-
nance programmes can improve depressive symptoms but robust 
effects on mood are not usual, nor are improvements in opioid or 
other drug use.
Lastly, although it is theoretically possible for naltrexone to 
worsen mood, this has not been seen clinically. Recent studies in 
newly abstinent heroin addicts have not found naltrexone induc-
tion and/or maintenance to worsen mood, but instead to improve 
it (Dean et al., 2006 (Ib); Mysels et al., 2011 (IIb)).
Alcohol and depression. Depressive and anxiety symptoms 
commonly co-occur in the withdrawal period, but mostly subside 
after 3–4 weeks of abstinence (Brown and Schuckit, 1988; Brown 
et al., 1991; Liappas et al., 2002). Factors leading to a diagnosis of 
depression include family history and a previous non-alcohol-
related depressive episode. Stopping alcohol is important in fully 
determining its role in the patient’s depression and anxiety.
Three meta-analyses examine pharmacotherapy of alcohol-use 
disorders and depressive disorders with broadly similar conclu-
sions (Iovieno et al., 2011; Nunes and Levin, 2004; Torrens et al., 
2005) (Ia). The meta-analysis by Nunes and Levin (2004) found 
significant or trend antidepressant effects in 8/14 studies (effect 
size of 0.38, 95% CI 0.18–0.58). Those with alcohol dependence 
were more likely to respond than for other drug addictions. The 
largest (71%) variance was explained by placebo response, with 
those studies reporting a placebo response of less than 25% more 
likely to find an antidepressant effect. A greater antidepressant 
effect was also more likely if the diagnosis of depression was 
made after at least a week of abstinence, which likely excluded 
those people with transient withdrawal-related symptoms. A lower 
response to antidepressants was associated with SSRIs, more 
women in sample and a concurrent manual-guided psychosocial 
intervention. The severity of depression did not influence 
outcome.
Those antidepressants with mixed pharmacology such as tricy-
clics (e.g. imipramine or desipramine) appear to be better than 
SSRIs (e.g. fluoxetine, sertraline) (Nunes and Levin, 2004) (Ia). A 
meta-analysis of four studies with SSRIs showed an OR = 1.85 
(95% CI 0.73–4.68), and the three studies with other antidepres-
sants showed an OR = 4.15 (95% CI 1.35–12.75) (Torrens et al., 
2005) (Ia).
The effect on alcohol outcomes was mixed: Nunes and Levin 
(2004) (Ia) found that in those studies with depression effect sizes 
over 0.5, the effect size on substance outcome was 0.56 (95% CI 
0.33–0.79), whereas almost no impact on substance use was seen 
in those studies with a lower depression effect size. Once again, 
antidepressants with mixed pharmacology performed better, 
resulting in significantly greater reductions in drinking (OR = 
1.99, 95% CI 0.78–5.08), whilst SSRIs did not (OR = 0.93, 95% 
CI 0.45–1.91) (Torrens et al., 2005) (Ia).
Patients comorbid for substance abuse and depression should 
be treated for their depression, but improving mood and/or antide-
pressants may not necessarily reduce their substance abuse; there-
fore specific, appropriate substance-focussed treatment should 
also be delivered. While the meta-analyses suggest that antidepres-
sants with mixed pharmacology tend to do better than SSRIs, there 
is little information on the newer drugs. An open study reported 
that mirtazapine (15–45 mg/day) was well tolerated in depressed 
alcoholics and resulted in reductions in depression, anxiety and 
alcohol craving over 8 weeks (Yoon et al., 2006) (IIb). One small 
double-blind RCT reported that both amitriptyline (titrated up to 
125–150 mg/day) and mirtazapine (titrated up to 45–60 mg/day) 
resulted in similar improvements in depression, anxiety and alco-
hol craving, although drinking outcomes were not reported 
(Altintoprak et al., 2008) (Ib). Mirtazapine was better tolerated.
One 26-week trial has reported that escitalopram (20 mg/day) 
or memantine (20 mg/day) resulted in similar improvements in 
depression and anxiety in patients with major depressive disorder 
(Muhonen et al., 2008) (Ib). No differences were seen in cognition 
during the trial or between groups and impact on drinking was not 
reported.
Relapse prevention medication in depression. More 
recently, combinations of antidepressants and relapse prevention 
pharmacotherapy have been investigated. A study over 14 weeks 
conducted in depressed alcoholics compared sertraline (200 mg/
day) and naltrexone (100 mg/day), each alone and in combination, 
with placebo (Pettinati et al., 2010) (Ib). CBT was also delivered. 
The combination resulted in a significantly better drinking out-
come, about half abstinent, whereas only about a quarter achieved 
this in the other groups. Also, by the last 3 weeks the mood of 
those on the combination tended to be better. It was not clear why 
naltrexone alone failed to show an advantage in this study over 
placebo in drinking outcomes.
A secondary analysis of the trial comparing naltrexone, disul-
firam alone and in combination, with placebo in a group of patients 
with alcohol dependence and psychiatric comorbidity compared 
those with and without current depression (Petrakis et al., 2005, 
2007) (Ib). Just over half (55%) met the current DSM-IV criteria 
for major depression, and depression improved during the trial in 
all treatment groups. However, there was no relationship between 
current depression and medication on alcohol or psychiatric out-
comes, or side-effect reporting. Therefore naltrexone and disulfi-
ram can be used safely in depressed alcoholics with comparable 
efficacy with those not depressed.
Krystal et al. (2008) (Ib) undertook a secondary analysis of the 
VA naltrexone trial where naltrexone failed to show significant 
advantage over placebo. During the study, about 10% of people 
required antidepressants since their mood worsened. Although 
drinking outcomes were worse in those requiring antidepressants, 
those on naltrexone had better outcomes than those who received 
placebo. Indeed, the outcomes on those receiving naltrexone was 
not different between those that were on antidepressants or not. 
One interpretation is that combination of antidepressant and nal-
trexone is better than either drug alone, but only in patients who 
are depressed.
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Given naltrexone’s theoretical impact on worsening mood, a 
recent exploratory survey of alcohol-dependent patients treated 
with the extended release form of naltrexone suggests that its 
impact on alcohol pleasure is not generalised. In patients, some 
treated for years (average 3.5 years), pleasure of being with 
friends, good food, sex and listening to music were rated higher 
than for alcohol or gambling (O’Brien et al., 2011).
A post-hoc analysis of 11 RCTs of acamprosate and Hamilton 
depression rating scale to define those with and without depres-
sion revealed that acamprosate has an indirect modest beneficial 
effect on depression by increasing abstinence (Lejoyeux and 
Lehert, 2011) (Ib). The effect of acamprosate is not altered by the 
presence of depression, nor was there evidence that it adversely 
impacts on depression.
A recent audit of baclofen in 13 patients with depressive disor-
der, some of which also had an anxiety disorder, reported that 
seven patients achieved abstinence and one reduced consumption 
to a non-problematic level (Dore et al., 2011) (III). However, two 
patients took overdoses and sedation was an issue, likely due to 
the sedative drugs also being prescribed.
Nicotine and depression. As described in the nicotine section, 
there are strong links between smoking and depressive symptoms. 
Most trials examining the impact of depressive disorder have 
studied those with a past rather than current history, and those 
with symptoms rather than a disorder. One meta-analysis con-
cluded that a lifetime history of major depression did not appear to 
be an independent risk factor for cessation failure in smoking ces-
sation treatment (Hitsman et al., 2003) (Ia). Another systematic 
review and meta-analysis reported identifying only three RCTs 
that included those with current depression, and only one involved 
pharmacotherapy (Gierisch et al., 2012) (Ia).
One RCT reported that an intervention integrating motiva-
tional feedback plus medication and psychological intervention 
improved smoking outcomes in smokers in treatment for 
depression compared with brief contact (Hall et al., 2006) (Ib). 
All patients were given nicotine patches, the strength depend-
ing on how much they smoked, and if they failed to quit they 
could then receive nortriptyline or bupropion (12% in control, 
18% in active intervention). One study included those with 
elevated depressive symptoms rather than a depressive disor-
der; the behavioural intervention did result in greater smoking 
cessation and improvement in depressive symptoms 
(MacPherson et al., 2010) (Ib). The remaining study reported 
that an exercise counselling intervention in depressed female 
smokers compared with health education was feasible (Vickers 
et al., 2009) (Ib).
Another RCT included both those with a current history or 
those with a past unipolar depressive disorder and compared 
bupropion with placebo in smokers being treated with standard 
group CBT and nicotine patch and not antidepressant medication 
(Evins et al., 2007) (Ib). The primary analysis did not show an 
advantage of bupropion over placebo; however, the drop-out rate 
was high (50%) and the effectiveness of other treatments may 
have led to a ceiling effect.
Taking into account the other studies that included those with 
depressive symptoms, Gierisch et al. (2012) concluded that 
patients with depression should be encourage to seek help from 
smoking cessation services that include both NRT and behav-
ioural mood management.
Recommendations: depression
x Antidepressants may improve mood but not necessarily 
substance use in those who are depressed with harmful or 
dependent substance use. Generally mood will only 
improve in those with a significant depressive disorder, 
and use of antidepressants should be restricted to this pop-
ulation and then with caution and monitored (A).x A comprehensive assessment is essential to determine how 
substance use and depression are linked (S).x Tricyclic antidepressants (TCAs) are not recommended due 
to potentially serious interactions between TCAs and sub-
stances, including cardiotoxicity and death in overdose (S).x Consider using an antidepressant with mixed serotonergic/
noradrenergic pharmacology since they may be better in 
improving mood in contrast to SSRIs, which have not 
shown consistent benefits in improving mood (D).x Medication for harmful substance use, abuse or depend-
ence should be considered such as optimising opioid sub-
stitution, use of alcohol relapse prevention such as 
naltrexone or acamprosate, use of nicotinic replacement 
therapy for smoking cessation (D).
Key uncertainties
x Which is the best antidepressant to use and evaluation is 
needed of newer antidepressants such as mirtazapine and 
venlafaxine?x What is the best combination of antidepressants and medi-
cation for treating depression and harmful substance use, 
abuse or dependence?x What is the best combination of pharmacological and psy-
chosocial approaches to address depression and harmful 
substance use, abuse or dependence?x What is the best approach to those with resistant 
depression?
Anxiety
Anxiety is a common symptom of substance misuse, occurring in 
intoxication, withdrawal and abstinence, depending on the sub-
stance. Therefore a comprehensive assessment is vital in order to 
determine how these factors are related and the likelihood of an 
independent anxiety disorder. For instance, anxiety disorders are 
associated with alcohol abuse or greater non-medical opioid use 
and vice versa (Martins et al., 2011; Regier et al., 1990). Ideally, 
abstinence should be attained to aid assessment and diagnosis, and 
a medically assisted withdrawal may be required. Identifying anx-
iety is critical, since it can have profound negative effects on the 
ability of someone to engage with treatment and predicts poor out-
come in cocaine and opioid dependence (Book et al., 2009; Lejuez 
et al., 2008). We describe the only available pharmacotherapy 
studies which are in alcohol use disorders.
Anxiety is a common symptom in people with harmful alcohol 
use, abuse, dependence and withdrawal, and alcohol is used as 
self-medication by many with anxiety disorders, especially social 
anxiety (Regier et al., 1990). Anxiety reduces during alcohol with-
drawal and in the following few weeks (Brown et al., 1991, 
Liappas et al., 2002), but if it persists, relapse rates increase up to 
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twofold (Brown et al., 1991; Kushner et al., 2005). Some studies 
show improvement in substance use by treating comorbid anxiety 
(e.g. Fals-Stewart and Schafer, 1992; Tollefson et al., 1992) (Ib), 
although others found no effect on substance use (e.g. Bowen 
et al., 2000; Schade et al., 2005; Thomas et al., 2008) (Ib).
The use of benzodiazepines is controversial in those with alco-
hol dependence, although abuse may not be as widespread as many 
people fear (Chick and Nutt, 2012; Ciraulo et al., 1988; Ciraulo 
and Nace, 2000). Mueller et al. (2005) (III) found no difference in 
benzodiazepine usage between those who developed alcohol use 
disorder and those that did not, and benzodiazepine use did not 
predict relapse or recovery in those with alcohol use disorder.
In the context of anxiety disorders, it may be that many people 
do not get adequate treatment due to concerns about using benzodi-
azepines. It has been reported that abstinent alcohol-dependent 
patients may be at greater risk of benzodiazepine abuse and depend-
ence, and patients who are severely dependent with antisocial per-
sonality disorder or with polysubstance abuse are most at risk of 
abusing benzodiazepines (Ciraulo and Nace, 2000) (IV). Therefore 
there should be a clear favourable risk:benefit ratio, but benzodiaz-
epines do have a role in treating anxiety and alcohol use disorders.
A meta-analysis of five RCTs showed that buspirone was ben-
eficial in improving anxiety but not alcohol consumption (Malec et 
al., 1996) (Ia). A series of studies investigating the effect of parox-
etine in patients seeking treatment for social anxiety who also had 
comorbid alcohol use disorder found paroxetine (up to 60 mg/day) 
was superior to placebo in improving social anxiety disorder but 
not drinking (Book et al., 2008; Thomas et al., 2008) (Ib), although 
there was less drinking to ‘self-medicate’ (Thomas et al., 2008).
Post-traumatic stress disorder (PTSD) is a risk factor for harm-
ful substance use, abuse or dependence, with ‘self-medication’ 
often cited as a significant contributor. Supporting this are studies, 
for example, which report improvements in PTSD resulting in 
improvements in substance use with minimal impact of improve-
ments in substance use on PTSD (Hien et al., 2010) (Ib). In a 
secondary analysis of their comorbidity trial investigating naltrex-
one and disulfiram alone and combined (cf above, Petrakis et al., 
2005), Petrakis et al. (2006c) (Ib) compared patients with (37%) 
and without (63%) PTSD and alcoholism. Either naltrexone or 
disulfiram alone or combined resulted in improved drinking out-
comes compared with placebo in those with PTSD. There was a 
suggestion that disulfiram may be particularly beneficial, and this 
could be due to a reduction in noradrenaline dampening arousal.
A recent study of Iraq and Afghanistan veterans compared par-
oxetine (titrated to 40mg/d) with desipramine (titrated to 200mg/d) 
(i.e. serotonergic vs noradrenergic uptake inhibitor) with or with-
out adjunctive naltrexone (Petrakis et al., 2012). Desipramine had 
comparable efficacy to paroxetine in treating PTSD but had supe-
rior efficacy in reducing alcohol consumption. Notably naltrexone 
did not show efficacy in this population for drinking outcomes 
compared to the previous secondary analysis (Petrakis 
et al., 2006c). This could have been due to the study design includ-
ing that patients were specifically recruited for the recent study 
and were started or changed their antidepressant rather than on 
long-standing pharmacotherapies. 
In patients with comorbid PTSD and alcohol dependence, ser-
traline (150 mg/day) was not superior to placebo in reducing alco-
hol consumption over 12 weeks, with both groups showing 
improvement in their drinking but not their PTSD (Brady et al., 
2005) (Ib). Further analysis revealed that sertraline in those whose 
PTSD predated their alcohol dependence improved alcohol out-
comes; however, in those that were more severely dependent, ser-
traline resulted in more drinking than placebo. This is similar to 
what is seen in early versus late-onset alcoholism (see alcohol sec-
tion), and emphasises that SSRI medication should be used with 
caution in those with harmful alcohol use, abuse or dependence.
While prospective RCTs are not available for other alcohol 
relapse medication in those with comorbid anxiety disorders, both 
acamprosate and baclofen have shown some benefit in reducing 
anxiety in post-hoc analyses of trials in alcohol dependence (see 
alcohol section).
Recommendations: anxiety
x Ideally patients should first undergo alcohol detoxifica-
tion (S).x If detoxification is not possible, treatment of the anxiety 
disorder should still be attempted: follow guidelines to 
select most appropriate pharmacotherapy for management 
of their anxiety disorder (B).x Assessment by a specialist addiction service is recom-
mended prior to using a benzodiazepine to treat their anxi-
ety (D).x Medication for the patient’s harmful substance use, abuse 
or dependence should be considered, such as optimising 
opioid substitution, use of alcohol relapse prevention such 
as naltrexone or acamprosate (D).
Key uncertainties
x Which is the best antidepressant/anxiolytic to use?x What is the best combination of medications for treating 
anxiety and substance abuse or harmful use?x What is the best combination of pharmacological and psy-
chosocial approaches to address anxiety and harmful sub-
stance use, abuse or dependence?
Personality disorder and treatment for 
substance use disorders
Authoritative reviews of studies of the co-occurrence of personal-
ity disorders and substance use disorders have been published (e.g. 
Seivewright and Daly, 1997; Verheul, 2001). These concentrate 
mainly on studies with larger samples that have used interview 
methods of assessment and clear diagnostic criteria. In Verheul’s 
review, median prevalence of any personality disorder of 56.5%, 
with antisocial personality disorder of 22.9%, followed by border-
line personality disorder at 17.7%. A more recent London-based 
study (Bowden-Jones et al., 2004) had similar findings, with over-
all prevalence of personality disorder of 37% among patients in 
treatment for drug-use disorders and 53% among patients in treat-
ment for alcohol-use disorders. Patients with dependent personal-
ity disorder may be at higher risk of development of dependence 
on benzodiazepines (e.g. Murphy and Tyrer, 1991).
Studies of pharmacological treatment for substance use disor-
ders typically do not exclude people with personality disorders, 
hence it is likely they were included in most studies. ‘Mainstream’ 
studies of drug treatments for substance use disorders are there-
fore of relevance to patients with personality disorder.
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There is a commonly held view that personality disorder pre-
dicts poor response to treatment for substance use disorders. 
However, there are a number of studies showing that although 
people with personality disorder may have greater pre- and post-
treatment problem severity, they can improve as much as those 
without personality disorders (Verheul, 2001) (IV). This suggests 
that drug and alcohol users with personality disorders probably 
benefit from standard treatments for substance use disorders. 
These studies range across MMT for opioid dependence (Alterman 
et al., 1998; Cacciola et al., 1996; Darke et al., 1996) (III), treat-
ments for alcohol dependence (Powell et al., 1992; Verheul et al., 
1999) (III), as well as some based on mixed populations of sub-
stance use disorders (Cacciola et al., 1995; Cecero et al., 1999) 
(III). In one study of disulfiram and naltrexone for treatment of 
alcohol dependence (Ralevski et al., 2007) (Ib), patients with 
comorbid Axis I psychiatric disorders and either antisocial person-
ality disorder or borderline personality disorder responded as well 
to treatment with either medication as patients without personality 
disorder. Moreover, Rohsenow et al. (2007) (Ib) found patients 
with antisocial traits had better alcohol outcomes in response to 
treatment with naltrexone than patients without antisocial traits.
Explicit reference to improvements in symptoms of personality 
disorder is rarely reported, and reported outcomes are often not 
limited to the presence or absence of substance misuse, but also 
include associated behaviours such as HIV risk behaviours, crimi-
nal activity, physical morbidity, overall mortality, and mortality 
from suicide (Caplehorn et al., 1996; Marsch, 1998, Ward et al., 
1999) (III). Several studies show the risk of suicidal and harmful 
behaviour continues in patients with personality disorder, even 
when the treatment for substance abuse has been successful (van 
den Bosch and Verheul, 2007) (IV). This pattern was apparent in 
the 3-year follow-up of the Australian Treatment Outcome Study 
(Darke et al., 2007) (III) in which patients with borderline person-
ality disorder maintained elevated risk levels across a number of 
domains, despite equivalent progress to patients without personal-
ity disorder in relation to abstinence from heroin and polydrug use.
Recommendations: personality disorder
x Patients with personality disorder can be offered the same 
range of treatment options as patients without personality 
disorder (B).x High-risk behaviour persists in patients with borderline 
personality disorder despite successful treatment of harm-
ful substance use, abuse or dependence, and such patients 
should also have treatment aimed at ameliorating the 
impact of the personality disorder (D).
Key uncertainties
x Whether any pharmacotherapy is particularly beneficial in 
personality disorder with harmful substance use, abuse or 
dependence?
Sleep
Insomnia is commonly seen in people who misuse substances and 
can occur during intoxication, withdrawal or become more evi-
dent during abstinence. Sleep problems are often cited by patients 
as a reason they began to drink heavily or relapse, and poor sleep 
has been shown to be associated with poorer outcomes (see 
Brower and Perron, 2010). As for other comorbidities, a compre-
hensive assessment is key to determine the relationship between 
sleep problems and substance use and to inform a management 
plan. Rather than use additional pharmacotherapy, review of their 
existing pharmacotherapy with advice about ‘sleep hygiene’ 
(Wilson et al., 2010) is likely to be the best approach.
Alcohol. Sleep problems may become first evident during alco-
hol detoxification, although adequate doses of benzodiazepines 
should minimise this. Both acamprosate and carbamazepine have 
been associated with improved sleep during withdrawal (Malcolm 
et al., 2002; Staner et al., 2006) (Ib). A placebo-controlled RCT of 
trazodone, an antidepressant often used for insomnia, found 
improved sleep quality in alcohol-dependent patients with insom-
nia (Friedmann et al., 2008) (Ib). However the improvement dis-
appeared once they stopped taking trazodone after 12 weeks, and 
they drank more than the placebo group in the follow-up period.
Some but not all studies of acamprosate in relapse prevention 
have reported beneficial effects on sleep (Johnson et al., 2003; 
Mason and Heyser, 2010) (Ib). Unlike many other medications 
such as some antidepressants, acamprosate does not appear to 
adversely affect sleep. Other drugs such as gabapentin and quetia-
pine have been shown to have potential in improving sleep in 
abstinence (see Arnedt et al., 2007 for review) (IV).
Opioids. Sleep dysregulation is commonplace in opioid addicts 
(Zutler and Holty, 2011). While clinically sleep problems are 
more recognised during withdrawal, and are often protracted, 
especially from methadone, they may also be present during 
maintenance or substitute therapy. However, a laboratory study of 
sleep difficulties revealed they may not be associated with the 
methadone dose, but benzodiazepine abuse or chronic pain (Peles 
et al., 2009).
Stimulants. Stimulant withdrawal may be associated with 
hypersomnia, with insomnia more likely seen during abstinence. 
Modafinil has shown some promise in treating cocaine depen-
dence (see above), and Morgan et al. (2010) (Ib) reported that it 
also improved diurnal sleep rhythm and sleep architecture.
Younger people: children and adolescence
The definition of young people may range from the age of 10–25 
years. For this document, we are focussing on children and young 
people under the age of 18. Young people are still physically and 
mentally growing, and their brain, particularly their frontal lobes, 
continues developing into the early 20s. Thus the neurobiological 
impact and consequences of substances on this developing plastic 
brain is likely to be different to those on an adult, fully developed 
brain. The ‘reward and motivation’ system, such as the ventral 
striatum, develops at an earlier stage before the ‘top-down’ con-
trol from the prefrontal cortex is established (Somerville and 
Casey, 2010). In addition, it may be that the exposure of a devel-
oping plastic brain to substances may result in increased risk of 
acquiring a chronic addictive disorder (O’Brien 2007; Spear, 
2007). There is also a potential increased risk of mental illness, for 
example cannabis and psychosis (Moore et al., 2007). Research 
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indicates that the experience of craving for, and withdrawal symp-
toms from, addictive substances are similar in adult and younger 
populations (Thomas et al., 2005).
Substance use is common in young people, with high levels of 
prevalence in the UK compared with elsewhere in Europe and 
USA (Frischer et al., 2003). Alcohol is the most common sub-
stance used (British Medical Association, 2003). About 1% of 
14–16-year-olds in the United Kingdom drink alcohol nearly 
every day, and are therefore at high risk of alcohol use disorder. 
Recently, the WHO estimated that the main risk factor for disabil-
ity-adjusted life years in 10–24-year-olds was alcohol, with illicit 
drug use also significantly contributing (Gore et al., 2011).
Young people generally present with problems with alcohol 
and/or cannabis to specialist drug and alcohol services. For recent 
guidance about assessment and prescribing in young people as 
well as underlying principles of care, responsibilities and consent 
see Gilvarry and Britton, (2009) (IV).
While emphasis is put on psychosocial, harm reduction and 
family interventions as appropriate approaches in young people, 
pharmacotherapy is an important component for some. As for 
adults, medication can be used for stabilisation, detoxification, 
relapse prevention and preventing complications. However, in 
younger people pharmacotherapy for relapse prevention is less 
commonly used and is not recommended for routine use (Gilvarry 
and Britton, 2009). This emphasises the need for a specialist mul-
tidisciplinary team, including specialists in addiction to initiate 
treatment and those to care for mental and physical health and 
social needs in young people.
A complicating factor is that pharmacotherapy is not generally 
licensed for use in ‘younger’ people, with age limits varying. For 
example, in the UK, acamprosate is licensed for over 18-year-
olds, methadone is not licensed for children under age of 13, and 
buprenorphine is licensed for those aged 16 and over. Doses of 
medication may need to be adjusted from those for adults, given 
the difference in pharmacokinetics and pharmacodynamics 
between adults and younger people. Generally, guidance is that 
pharmacotherapy should only be used after careful assessment of 
risks and benefits, and in the context of a comprehensive treat-
ment plan embracing various psychosocial approaches (Gilvarry 
and Britton, 2009; Upadhyaya and Deas, 2008) (IV). With only a 
few studies and the majority conducted in the USA with generally 
small numbers, mostly male participants, and short treatment or 
follow-up periods, there is little evidence on which to base guid-
ance. Nevertheless, pharmacotherapy should be considered in 
young people with a diagnosis of dependence.
Alcohol
The assessment and management, including psychosocial and 
pharmacological approaches, of harmful alcohol use and depend-
ence in children and young people has recently been reviewed 
(NICE, 2011a). The number of younger people dependent on alco-
hol that need pharmacotherapy to cover withdrawal is likely to be 
small. In the absence of any studies to inform guidance, approaches 
used in adults are an appropriate benchmark, although possibly 
with a lower threshold of admitting to hospital (NICE, 2011a) (Ia). 
Chlordiazepoxide has been recommended, with need to consider 
what dose is appropriate (Gilvarry and Britton, 2009) (IV).
A placebo-controlled RCT of acamprosate (1332 mg/day two 
tablets, one tablet, one tablet) in 26 16–19-year-olds with chronic 
or episodic alcohol dependence reported improved drinking out-
comes in the acamprosate group during the 90-day study 
(Niederhofer and Staffen, 2003a) (Ib). They reported that the pro-
portion of patients who remained abstinent was higher in the 
acamprosate group (seven vs. two) and that the mean cumulative 
abstinence duration was significantly greater in the acamprosate 
group (79.8 (SD 37.5) vs. 32.8 (SD 19.0)). Acamprosate was well 
tolerated with no difference in reported side effects to placebo.
A case report of naltrexone (50 mg/day) described reduced 
alcohol cravings and abstinence from alcohol and cannabis for 30 
days in a 17-year-old (Wold and Kaminer, 1997) (III). An open-
label pilot study of naltrexone (25 mg or 50 mg) in five outpatient 
treatment-seeking adolescents reported reduction in craving and 
drinking (Deas et al., 2005) (III). In this study, nausea was reduced 
if naltrexone was taken with food. A double-blind placebo- 
controlled study of naltrexone (50 mg/day) in 60 16–19-year-olds 
reported that significantly more patients on naltrexone remained 
abstinent during the 90 days, with cumulative abstinence of 70 
days compared with 23 days (Niederhofer et al., 2003) (Ib). There 
was no significant difference in the two groups for side effects.
Disulfiram (250 mg/day) use in a 16 and in a 17-year-old resulted 
in prolonged abstinence for one young man but not the other, in 
whom compliance was poor (Myers et al., 1994) (III). A double-
blind placebo-controlled study of disulfiram 200 mg daily (two 50 
mg tablets mane, one 50 mg tablet at midday and one 50 mg tablet 
in the evening) in 26 16–19-year-olds reported disulfiram resulted 
in significantly greater abstinence (Niederhofer and Staffen, 2003b) 
(Ib). No significant difference was seen between the groups.
A prospective open-label trial of ondansetron (4 µg/kg) along-
side weekly CBT in 12 treatment-seeking 14–20-year-olds found 
improvement in drinking outcomes over 8 weeks (Dawes et al., 
2005) (IIb). However, there was no placebo group.
Opioids
The use of opioids, including ‘street’ and prescription opioids, 
appears to be on the rise in young people and has recently been 
reviewed (Subramaniam et al., 2009). Gilvarry and Britton (2009) 
(IV) provide guidance about prescribing opioid substitutes to 
young people. While in adults, stabilisation with an opioid substi-
tute followed by long-term maintenance is common, this is a more 
controversial approach in young people with a limited history of 
opioid use and minimal adverse consequences. In such cases, sub-
stitution followed soon after by detoxification may be a more 
appropriate approach.
Optimal pharmacotherapy for detoxification has limited evi-
dence, so advice for adults can be followed (Gilvarry and Britton, 
2009, (IV); NICE, 2007 (Ia)). Buprenorphine, particularly with 
naloxone, is favoured by some due to its better tolerability, adverse 
event profile, and easier dose reduction to abstinence. An RCT 
compared buprenorphine with clonidine in detoxification of 36 
opioid-dependent adolescents (13–18 years old; Marsch et al., 
2005) (Ib). Buprenorphine improved retention in treatment for 1 
month compared with clonidine (72% vs. 39%), provided more 
opiate-free urines (64% vs. 32%), and more started naltrexone 
afterwards (61% vs. 5%).
Another randomised trial compared two different regimens of 
buprenorphine–naloxone over 12 weeks in 150 15–21-year-olds 
(Woody et al., 2008) (Ib). It compared buprenorphine–naloxone, 
24 mg per day for 9 weeks, then tapered to week 12 with 
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buprenorphine–naloxone prescribed up to 14 mg per day and 
then tapered to day 14 (called ‘detox’ group). Compared with the 
buprenorphine–naloxone group, the ‘detox’ group had more 
opioid-positive urines at weeks 4 (61% vs. 26%) and 8 (54% vs. 
23%) but not 12 (51% vs. 43%) when both groups were not 
receiving any substitute prescription. Retention in treatment was 
better in the buprenorphine–naloxone group (70% vs. 20%). The 
majority in both groups resumed opioid use in the following 12 
months. This study suggests that short-term treatment with 
buprenorphine–naloxone results in better outcomes than detoxifi-
cation; however, once treatment stops, this gain is lost.
Concerning opioid maintenance, a recent Cochrane review of 
this approach identified two trials of maintenance treatment 
(Minozzi et al., 2009) (Ia). One was the Woody et al. (2008) (Ib) 
trial described above using buprenorphine–naloxone, and the 
other reported no difference between methadone and LAAM 
maintenance in 37 heroin addicts (Lehmann, 1973) (IIa).
For relapse prevention, the extended-release formulation of 
naltrexone (XR-naltrexone) requires monthly injections which 
can overcome compliance issues. In a case series of 16 individu-
als, average age 18 (range 16–20 years), XR-naltrexone was well 
tolerated, with 10 being retained for the 4-month treatment period 
(Fishman et al., 2010) (III). The majority of patients (11) were 
abstinent or had substantial reductions in opioid use, and nine met 
criteria for a ‘good’ outcome at 4 months. Importantly, there were 
no reports of overdoses despite many testing the blockade.
Nicotine
A recent Cochrane review of smoking cessation trials in young 
people reported the majority of trials included some form of moti-
vational enhancement, and that complex psychological interven-
tions showed promise (Grimshaw and Stanton, 2006) (Ia). A small 
trial of NRT alone, one with bupropion and one with bupropion 
alone failed to show efficacy in adolescent smokers (Killen et al., 
2004; Moolchan et al., 2005; Muramoto et al., 2007) (Ib).
Other substances of abuse
There is no evidence to inform practice. For benzodiazepine 
dependence, maintenance prescribing is not recommended and 
detoxification with diazepam is recommended (Gilvarry and 
Britton, 2009) (IV). For all other substances of abuse, including 
stimulants, cannabis and Ecstasy, psychosocial approaches are 
considered the best approach and medication, if required for 
reducing problems such as insomnia, should only be used cau-
tiously on a limited basis.
Comorbidity
As for adults, a coordinated approach for managing comorbidity 
of substance use disorder and another psychiatric disorder is 
required, perhaps even more so in younger people (Gilvarry and 
Britton, 2009; Lamps et al., 2008) (IV). High levels of such 
comorbidity at 60–88% have been reported in young people 
(Deas, 2006). Careful assessment is essential to understand the 
relationship between the two (or more) disorders and possible 
aetiology (NICE, 2011b) (Ia).
A pilot placebo-controlled trial of sertraline alongside CBT in 
10 depressed alcohol-dependent adolescents reported that mood 
and drinking improved similarly in both groups (Deas et al., 2000) 
(Ib). Sertraline (25 mg/day increased to 100 mg by week 4) was 
well tolerated over the 12-week trial. An open-label 12-week trial 
of fluoxetine in depressed alcohol-dependent and alcohol-abusing 
adolescents reported significantly improved depression and drink-
ing outcomes (Cornelius et al., 2001) (IIb). Fluoxetine was well 
tolerated. However, there was no placebo group, which limits 
drawing conclusions from this study.
A double-blind placebo-controlled trial over 6 weeks in 25 
adolescents, mean age of 16 years, with bipolar disorder and sec-
ondary substance dependence reported that lithium was an effica-
cious treatment of both (Geller et al., 1998) (Ib). Alcohol and 
cannabis were the most common dependencies, although nicotine 
is not mentioned.
Recommendations: younger people. There is limited evi-
dence on treatment of substance use disorders in younger people 
on which to base recommendations to guide specific pharmaco-
logical approaches. However, it is important that pharmacother-
apy be considered, particularly in alcohol, opioid or nicotine 
dependence, and ideally by a specialist multidisciplinary service.
x Pharmacological treatment should follow the evidence 
base for the general adult population with appropriate dose 
adjustments for age-related pharmacokinetic and pharma-
codynamic changes (C).x Younger people with harmful substance use, abuse or 
dependence should have full routine health screens with 
identification and treatment of psychiatric or physical 
health problems (S).x There should be a lower threshold for admission for inpatient 
assessment and treatment, for example for assisted alcohol 
withdrawal, opioid stabilisation in younger people (D).
Key uncertainties
x What is the long-term outcome after alcohol or opioid 
detoxification?x What is the optimal opioid substitution regimen for opioid 
dependence in this age group?x What is the effectiveness of alcohol relapse prevention 
medication in younger people?
Older adults
In 2001, people over 65 made up 16% of England’s population and 
this is forecast to rise to 21% by 2026 (Falaschetti et al., 2002), 
increasing demands on the substance misuse treatment system over 
the next two decades (Gfroerer et al., 2003). A recent report is 
recommended reading (Crome, 2011). Some key points in this 
report are that psychiatric comorbidities of substance misuse are 
common in older people; older people are at increased risk of 
adverse physical effects of substance misuse, even at relatively 
modest levels of intake; older men are at greater risk of developing 
alcohol and illicit drug misuse problems than older women; and 
older women are at greater risk of developing problems associated 
with prescribed or over-the counter medication than men. In addi-
tion, the relationship between cognitive function and substance 
(particularly alcohol) use is complex, as is that between functional 
mental health problems (e.g. anxiety and depression) and substance 
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use, with the direction of causality often unclear. Lower safe levels 
of alcohol consumption (1.5 units/day; 11/week) are proposed. 
Older people can and do benefit from treatment, and in some cases 
have better outcomes than younger people (Moy et al., 2011).
There is a lack of evidence to guide practitioners on managing 
substance misuse in older adults. Elderly people are typically 
excluded from clinical trials of pharmacotherapy, despite the 
increasing need for an evidence base as the UK population ages. 
According to recent figures for England and Wales, 1.5% of the 
55–59 year age group among the general population reported use 
of any illicit drug in the previous year, with 0.1% reporting use of 
a class A drug. This compares with 18.1% and 7.8%, respectively, 
for 20–24 year olds (Hoare and Moon, 2010).
There are difficulties in the detection and management of sub-
stance misuse problems in older adults. Reasons include inadequate 
drug and alcohol history-taking in the elderly, low referral rates to 
specialist drug and alcohol services, and greater use of prescription 
drugs with potential for misuse (Gottlieb, 2004; McInnes and 
Powell, 1994; Simoni-Wastila and Yang, 2006). Treatment should 
be within multidisciplinary settings with input from addiction spe-
cialists and specialists in older people’s physical and mental health.
The normal physiological changes of ageing result in impor-
tant pharmacokinetic and pharmacodynamic changes. 
Pharmacokinetic changes result from changes in body composi-
tion and hepatic and renal function. This results in an increased 
volume of distribution of lipid-soluble drugs and reduced hepatic 
and renal clearance. These changes lead to prolongation of plasma 
elimination half-life. From a pharmacodynamic perspective, age-
dependent changes tend to increase sensitivity to drugs. Reduced 
homeostatic mechanisms may lengthen the time older adults 
require to regain steady-state levels following changes in drug 
therapy (Mangoni and Jackson, 2004). Pharmacological treatment 
should be started at a low dose and titrated slowly.
Drug misusers have higher mortality rates than the age-
matched general population, and older drug users have addition-
ally to deal with the increasing physical health problems of ageing. 
Older opioid users are at greater risk of death due to traumatic and 
somatic causes (Clausen et al., 2009). Clausen et al. (2009) also 
found that older opioid users were at higher risk of fatal overdose 
after leaving opioid maintenance treatment. Cardiovascular dis-
eases and tumours (often hepatic) were the most common causes 
of death among drug users aged 55 or over in one long-term fol-
low-up study (Stenbacka et al., 2010).
Opioids
The proportion of older adults attending treatment services is 
increasing. In 2009/10 in England 26% of the 206,889 in contact 
with structured drug treatment services were over 40 years old 
compared with 18% in 2005/6 (National Treatment Agency and 
Department of Health, 2010b). In addition, in recent years there 
have been increasing numbers of people above 40 years of age 
presenting for new treatment episodes to structured drug treat-
ment services, mainly with problematical heroin use (National 
Treatment Agency and Department of Health, 2010b). Cochrane 
reviews of maintenance treatments for opioid dependence report 
participants to be ‘approximately 30–40 years of age’ (Mattick 
et al., 2008, 2009) (Ia).
Firoz and Carlson (2004) (III) compared outcomes for metha-
done treatment in 54 older adults (>55 years) with 705 adults 
under 55 years of age. The mean age for the older adults was 62 
years (range 55–82). The older adults had improved outcomes on 
drug use measures at 9 months compared with the younger adults. 
The groups did not differ in medical or psychiatric problems.
Among entrants to a New York methadone programme, older 
adults were more likely to have had longer periods of treatment, 
less likely to report current heroin use and overall drug use, but 
were more likely to have a history of comorbid alcohol misuse 
(Rajaratnam et al., 2009) (III). Fareed et al. (2009) (III) conducted 
a retrospective chart review of older patients enrolled in a metha-
done maintenance programme. Patients who remained in treat-
ment showed statistically significant improvements in drug use, 
psychiatric, medical and legal problems.
There is no direct evidence about methadone dosing regimens 
for maintenance treatment in older adults. Guidance from the pain 
management literature recommends opioid doses should be 
reduced, there should be a longer time interval between doses, and 
creatinine clearance should be monitored (Pergolizzi et al., 2008) 
(IV). As maintenance treatment utilises daily dosing of metha-
done, slower dose titration is advisable.
In the absence of a specific evidence base for buprenorphine 
and naltrexone in this population, treatment decisions should be 
based on extrapolations from the general opioid evidence base. 
Clinicians should be mindful of the changes of ageing and accom-
panying increases in comorbidity which may necessitate dose 
adjustments. Evidence from the alcohol literature can be used to 
inform about the safety of naltrexone. Buprenorphine may be the 
optimal choice for those with renal dysfunction requiring mainte-
nance treatment (Pergolizzi et al., 2008) (IV).
Alcohol
Older adults are at increased risk of alcohol-related harm 
(O’Connell et al., 2003). The prevalence of alcohol dependence 
has been reported as 2.3% in 50–54-year-olds (Drummond et al., 
2005). Of the 100,098 clients in contact with structured treatment 
services for a primary alcohol problem in 2008/9, 12,719 (13%) 
were over 55 years of age (National Treatment Agency and the 
Department of Health, 2010a). For a summary of the patterns of 
alcohol use, alcohol-related health problems and assessment and 
screening in the elderly see Dar (2006). NICE summarises the 
complexities of treating alcohol use disorders in older adults 
(NICE, 2011a).
There should be a lower threshold for admission for inpatient 
assisted alcohol withdrawal in older people (NICE, 2011a). 
Brower et al. (1994) reported a more protracted and severe alco-
hol withdrawal syndrome in the elderly compared with younger 
people with equal drinking severity. However, a prospective study 
of admissions to a specialist detoxification unit did not find a rela-
tionship between the severity of alcohol withdrawal and age 
(Wetterling et al., 2001).
Benzodiazepines remain the treatment of choice, but the doses 
may need to be reduced in older people (NICE, 2011a). Shorter 
acting benzodiazepines (e.g. oxazepam) may be preferred, espe-
cially where there is concern about accumulation leading to over-
sedation (Mayo-Smith et al., 2004) (III).
There is an absence of high-quality evidence on pharmacologi-
cal interventions for maintaining abstinence in older people, and 
extrapolations should be made from the adult evidence base 
(NICE, 2011a). In trials of naltrexone treatment only 2.6% of 
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subjects were over 65 years of age, and in placebo- 
controlled clinical trials of acamprosate 1% were 65 years or older 
(Teter, personal communication).
There have been concerns about the increased risk of serious 
adverse effects in older adults prescribed disulfiram due to physi-
cal comorbidities and polypharmacy and the risks of precipitating 
a confusional state (Dufour and Fuller, 1995; Dunne, 1994; 
Schonfeld and Dupree, 1995 (IV)) and cardiovascular concerns if 
there was a drug–alcohol interaction (Barrick and Connors, 2002) 
(IV). However, Zimberg (2005) (IV) reports that disulfiram is safe 
and effective in a dose of 125 mg per day in elderly patients who 
are not suffering from significant cardiovascular or liver disease 
and who do not have significant cognitive impairment. 
Acamprosate is known to have a good safety profile except in 
renal insufficiency. Dose adjustment may be required in older 
adults due to age-related kidney disease. Naltrexone appears to be 
safe in older adults. A 12-week double-blind, placebo-controlled 
study of naltrexone (50 mg per day) in alcohol-dependent subjects 
over 50 years of age found no difference in frequency of adverse 
events, including changes in liver enzymes, between placebo and 
naltrexone-treated groups (Oslin et al., 1997) (Ib). In a randomised, 
double-blind, placebo-controlled efficacy trial of naltrexone (100 
mg per day), older adults (over 55 years of age) were more likely 
to adhere to the medication regime than younger adults (OR = 
3.28; 95% CI 1.19–9.08, p = 0.022) (Oslin et al., 2002) (Ib).
Nicotine dependence
Orleans et al. (1994) (III) reported the results of a 6-month tele-
phone follow-up survey of smokers aged 65–74 years prescribed 
nicotine patches. Some 29% reported current abstinence (of at 
least 7 days duration) at 6-month follow-up. Miller et al. (2005) 
(III) also report a follow-up survey conducted 6 months after free 
distribution of NRT. Smokers who phoned a toll-free quit line 
were sent a 6-week course of NRT and had brief follow-up coun-
selling calls. The highest quit rates were associated with those 
older than 65 years. Also, placebo-controlled trials of nicotine 
patches on patients with coronary artery disease have found no 
evidence for an increased risk of cardiac complications (Joseph 
et al., 1996; Tzivoni et al., 1998) (Ia).
In studies of immediate and sustained release bupropion in 
depression and smoking no overall differences in safety or effective-
ness were observed between subjects over 65 years of age and 
younger subjects (Teter, personal communication). A maximum dose 
of 150 mg bupropion daily is recommended in the elderly. There is no 
specific dose reduction recommended in older adults for varenicline 
except where there is coexisting renal insufficiency (see BNF).
Benzodiazepines and hypnotics
There are ongoing concerns about inappropriate prescribing of 
benzodiazepines to older adults (Reay, 2009). Unlike research in 
opioid and alcohol dependence, many of the studies of benzodiaz-
epine discontinuation have been conducted in elderly populations. 
These have usually involved patients in general practice or outpa-
tient settings and patients who have ‘therapeutic dose’ depend-
ence (Parr et al., 2008). In these studies minimal interventions 
(1a) and graded discontinuation (1b) have proven effectiveness. 
The addition of psychological interventions to graded discontinu-
ation has shown increased effectiveness compared with gradual 
dose reduction alone, and may be particularly beneficial where 
there is problematical insomnia (Oude Voshaar et al., 2006b; Parr 
et al., 2008) (Ia).
Recommendations: older adults. There is limited evidence on 
treatment of harmful substance use, abuse or dependence in older 
adults on which to base recommendations to guide pharmacologi-
cal approaches.
x Pharmacological treatment should follow the evidence 
base for the general adult population, with appropriate 
dose adjustments for age-related pharmacokinetic and 
pharmacodynamic changes and for psychiatric and physi-
cal comorbidities (C).x Older adults with harmful substance use, abuse or depend-
ence should have full routine health screens with identifi-
cation and treatment of psychiatric and physical health 
problems (S).x There should be a lower threshold for admission for inpa-
tient assisted alcohol withdrawal in older people (D).x ‘Therapeutic dose’ benzodiazepine users should be offered 
minimal interventions or graded discontinuation depend-
ing on the clinical picture (A).
Key uncertainties
x What is the long-term outcome after alcohol or opioid 
detoxification?x What is the optimal opioid substitution regimen for opioid 
dependence in this age group?x What is the efficacy of acamprosate and naltrexone in 
older adults?
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